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Introduction

Human immunodeficiency virus (HIV)
In 1981, a sudden Increase of Kaposi’s sarcoma was reported amongst young 
homosexual men (1). In that same year, there was an outbreak of the rare lung Infection 
Pneumocystis carinii pneumonia (PCP) In homosexual men and drug abusers (2).
Both problems reflected a severe deficiency in the immune system, which was 
named ‘Acquired Immune Deficiency Syndrome’ (AIDS). The causative agent of 
AIDS turned out to be a retrovirus; which was called ‘human immunodeficiency 
virus’ (HIV) (3;4). HIV enters predominantly helper T cells of the human immune 
system by binding to CD4 receptors. HIV kills the CD4 positive immune cells that it 
infects, thereby crippling the immune system. A distinction is made between HIV-1 
and HIV-2, the latter being less virulent and prevalent than HIV-1. HIV-2 is mostly 
prevalent in West-Africa (5).
HIV can be transmitted through unprotected sexual intercourse, intravenous drug 
use with contaminated injection needles, transfusion of HIV-infected blood, and by 
mother-to-child-transmission during pregnancy, delivery and breast feeding.
HIV is still a major global health problem. In 2008, AIDS killed approximately 2.0 
million people while in the same year, 2.7 million people were newly infected with 
HIV. By the end of 2008, 33.4 million people were living with the virus, more people 
than ever before (6). Nonetheless, there are promising results in the fight against 
HIV. First, the continuing rise in the number of HIV-infected patients is not only the 
result of continued high rates of new HIV-infections. It is also a reflection of the 
beneficial impact of increased global access to antiretroviral therapy (6). Second, 
the number of new HIV infections has decreased from a peak of 3.6 million in 1996 
to 2.7 million in 2008 (6). Finally, the number of AIDS-related deaths has declined 
from 2.2 million in 2004 to 2.0 million in 2008.
A n tire tro v ira l d rugs
In 1987, zidovudine was introduced, the first drug for the treatment of HIV and AIDS, 
which is still part of the current antiretroviral armamentarium. Unfortunately, it took 
approximately another 10 years before sustained suppression of HIV replication 
became achievable. Combination antiretroviral therapy (cART), consisting of at 
least three drugs, coming from at least two drug classes, appeared to be essential 
for controlling the virus. Since 1996, the introduction of cART has led to a sustained, 
well-documented reduction in AIDS-related mortality and morbidity among those 
who had access to cART (7).
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Current HIV treatment guidelines still recommend the use of cART (8). At this 
moment, drugs from six different classes are available (figure 1, table 1).
Figure 1 Targets of the slx different classes of antiretroviral drugs.
Adapted from (50).
Nuc leos ide and nuc leo tide  ana logue reve rse  transc rip ta se  inh ib ito rs
Nucleoside analogue reverse transcriptase Inhibitors are pro-drugs that require 
Intracellular phosphorylation to their active tri-phosphate metabolites to become 
pharmacologically active. The triphosphate metabolites compete with the cell’s 
endogenous deoxynucleotide triphosphates for incorporation into the nucleic acid 
chain and, after incorporation, terminate the DNA chain by preventing addition of 
new bases (9). Tenofovir is a nucleofide analogue, because it already contains a 
phosphate group itself, in contrast to the nucleoside analogue reverse transcriptase 
inhibitors (10).
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Table 1 Overview of available antiretroviral drug classes in The Netherlands.
NRTIs NNRTIs Protease
inhibitors
Fusion
inhibitors
CCR5
receptor
antagonists
Integrase
inhibitors
Abacavir Efavirenz Atazanavir Enfuvirtide Maraviroc Raltegravir
Didanosine Etravirine Darunavir
Emtricitabine Nevirapine Fosamprenavir
Lamivudine Indinavir
Tenofovir Lopinavir
Stavudine Nelfinavir
Zidovudine Ritonavir
Saquinavir
Tipranavir
NRTIs, nucleoside analogue reverse transcriptase inhibitors, 
NNRTIs, non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reve rse  transc rip ta se  inh ib ito rs
Non-nucleoside reverse transcriptase Inhibitors (NNRTIs) decrease HIV-1 reverse 
transcriptase activity by allosteric inhibition but, unlike nucleoside analogue reverse 
transcriptase inhibitors, do not require intracellular phosphorylation to become 
pharmacologically active (11). Nevirapine and efavirenz were the first NNRTIs on 
the market. They are still used by many HIV-infected patients, both as part of the 
initial regimen or as part of a maintenance regimen after starting with a protease 
inhibitor-based cART regimen. Recently, a new NNRTI, called etravirine, was 
approved for the treatment of HIV-1 infection in treatment-experienced patients. 
Etravirine has a higher genetic barrier to the development of resistance than 
efavirenz and nevirapine have (12).
P ro tease inh ib ito rs
Protease inhibitors (Pis) inhibit the HIV protease enzyme and prevent cleavage of 
the gag-pol polyprotein, thus preventing nascent viral particles from reaching a 
mature, infectious state (13). A major advance in PI-based antiretroviral therapy has 
been the co-administration of PIs with a low ‘boosting’ dose of ritonavir, which 
increases PI drug exposure. This reduces the risk of emergence of resistance and 
has allowed twice-daily and, for some PIs, once-daily dosing (14;15).
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CCR5 antagon ists
Interaction of the HIV envelope with CD4 is followed by binding to an additional 
co-receptor, either the chemokine receptor CCR5 or the chemokine receptor 
CXCR4. In 2007, the first CCR5 co-receptor antagonist, maraviroc, was approved 
for the treatment of HIV-1 infection in treatment-experienced patients. Maraviroc is 
only useful in the treatment of patients who have HIV strains that utilize the CCR5 
co-receptor for cell-entry (‘R5-tropic HIV-1 virus’) (16).
Fusion inh ib ito rs
The first and still only available fusion inhibitor, enfuvirtide, was approved for the 
treatment of HIV-1 infection in treatment-experienced patients in 2003. Enfuvirtide 
is a synthetic peptide which binds to the HIV envelop glycoprotein 41, thereby 
preventing the fusion of viral and cellular membranes. Enfuvirtide has to be 
administered subcutaneously; local injection site reactions are common (17).
In teg rase inh ib ito rs
In 2007, the first HIV integrase inhibitor, raltegravir, was approved for the treatment 
of HIV-1 infection. Raltegravir acts by targeting the HIV integrase, thereby preventing 
the integration of HIV DNA into the genome of the human host-cell (18). In part II of 
this thesis, two drug-drug interaction studies with raltegravir are presented.
C lin ica l pharm aco logy
Clinical pharmacology is a biomedical science which focuses on pharmaco­
dynamics and pharmacokinetics of drugs in humans. Pharmacodynamics deals 
with the effect of drugs on the human body, while pharmacokinetics describes the 
effects of the human body on drugs, such as drug metabolism. For a number of 
antiretroviral drugs, relationships have been established between drug plasma 
concentrations (pharmacokinetics) and antiretroviral efficacy (pharmacodynamics) 
(19). Specifically for most PIs and NNRTIs, there is international consensus on 
concentration-based target concentrations for efficacy (8;19). Plasma concentrations 
below the lower threshold for efficacy may lead to higher rates of virologic failure 
and the development of drug resistance (20;21).
Adequate drug exposure is thus essential in the treatment of HIV. Nevertheless, 
obtaining adequate drug exposure in an individual can be challenging because of 
the considerable interindividual variability in plasma concentrations among patients 
taking the same dose (22).
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There are numerous factors which may lead to interindividual variations in pharma­
cokinetics, such as genetic constitution, gender, age, body weight, noncompliance 
or the occurrence of drug-drug interactions (23-29).
T he rapeu tic  d rug m onito ring
One tool to obtain optimal drug exposure in an individual is therapeutic drug 
monitoring (TDM). TDM pursues tailor-made antiretroviral therapy by using the 
individual’s plasma concentrations to select the optimal dose for that individual. 
The first part of this thesis focuses on the application of TDM in current clinical 
practice.
At the end of the 20th century, there were many problems with the early cART 
regimens, such as frequent inadequate absorption, large interpatient variability with 
frequent suboptimal or toxic exposure to antiretroviral agents, many drug-drug 
interactions and a high and frequent daily intake of pills. These problems were the 
incentive for introducing TDM into the HIV field. Ever since, many drugs that were 
used in the early cART regimens, such as indinavir and nelfinavir, have been 
replaced by drugs with better pharmacokinetic profiles. Consequently, the role of 
TDM has evolved. Chapter 1 provides a review of the current evidence for TDM, 
focusing on arguments which are in favor and arguments that refute the use of TDM 
in current clinical practice.
There are only two antiretroviral drugs for which a well-defined upper threshold 
plasma concentration for toxicity has been established, namely indinavir for renal 
toxicity and efavirenz for central nervous system (CNS) toxicity (19). For efavirenz, 
however, conflicting data exist. Some studies have reported an association between 
elevated efavirenz plasma concentrations and CNS disturbances (21;30-32), but 
other studies reported a lack of such an association (33-36). To provide more 
insight into this matter, we undertook the retrospective analysis described in 
chapter 2, which aimed to determine whether patients in the EuroSIDA study with 
high efavirenz plasma concentrations had an increased likelihood of toxicity-driven 
discontinuations of efavirenz.
Despite the conflicting data described above, pharmacists at our TDM practice 
advise dose reduction of efavirenz in patients with high plasma concentrations who 
suffer from persistent CNS disturbances. Anecdotally, this has been reported to be 
an effective intervention, but the outcome of this intervention had never been 
formally evaluated. The retrospective analysis with data from the ATHENA cohort
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study, described in chapter 3, evaluates whether dose reduction in patients with 
high efavirenz plasma is safe with regards to virologic efficacy and whether dose 
reduction reduces the risk of toxicity-driven efavirenz discontinuations. Chapter 4 
describes an HIV-tuberculosis co-infected patient who had unexpectedly high 
efavirenz plasma concentrations and concomitant CNS toxicities, despite 
co-administration of the strong enzyme inducer rifampicin. This chapter illustrates 
the value that TDM can have in individualized patient management.
In 2005, the Dutch Association of AIDS Physicians (NVAB) issued guidelines for the 
treatment and management of HIV-infected patients, including recommendations 
for Therapeutic Drug Monitoring (TDM) (37). Chapter 5 provides an evaluation of 
the uptake of these recommendations in the Dutch HIV treatment centres.
Drug-drug in te rac tions
As depicted above, drug-drug interactions may lead to undesirable low or high 
plasma concentrations of antiretroviral drugs. In addition, drug-drug interactions 
may lead to clinically significant changes in the pharmacokinetics of drugs that 
patients receive for the treatment of co-existing medical conditions (38). It is 
therefore important to study potentially relevant drug-drug interactions. The second 
part of this thesis contains four drug-drug interaction studies between antiretroviral 
drugs and drugs being used for the prevention and treatment of co-existing medical 
conditions.
The mechanism of many of the potential drug-drug interactions between antiretroviral 
drugs and concomitant drugs involves Cytochrome P450 (CYP450)-mediated 
metabolism (39). HIV-protease inhibitors may be both substrates, inducers and 
inhibitors of several CYP450 subtypes, whereas most NNRTIs are both substrates 
and inducers of this system.
Less attention has been paid to other types of drug-drug interactions, for instance 
via mediation of glucuronidation of drugs. Yet, PIs and NNRTIs may induce 
glucuronidation of concomitantly administered drugs and this may lead to clinically 
significant reductions in plasma concentrations of UDP-glucuronosyltransferase 
(UGT) substrates (40;41).
Atovaquone co-formulated with proguanil is frequently used by western HIV-infected 
patients who travel to malaria-endemic destinations. Atovaquone is considered a 
substrate for glucuronidation (42). Chronic use of PIs or NNRTIs may hence lead to
18
diminished atovaquone plasma concentrations and possibly suboptimal prophylaxis 
of malaria.
To study this potential problem, we designed the study described in chapter 6, 
which compared atovaquone/proguanil plasma concentrations between healthy 
volunteers and HIV-infected patients who were treated with efavirenz, lopinavir/ 
ritonavir, or atazanavir/ritonavir.
Chapters 7 and 8 describe drug-drug interaction studies of the recently approved 
HIV-1 integrase inhibitor raltegravir with lamotrigine and pravastatin, respectively. 
Raltegravir is metabolized by UGT1A1 and hence its pharmacokinetics can be 
influenced by inhibitors (e.g., atazanavir) or inducers (e.g., etravirine, tipranavir, 
rifampicin) of UGT1A1 (43-46). However, the influence of raltegravir itself on UGT 
substrates had not been evaluated in clinical studies. Therefore, we undertook the 
study described in chapter 7 to investigate the influence of raltegravir on the UGT 
substrate lamotrigine.
Dyslipidemia is a common complication during chronic HIV infection. One strategy 
to manage dyslipidemia is the use of lipid-lowering drugs. Pravastatin is considered 
a preferred lipid-lowering drug for HIV-infected patients (47;48) and frequent 
combined use of raltegravir and pravastatin can be expected in the ageing 
HIV-infected population (49). Because both drugs share a common metabolic 
pathway, we studied the effect of the new HIV-integrase inhibitor raltegravir on 
pravastatin pharmacokinetics and vice-versa (Chapter 8).
Fungal infections are among the most prevalent opportunistic infections in 
HIV-infected patients. It is thus important to study potential drug-drug interactions 
between antiretroviral drugs and antifungal drugs. Chapter 9 describes the 
drug-drug interaction study that we performed between the second generation 
triazole posaconazole and the protease inhibitor fosamprenavir. In this study we 
investigated whether ritonavir could be replaced by posaconazole as an alternative 
booster of the pharmacokinetics of fosamprenavir.
O b jec tives  of th is  thes is
All studies in this thesis focus on clinical pharmacology issues in HIV treatment. 
Part I of the thesis presents studies that were performed to obtain more insight into 
the use of TDM in current clinical practice. Part II of this thesis presents pharma­
cokinetic drug-drug interaction studies between antiretroviral drugs and drugs 
being used for the prevention and treatment of co-existing medical conditions. 
Finally, a general discussion is presented.
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Abstract
Purpose of review
Therapeutic drug monitoring is frequently used in several European countries, and 
international guidelines recommend it in selected cases. We discusses the main 
arguments for and against therapeutic drug monitoring in HIV infection.
Recent findings
Accumulating evidence favors the use of therapeutic drug monitoring in the 
management of drug concentration-related toxicities. Interindividual variability in 
the pharmacokinetics of antiretroviral drugs is at least partially caused by genetic 
polymorphisms. Additionally, body weight, sex and ethnicity have been identified 
as independent predictors of pharmacokinetics. Several studies have revealed 
subtherapeutic drug concentrations in children who were treated in accordance 
with the label information, which is in favor of therapeutic drug monitoring in children. 
The inhibitory quotient concept has been further explored, but more work is needed 
to justify full implementation into routine clinical practice. A limitation of therapeutic 
drug monitoring is the significant intraindividual variability in protease inhibitor 
concentrations. Furthermore, there is a lack of sufficiently powered randomized 
controlled trials that assess the use of routine therapeutic drug monitoring for 
current first-line antiretroviral drugs.
Summary
Although routine therapeutic drug monitoring cannot be recommended for current 
first-line antiretroviral drugs, there are many frequently encountered clinical 
situations in which therapeutic drug monitoring provides valuable information.
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Introduction
Therapeutic drug monitoring (TDM), namely use of drug concentrations to optimize 
antiretroviral therapy, is frequently used in some European countries, such as the 
UK, France and the Netherlands. In addition, the US department of Health and 
Human Services guidelines (1) and the British HIV Association guidelines (2) 
recommend the use of TDM for several categories of patients, such as those with 
suspected drug interactions, pregnant women and patients with hepatic 
dysfunction.
This review discusses relevant publications (published from January 2005 to 
November 2007), that favor or refute the use of TDM. Finally, the pros and cons are 
weighed in order to draw conclusions regarding the clinical utility of TDM in HIV 
disease.
Pro TDM: D rug concen tra tions co rre la te  w ith  v iro log ica l response
A prerequisite for the use of TDM is that antiretroviral drug concentrations correlate 
with virological response. Indeed, there is extensive evidence on concentration- 
response relationships for both protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), which has led to international consensus on the 
concentration-based cutoff values for performing TDM in antiretroviral therapy 
naïve patients (table 1) (3).
These cutoff values are not applicable to protease inhibitor experienced patients, 
who may need higher plasma concentrations because of the emergence of protease 
inhibitor-related mutations. Furthermore, concentration-based cutoff values have 
not been established for the fusion inhibitor enfuvirtide or for the nucleoside reverse 
transcriptase inhibitors (NRTIs). NRTIs are pro-drugs that require intracellular 
phosphorylation to become pharmacologically active and therefore plasma 
concentrations do not necessarily correlate with efficacy (3).
For enfuvirtide, there seems to be no correlation between plasma concentrations 
and virological response (4).
Pro TDM: The IQ concept m ight benefit trea tm ent-experienced patients
NNRTIs have a limited genetic barrier to resistance, because just one mutation can 
render them therapeutically ineffective. Consequently, it is generally thought that it 
is futile to try to overcome NNRTI resistance by increasing plasma concentrations. 
In contrast, for protease inhibitors the extent of a patient’s resistance is a result of 
the cumulative number of relevant protease inhibitor mutations, and there is
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Table 1 Cutoff concentrations (mg/L) for performing TDM of antiretroviral
agents in therapy-naive patients. Adapted with permission from (3).
Eficacy (Ctrough) Toxicity
Atazanavir 0.15
Fosamprenavir 0.40
Indinavir 0.10 C 10.0max
Lopinavir 1.0
Nelfinavir 0.80
Ritonavir8 2.1
Saquinavir 0.10
Tipranavir# 20.5
Efavirenz 1.0f 4.0f
Nevirapine 3.0f
& as a single PI
# in therapy-experienced patients
f for efavirenz and nevirapine, plasma concentrations can be randomly taken 
during the dosage interval
increasing evidence that raising plasma protease inhibitor concentrations to a level 
that exceeds the degree of resistance of a particular virus strain may help to 
overcome its reduced susceptibility (5).
To define an individualized target protease inhibitor plasma concentration based on 
the susceptibility of the virus, the inhibitory quotient concept has been introduced 
into HIV therapy, which combines the results of TDM and resistance testing (5).
Elsewhere, La Porte et al. (6) discuss the inhibitory quotient concept in greater 
detail. In summary, a number of recent retrospective observational studies have 
demonstrated that the genotypic inhibitory quotient (GIQ), which is defined as the 
ratio of the protease inhibitor trough concentration to the number of primary 
protease inhibitor-associated genotypic mutations in the HIV RNA (5), is significantly 
correlated with virological response (7-9;9-13). Moreover, the general picture is that 
the integration of resistance data with pharmacokinetics provides equal or better 
prediction of virological response than resistance data or pharmacokinetic data
3 0
alone. Notwithstanding this benefit, some limitations apply to the GIQ-concept. 
First, there is a need for standardization: different studies still use different lists of 
mutations to calculate the GIQ for the same protease inhibitor (9;14-16). Second, all 
mutations are weighed equally, although it is well established that not every mutation 
contributes equally to the degree of resistance. Finally, none of the proposed GIQ 
cut off values has been validated in prospective studies.
Pro TDM: TDM is a tool to manage concentration-related toxicities
There are relatively few data that relate plasma concentrations to toxicity. To date, 
the evidence is the strongest for indinavir, atazanavir and efavirenz.
Recent studies reported improved clinical outcomes in patients with high indinavir 
or efavirenz concentrations that received dose adjustments under the guidance of 
TDM. Two studies demonstrated improved renal function (17) and overall tolerability 
(18) in patients who underwent TDM-guided indinavir dose reduction. In both 
studies, virological suppression was maintained, which demonstrates the safety of 
this strategy.
High efavirenz plasma concentrations have been linked to central nervous system 
(CNS) toxicity and the study of Gutierrez et al. confirmed previous findings (19). 
Two other recent publications, however, have challenged the concept of there being 
a relation between efavirenz plasma concentrations and CNS toxicity (20) (21). 
Nevertheless, successful efavirenz dose reduction in terms of diminished drug 
toxicity has been described in patients with high efavirenz plasma concentrations, 
both in Japanese (22) and in Dutch HIV-infected patients (23). The Japanese study 
prospectively selected patients who had high (> 6.0 mg/L) efavirenz plasma 
concentrations because of single nucleotide polymorphisms of the CYP2B6 enzyme 
and observed an improvement of CNS-related adverse effects after dose reduction 
(22). The Dutch study retrospectively compared patients with high (>4.0 mg/L) 
efavirenz plasma concentrations who did or did not undergo dose reduction in 
routine clinical practice. After 1 year, there was a trend towards a decrease of 
toxicity-related efavirenz discontinuations in patients in whom the dosage was 
reduced (23). Both studies established the safety of TDM guided dose reduction 
with regards to virological suppression.
Several studies highlighted the existence of a relation between atazanavir plasma 
concentrations and its main adverse effect, namely increased serum bilirubin 
concentrations (13;24-27). Nevertheless, this side effect is usually asymptomatic
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and it may have to be accepted in return for efficacy in protease inhibitor-pretreated 
patients. Although there is a lack of formal evidence, TDM might be applied to 
reduce the dose of atazanavir in protease inhibitor-naïve patients with high atazanavir 
plasma concentrations (e.g., Ctrough > 0.63 mg/L (27)) who experience toxicity.
Pro TDM: There is large interindividual variability in pharmacokinetics
One of the main incentives to perform TDM in HIV disease management has been 
the marked interindividual variability in the pharmacokinetics of antiretroviral 
drugs. This was once more illustrated by Molto et al. who reported large inter 
individual variability for both protease inhibitors and NNRTIs in a routine outpatient 
setting (28).
New information was published on the patient characteristics that determine 
interpatient variability of antiretroviral drugs. The pharmacokinetics of atazanavir 
appeared significantly influenced by the 3435C>T polymorphism of the gene that 
encodes p-glycoprotein. Patients with two wild-type alleles had significantly higher 
plasma concentrations of atazanavir compared to patients with at least one mutant 
allele, both in boosted (25) and unboosted regimens (26).
The pharmacokinetics of efavirenz are influenced by gender and ethnicity, with 
higher efavirenz plasma concentrations in females and non-Caucasian patients 
(29-31), and there is evidence that interracial differences in CYP2B6 activity (32) 
play a role in the observed differences between races. Furthermore, female gender 
and positive hepatitis B status have been related to diminished nevirapine clearance 
(29), and body weight appeared to be inversely related to plasma concentrations 
of lopinavir (33).
Pro TDM: TDM is a tool for managing drug-drug interactions
Numerous potential drug interactions are yet to be formally studied, and the 
outcomes of such studies are sometimes unexpected (34). Repeated measurement 
of drug concentrations is advisable if a (potentially) interacting agent is started or 
withdrawn in order to prevent reduced efficacy or increased toxicity of antiretroviral 
treatment (35). Park-Willie et al. recently showed the importance of the appropriate 
handling of drug interactions, as patients with efavirenz-based interactions who 
received dosage adjustments had a significantly greater mean reduction in viral 
load than did patients with unadjusted dosages (36).
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Pro TDM: TDM may reveal non-adherence
Adherence to antiretroviral therapy is a key determinant of virological response. 
Unfortunately, there is no ‘gold standard’ with which to assess adherence. One of 
the tools used to measure adherence is TDM, which provides objective and direct 
proof of the presence of a drug in the patient’s body (37). Once one uses TDM to 
investigate adherence, it is important to recognize that a therapeutic drug 
concentration does not necessarily reflect good adherence, because it only reflects 
recent drug intake. On the other hand, an extremely low plasma concentration is an 
indication of poor adherence.
Pro TDM: Special patient populations may benefit from TDM
Patients with renal dysfunction or elevated liver enzymes are frequently excluded 
from clinical trials, and so there is relatively little knowledge on the behavior 
of antiretroviral drugs in these patient categories. Consequently, dose 
recommendations are frequently not available, especially in liver impairment (1). 
Nevertheless, liver impairment may have significant influence on antiretroviral drug 
pharmacokinetics. For example, Barreiro et al. showed that efavirenz plasma 
concentrations above the toxic threshold (>4.0 mg/L) were significantly more 
common among patients with liver cirrhosis. They observed a similar trend for 
nevirapine, but not for lopinavir and atazanavir (38). Another study, however, did 
demonstrate altered lopinavir pharmacokinetics in patients with moderate liver 
impairment (39). Clearly, there is a rationale for performing TDM in patients with 
moderate to severe hepatic impairment in order to prevent them from exposure to 
unnecessary high plasma concentrations.
Recent publications demonstrated a high prevalence of subtherapeutic efavirenz 
and lopinavir plasma concentrations among children who were dosed in 
accordance with current guidelines (40-42). These findings are in favor of routine 
TDM in children in order to prevent them from being underdosed. Moreover, TDM is 
an objective method for detecting non-adherence, which is a substantial problem 
in HIV-infected children.
A report on a pregnant woman who had a virological relapse associated with low 
nelfinavir plasma concentrations provided an important incentive to recommend 
use of TDM during pregnancy to prevent such episodes (43). Lowered exposure 
during the third trimester has also been demonstrated for lopinavir (44). As a result 
of the altered pharmacokinetics during pregnancy, frequent measurement of 
protease inhibitor plasma concentrations is advisable.
33
Ch
ap
ter
 1 
Us
e 
of 
the
rap
eu
tic
 
dru
g 
mo
nit
ori
ng
 
in 
HIV
 
dis
ea
se
Contra TDM: Only one component of the antiretroviral regimen is measured
Current treatment regimens exist of two NRTIs plus either a protease inhibitor or a 
NNRTI, but in TDM, plasma concentrations of only the protease inhibitor or the 
NNRTI are measured. It may appear inadequate to measure only one component 
of a regimen in an evaluation of virological response. Nonetheless, a number of 
studies have demonstrated a relation between the single NNRTI or protease inhibitor 
component and therapeutic response (3;45). TDM of a single component, therefore, 
may still contribute to improved response.
Contra TDM: Large intra-individual variability in antiretroviral TDM results
Large intra-individual variability limits the value of a single drug concentration 
measurement. Nettles et al. used frequent sampling in 10 HIV infected patients to 
obtain a total of 36 plasma samples per patient and reported modest and 
considerable intra-individual variability for the NNRTIs (25%) and the protease 
inhibitors (44%), respectively (46). The POPIN trial yielded similar results (47).
The main reason for significant intra-individual variability is probably the variation in 
compliance with regular drug intake, which has been reported to account for 55% 
of intra-individual variability (48). Noncompliance with food instructions and 
inaccurate reporting of the time of drug intake may also contribute to intraindividual 
variations in plasma protease inhibitor concentrations.
Given the considerable intraindividual variability, one must interpret with caution a 
single concentration measurement of an antiretroviral drug, particularly in the case 
of protease inhibitors. On the other hand, outlying plasma concentrations or highly 
fluctuating concentrations within an individual may indicate poor adherence. 
Suspicion of poor adherence is one of the indications for TDM (2).
Another more general conclusion is that important clinical decisions, such as dose 
adjustments, must not be made solely on the basis of a single blood concentration 
measurement. TDM will only benefit patient outcome if it is used as one the input 
factors in a decision-making process, along with other essential patient-related 
data, such as adherence history or viral load data. If the outcome of the decision 
making process is a dose adjustment for a protease inhibitor, it may be wise to 
repeat a concentration measurement if only one recent measurement is available.
Contra TDM: TDM does not measure unbound drug concentrations
Most currently used protease inhibitors and NNRTIs are highly bound to the plasma 
proteins alpha-1-acid glycoprotein (AAG) and/or albumin. Nevertheless, it is the
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free fraction of the drug that exerts its pharmacological effect. AAG is an acute 
phase protein and AAG concentrations may fluctuate during acute and chronic 
infections. In addition, the concentrations of albumin are prone to major decreases 
in patients with severe states of disease.
Little is known regarding the clinical relevance of this limitation of TDM. Nevertheless, 
it appears appropriate to interpret plasma concentrations with caution in unstable 
clinical conditions.
Contra TDM: Absence of evidence from Randomized Controlled Trials
In 2003, the results of randomized controlled trials provided indisputable evidence 
on the benefits of routine TDM in therapy-naïve patients who started on indinavir- 
containing or nelfinavir-containing antiretroviral regimens (45;49). At present 
however, we have entered a new era in which indinavir and nelfinavir have largely 
been replaced by drugs with better pharmacokinetic profiles.
The drugs that are currently in use as first-line agents (lopinavir/ritonavir, efavirenz, 
and nevirapine) provide sufficiently high plasma concentrations in the great majority 
of antiretroviral therapy naïve patients (31). The improved pharmacokinetic charac­
teristics of these drugs is reflected in the large numbers of participants that would 
be needed in prospective randomized controlled trials to obtain enough statistical 
power to judge the potential benefits of routine TDM. According to Khoo et al, 
approximately 1,000 to 2,000 patients would be required (47). For most clinical 
research groups it is not possible to conduct such a large and expensive trial.
In view of this, it is not surprising that both the POPIN trial and the recent study of 
Best et al. were unable to detect significant differences in virological suppression or 
toxicity in the TDM arms compared to the standard of care (SOC) arms in their 
studies (47) (50). The POPIN trial compared adherence support combined with 
TDM to SOC and included 122 patients; Best et al. obtained data from 190 patients. 
Clearly, both trials were statistically underpowered to detect a difference in 
virological suppression between the TDM and the SOC arms. It must be noted that 
Best et al. acknowledged this in advance. Their trial was designed to identify those 
patients who were most likely to achieve concentrations outside the therapeutic 
range, and they identified use of efavirenz, lopinavir/ritonavir and a high body weight 
as independent predictors of non-target concentrations (50).
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Conclusion on the clinical utility of TDM
Although both protease inhibitors and NNRTIs meet most of the requirements of 
candidacy for TDM, the currently available evidence does not allow one to 
recommend routine use of TDM in antiretroviral-naive patients. For treatment- 
experienced patients, the inhibitory quotient concept still is promising but its use 
urgently requires validation in prospective studies to clarify its role in routine clinical 
practice.
TDM may be recommended in those specific situations in which it is proven to be 
or likely to be beneficial. These situations include suspected non-adherence, 
manifestations of concentration-dependent toxicities, and all situations in which 
patients are more likely to achieve concentrations outside the therapeutic range, for 
instance use of antiretroviral drugs in children and pregnant women, and in patients 
taking drugs that may influence the pharmacokinetics of antiretroviral drugs.
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Abstract
Background: Conflicting data exist regarding the effect of efavirenz (EFV) plasma 
concentrations on central nervous system (CNS) toxicity. We aimed to determine 
whether patients with high EFV plasma concentrations have an increased likelihood 
of toxicity-driven EFV discontinuations.
Methods: EFV plasma concentrations were measured from patients in the EuroSIDA 
study starting EFV after 1 January 1999. Patients with a plasma concentration 
available were divided into those that discontinued EFV due to any toxicity or by the 
choice of the patient or physician within 2 years (TOXPC group) and those that 
continued EFV for > 2 years (no toxicity group). Multivariable logistic regression 
modeling was used to investigate the effect of the EFV plasma concentration and 
those of other potentially relevant factors on the risk of toxicity-induced EFV 
discontinuations.
Results: A total of 843 patients were included. Of these patients, 138 patients 
(16.4%) discontinued EFV due to TOXPC and 705 (83.6%) patients continued 
EFV for > 2 years. A total of 20 (14.5%) patients in the TOXPC group had high 
EFV plasma concentrations (>4.0 mg/L) compared to 99 (14.0%) of the patients in 
the no toxicity group, p=0.89. A positive hepatitis C status (p=0.026), but not the 
EFV plasma concentration, was an independent predictor of toxicity-driven EFV 
discontinuations.
Conclusions: No association was found between EFV plasma concentrations and 
the risk of EFV discontinuations because of (CNS) toxicity. This result questions the 
designation of EFV plasma concentrations >4.0 mg/L as being ‘toxic’, at least when 
defined by treatment discontinuation.
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Introduction
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is 
used as a first line agent in the treatment of HIV infection. It combines patient-comfort 
(one pill; once-daily dosing and no food restrictions) with potent antiretroviral 
activity and favorable safety properties (1;2).
A well-known disadvantage of EFV is its central nervous system (CNS) side effects, 
such as insomnia, dizziness and headache. In a large clinical trial, >50% of the 
patients treated with EFV-containing regimens experienced CNS adverse effects 
(3). However, CNS toxicity is usually transient and pooled data from controlled 
clinical trials show that only 2.7% of EFV-treated patients discontinued EFV because 
of CNS toxicity (4). Nonetheless, discontinuation might occur more frequently in 
clinical practice given the high discontinuation rates (13% and 24%) reported by two 
small observational studies (5;6).
A number of studies (6-9) have described a relationship between CNS toxicity and 
higher EFV plasma concentrations. This has led to an international consensus on a 
toxic threshold (that is, 4.0 mg/L) of EFV plasma concentrations in guidelines for 
therapeutic drug monitoring (TDM) (10). However, most of these studies had small 
sample sizes and routine TDM is currently not recommended for EFV because of a 
lack of data from large prospective trials (1;2). Moreover, several studies did not 
establish an increased risk of CNS toxicity in patients with EFV plasma concentrations 
>4.0 mg/L (11-14). Clearly, there still is a need for large studies on the relation 
between EFV pharmacokinetics and pharmacodynamics to provide more insight 
into the potential advantages of TDM of EFV.
An important outstanding issue is the consequence of interindividual differences 
in EFV pharmacokinetics in terms of treatment discontinuation. It is important to 
know whether patients with high EFV plasma concentrations are at increased risk 
of toxicity-induced EFV discontinuations. If so, routine application of TDM for EFV 
might prevent (unnecessary) discontinuations from this potent antiretroviral drug.
In the present study, we used the EuroSIDA database to study whether patients with 
high EFV plasma concentrations had an increased likelihood of toxicity-driven EFV 
discontinuations. Furthermore, we evaluated the influence of other potentially 
relevant factors, such as the hepatitis status of the patients, on the risk of EFV 
discontinuations because of toxicity.
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Methods
Patients
EuroSIDA is a prospective pan-European cohort study of >14,000 HIV type-1 
(HIV-1) infected patients in 93 centres from 31 countries across Europe (also 
including Israel and Argentina). Details have been previously published (15). 
At 6 monthly intervals, a blood sample is taken and stored for each patient, leading 
to the accumulation of a large sample repository. To date, no pharmacokinetic 
analyses have been performed on these samples. Although time between last 
intake and time of sampling is not noted, these samples could still be suitable for 
pharmacokinetic analyses of EFV because the long elimination half-life (40-55 h) of 
the drug results in minimal variability of plasma concentrations during a dose 
interval (7;16).
The EuroSIDA sample repository was searched for patients with a plasma sample 
collected after having started EFV treatment. Only patients that had started EFV 
after 1 January 1999 were included; reasons for discontinuation of antiretroviral 
agents were collected thereafter.
As only 30 patients with an available sample had discontinued EFV because of 
CNS toxicity, and to ensure that we were not missing any CNS-associated toxicity 
that might have been recorded as physician’s/patient’s choice, we divided patients 
into those that discontinued EFV because of any toxicity (including CNS toxicity) or 
patient’s/physician’s choice within 2 years (TOXPC group) and those that continued 
on EFV for > 2 years (no toxicity group). Patients that had discontinued EFV because 
of other reasons (for example, virologic failure) within 2 years were excluded.
For each included patient, one sample was analyzed to determine the EFV plasma 
concentration. Patients with an undetectable plasma concentration (<0.20 mg/L) 
were excluded to prevent bias caused by non-adherence.
EFV analyses
Plasma samples were analyzed at the laboratory of the Department of Clinical 
Pharmacy of the Radboud University Nijmegen Medical Centre (Nijmegen, The 
Netherlands) by a previously described validated reversed-phase HPLC method (17).
Statistical methods
Patient characteristics at the time of starting EFV were compared between patients 
who continued EFV for > 2 years, those who discontinued because of CNS toxicity 
and those who discontinued because of another toxicity or patient’s/physician’s
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choice. EFV plasma concentrations and proportions with high concentrations (>4.0 
mg/L) were compared in the TOXPC group versus the no toxicity group and in 
Caucasians versus non-Caucasian patients. They were also compared in the no 
toxicity group versus patients who discontinued because of CNS toxicity only. 
Chi-squared tests were used for categorical data and Kruskal-Wallis tests for 
continuous data. All tests were two-sided and a p-value of <0.05 was taken to be 
statistically significant.
Multivariable logistic regression modeling was used to investigate the effects of EFV 
plasma concentration on whether EFV was discontinued because of toxicity, after 
adjustment for potentially confounding variables. Factors that were significant in 
univariable analyses (p<0.10) were included in multivariable analyses and a stepwise 
selection method was used to confirm final model selection. The factors investigated 
included gender, ethnicity, HIV exposure group, region of Europe in which patients 
visited the clinical centre, prior diagnosis of any AIDS defining illness, hepatitis B virus 
(HBV) and hepatitis C virus (HCV) status, whether patients had previously received 
antiretroviral therapy (ART), number of drugs in regimen, calendar year of starting 
EFV, age, baseline CD4 count, nadir CD4 count, viral load, time from HIV positive 
diagnosis and type of nucleoside analogue reverse transcriptase inhibitor (NRTI) 
backbone. Analyses were repeated in the subset of patients with baseline weight and 
height available, adjusting for body mass index (BMI; weight in kg/ height in m2). 
Sensitivity analyses were carried out with the outcomes: whether patients discontinued 
EFV because of CNS toxicity, whether patients discontinued any drug in the 
EFV-based regimen and whether patients discontinued EFV within 6 months because 
of toxicity. SAS software version 9.1 (SAS institute, Cary, North Carolina, USA, 
2002-2003) was used for all statistical analyses.
Results
A total of 872 patients met the inclusion criteria and had plasma samples collected 
after having started EFV. Of these patients, 29 (3.3%) were excluded from further 
analysis because their plasma samples did not contain EFV; thus, 843 patients 
were included in the study.
In Table 1, patient characteristics are compared between 705 (83.6%) patients in 
the no toxicity group and 138 (16.4%) patients in the TOXPC group, which is split 
into those who discontinued because of CNS toxicity (n=30, 3.6%) and those who 
discontinued because of another toxicity or patient’s/physician’s choice (n=108, 
12.8%).
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Table 1 Patient characteristics at start of EFV treatment.
Characteristic Total Continued
on EFV
n % n %
All patients 843 100.0 705 83.6
Male 677 80.3 565 80.1
Exposure group
IDU 119 14.1 97 13.8
Other 724 85.9 608 86.2
Ethnicity
Caucasian 776 92.1 643 91.2
Non-Caucasian 67 7.9 62 0000
Region of Europe
North 413 49.0 333 47.2
South 99 11.7 77 10.9
Central West 171 20.3 153 21.7
East 160 19.0 142 20.1
Previous AIDS 267 31.7 226 32.1
Hepatitis B status
Negative 644 76.4 533 75.6
Positive 55 6.5 45 6.4
Unknown 144 17.1 127 18.0
Hepatitis C status
Negative 445 52.8 383 54.3
Positive 131 15.5 103 14.6
Unknown 267 31.7 219 31.1
Discontinued EFV 
because of 
CNS toxicity
Discontinued EFV 
because of 
other toxicitiesa P-value
n % n %
30 3.6 108 12.8 -
28 93.3 84 77.8 0.16b
0.27b
4 13.3 18 16.7 -
26 86.7 90 83.3 -
0.12b
29 96.7 104 96.3 -
1 3.3 4 3.7 -
0.004b
23 76.7 57 52.8 -
2 6.7 20 18.5 -
3 10.0 15 13.9 -
2 6.7 16 14.8
9 30.0 32 29.6 0.86b
0.42b
25 83.3 86 79.6 -
3 10.0 7 6.5 -
2 6.7 15 13.9
0.25b
12 40.0 50 46.3 -
6 20.0 22 20.4 -
12 40.0 36 33.3 -
Previous ART 670 79.5 552 78.3 24 80.0 94 87.0 0.11b
Number of ART drugs 
in regimen
0.42b
< 3 588 69.8 497 70.5 20 66.7 71 65.7 -
4 161 19.1 136 19.3 5 16.7 20 18.5 -
> 5 94 11.2 72 10.2 5 16.7 17 15.7 -
Median IQR Median IQR Median IQR Median IQR
EFV plasma concentration (mg/L) 2.2 1.6-3.2 2.2 1.6-3.3 2.6 1.9-3.9 2.3 1.6-3.0 0.51c
Date of starting EFV 4/01 1/00-9/02 4/01 2/00-10/02 1/02 1/00-6/03 2/01 12/99-2/02 0.12C
Date of enrolment 06/97 11/96-11/01 07/97 01/97-11/01 02/97 07/94-03/99 04/97 02/97-05/99 0.033‘
Age (yrs) 41 35-49 41 35-49 41 35-49 42 36-48 0.99°
CD4 count (/mm3)
Baseline"1 359 205-538 353 204-529 353 250-590 403 207-573 0.56°
Nadir0 131 50-220 129 49-214 141 47-249 161 67-237 0.18C
Time from nadir (months) 37 6-60 37 5-59 49 18-70 36 11-57 0.37°
Viral load (log10copies/mL)
Baseline' 3.2 1.7-4.7 3.1 1.7-4.7 3.9 1.7-4.8 3.5 1.7-4.8 0.62°
Maximum9 4.9 4.2-5.4 4.9 4.2-5.4 5.0 4.2-5.3 5.0 4.0-5.5 0.98°
Time from HIV-1 diagnosis (months)1 92.1 48-141 91.0 46-139 116.0 75-176 97.1 51-154 0.014‘
Baseline weight (kg)1 70.4 62-77 70.1 63-77 76.0 65-80 71.2 61-77 0.34°
Height (cm)' 176.0 170-181 176.0 170-181 178.0 172-182 175.0 170-180 0.51c
“Including patients who discontinued etavlrenz (EFV) because of patient’s/physician’s choice. bChl-squared tests and 'Kruskal-Wallis tests were used. 
dBaseline CD4 count was available for 819 patients. eNadlr CD4 count was available for 839 patients. 'Baseline viral load was available for 803 patients. 
¡Maximum viral load was available for 826 patients. hDate of HIV type-1 (HIV-1) diagnosis was available for 831 patients. 'Baseline weight was available 
for 484 patients. 'Height was available for 772 patients.
CNS, central nervous system; IDU, Intravenous drugs use; IQR, interquartile range.
-l^
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Other toxicities included 9 patients with clinical fat abnormalities, 4 with dyslipidemia, 
1 with a hypersensitivity reaction, 11 with toxicity in the abdomen/gastrointestinal 
tract, 1 with toxicity in the endocrine system and 23 with any other toxicity. A total of 
33 patients discontinued because of their own choice and 26 because of the 
physician’s choice. The median (interquartile range (IQR)) duration of EFV treatment 
before EFV discontinuation was 12 (7-17) months and 10 (6-19) months in the 
TOXPC and CNS toxicity groups, respectively.
Characteristics were mostly similar between all three groups; however, the 
distribution of patients across the EuroSIDA geographical regions differed 
significantly with 23 out of the 30 (76.7%) patients who discontinued because of 
CNS toxicity coming from the north of Europe. The majority of patients (79.5%) were 
ART-experienced when they started EFV. These patients had a median (IQR) 
duration of previous treatment of 67 (43-92) months.
EFV plasma concentrations
In the 843 plasma samples with detectable EFV plasma concentrations, the median 
(range) EFV plasma concentration was 2.2 (0.2-25.5) mg/L. A total of 50 samples 
(5.9%) contained a subtherapeutic EFV plasma concentration (<1.0 mg/L). By 
contrast, a total of 119 samples (14.1%) contained a high EFV plasma concentration 
(>4.0 mg/L).
TOXPC group versus no toxicity group
No significant difference was found in the EFV plasma concentrations between the 
TOXPC group and the no toxicity group (median [range] 2.3 [0.6-12.3] mg/L versus
2.2 [0.2-25.5] mg/L, respectively, p=0.68). A total of 20 (14.5%) patients in 
the TOXPC group had EFV concentrations > 4.0 mg/L compared with 99 (14.0%) of 
the patients in the no toxicity group (p=0.89).
From the TOXPC group, 30 patients discontinued because of CNS toxicity. Again 
there was no significant difference in median concentrations between the CNS 
toxicity group and the no toxicity group (median [range] 2.6 [0.9-11.3] mg/L versus
2.2 [0.2-25.5] mg/L, respectively, p=0.24). There was also no significant difference 
between the proportions of patients with high concentrations in the CNS toxicity 
group compared with the no toxicity group (16.7% versus 14.0%, respectively 
(p=0.60)).
Caucasians versus non-Caucasians
A total of 776 Caucasian patients and 67 non-Caucasian patients were included in 
the analyses, of whom 16 (23.9%) were Asian and 51 (76.1%) were Black. There was
50
a borderline significant difference in EFV plasma concentrations between 
Caucasians and non-Caucasians (median [range] 2.2 [0.2-25.5] mg/L versus 2.6 
[0.4-21.9] mg/L, respectively, p=0.081).
A significantly higher proportion of non-Caucasian patients were found to have high 
concentrations of EFV (18 [26.9%] non-Caucasians versus 101 [13.0%] Caucasians 
had EFV plasma concentrations >4.0 mg/L, p=0.002).
Factors affecting discontinuation of EFV because of TOXPC
Univariable logistic regression models showed that factors such as the region of 
Europe in which patients visited a clinical centre, HCV status, whether patients had 
previously received ART, the type of NRTI backbone started as part of the regimen 
and nadir CD4 count significantly affected whether patients discontinued EFV 
because of toxicity. A stepwise selection method also identified baseline viral load 
as significant after adjustment. In a multivariable model containing all these 
variables, there was no significant difference in the odds of discontinuation between 
patients with an EFV plasma concentration of <1.5 mg/L compared with 1.5-1.9 
mg/L (p=0.90), 2.0-2.9 mg/L (p=0.73) or > 3.0 mg/L (p=0.77). Patients with a 
positive HCV status had an 87% increased odds of discontinuation when compared 
with patients with a negative HCV status (p = 0.026) and there was a borderline 
significant difference for ethnicity with non-Caucasians having a 59% reduced odds 
of discontinuation compared with Caucasians (p=0.072; Table 2).
In a subset of 449 patients with baseline weight and height data available, BMI was 
also entered as a categorical covariate in the model, with the categories BMI <18.5, 
18.5-25 and >25 kg/m2. There was a borderline significant difference in median 
(IQR) EFV plasma concentrations between these three BMI groups: 3.4 ( 2.0-4.1) 
mg/L, 2.4 (1.6-3.4) mg/L and 2.2 (1.6-2.9) mg/L, respectively, for <18.5, 18.5-25 
and > 25 kg/m2 (p=0.056). In the multivariable model, BMI was not found to be a 
significant predictor for toxicity-induced EFV discontinuations, p=0.71.
Sensitivity analyses
A total of 30 patients discontinued EFV because of CNS toxicity only. After 
adjustment for the variables as in the main analysis, no significant differences were 
found in the odds of discontinuation because of CNS toxicity between patients with 
different EFV plasma concentrations (Table 3).
A total of 246 patients discontinued > 1 drug because of toxicity within 2 years of 
starting the EFV-based regimen. Of these patients, 40 (16.3%) discontinued their 
first drug because of CNS toxicity.
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Table 2 Odds ratios and 95% confidence intervals for d iscontinuation of EFV due to TOXPC
Univariable Multivariable
OR 95% Cl P OR 95% Cl P
EFV plasma concentration
<1.5 mg/L 1.00 - - 1.00 - -
1.5-1.9 mg/L 1.01 (0.56, 1.82) 0.97 1.04 (0.56, 1.93) 0.90
2.0-2.9 mg/L 1.17 (0.70, 1.94) 0.56 1.10 (0.64, 1.88) 0.73
>3.0 mg/L 1.02 (0.61, 1.72) 0.93 0.92 (0.52, 1.61) 0.77
Ethnicity
Caucasian 1.00 - - 1.00 - -
Non-Caucasian 0.39 (0.15, 0.99) 0.047 0.41 (0.16, 1.08) 0.072
Region
North 1.00 - - 1.00 - -
South 1.19 (0.70, 2.03) 0.52 0.96 (0.53, 1.75) 0.90
Central West 0.49 (0.28, 0.85) 0.010 0.43 (0.24, 0.77) 0.004
East 0.53 (0.31, 0.91) 0.022 0.33 (0.17, 0.64) 0.001
Hepatitis C status
Negative 1.00 - - 1.00 - -
Positive 1.68 (1.02, 2.76) 0.041 1.87 (1.08, 3.23) 0.026
Unknown 1.35 (0.90, 2.04) 0.15 1.19 (0.76, 1.85) 0.45
Previous ART 1.64 (0.99, 2.71) 0.057 2.34 (1.21, 4.53) 0.012
Type of NRTI backbone
ZDV/3TC 1.00 1.00
ddl/d4T 2.40 (1.26, 4.55) 0.008 2.61 (1.28, 5.31) 0.009
ddl/3TC 0.21 (0.03, 1.58) 0.13 0.21 (0.03, 1.60) 0.13
ddl/ABC 1.21 (0.39, 3.76) 0.75 0.99 (0.29, 3.38) 0.98
d4T/3TC 1.05 (0.60, 1.84) 0.87 1.24 (0.68, 2.25) 0.48
d4T/ABC 0.52 (0.12, 2.29) 0.39 0.44 (0.09, 2.07) 0.30
3TC/ABC 1.06 (0.46, 2.43) 0.90 1.01 (0.42, 2.41) 0.99
Other dual NRTI 0.46 (0.16, 1.36) 0.16 0.41 (0.13, 1.27) 0.12
> 2 NRTIs 1.23 (0.65, 2.31) 0.52 1.00 (0.51, 1.98) 0.99
< 2 NRTIs 1.09 (0.62, 1.94) 0.76 1.19 (0.62, 2.28) 0.60
Baseline viral load (copies/mL)
< 500 1.00 1.00
500-10,000 1.08 (0.63, 1.85) 0.77 1.24 (0.69, 2.25) 0.47
>10,000 1.38 (0.92, 2.09) 0.12 2.24 (1.35, 3.72) 0.002
Missing 1.26 (0.53, 3.00) 0.60 3.22 (1.21, 8.61) 0.020
Nadir CD4 count per 100 cells/mm3 increase 1.13 (0.98, 1.30) 0.085 1.27 (1.08, 1.49) 0.005
OR, Odds ratio; Cl, confidence Interval; ART, antiretroviral therapy; EFV, efavirenz; NRTI, nucleoside analogue reverse transcriptase Inhibitor; ABC, abacavlr; AZT, 
zidovudine; ddl, didanoslne; d4T, stavudine; 3TC, lamivudlne; TOXPC, discontinuation because of toxicity or by choice of the patient or physician.
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Table 3 Odds ratios and 95% confidence intervals for d iscontinuation of EFV because of CNS toxicity.
Univariable Multivariable
OR 95% Cl P OR 95% Cl P
EFV plasma concentration
<1.5 mg/L 1.00 1.00
1.5-1.9 mg/L 0.63 (0.16, 2.58) 0.52 0.63 (0.15, 2.65) 0.53
2.0-2.9 mg/L 1.32 (0.47, 3.72) 0.60 1.38 (0.48, 3.99) 0.55
> 3.0 mg/L 1.41 (0.51, 3.89) 0.51 1.59 (0.55, 4.62) 0.40
Ethnicity
Caucasian 1.00 1.00
Non-Caucasian 0.36 (0.05, 2.67) 0.32 0.28 (0.04, 2.16) 0.22
Region
North 1.00 1.00
South 0.38 (0.09, 1.63) 0.19 0.26 (0.06, 1.18) 0.081
Central West 0.28 (0.08, 0.96) 0.043 0.24 (0.07, 0.84) 0.026
East 0.20 (0.05, 0.88) 0.033 0.11 (0.02, 0.57) 0.008
Hepatitis C status
Negative 1.00 1.00
Positive 1.86 (0.68, 5.07) 0.23 2.39 (0.82, 6.94) 0.11
Unknown 1.75 (0.77, 3.96) 0.18 1.47 (0.63, 3.44) 0.38
Previous ART 0.90 (0.36, 2.25) 0.83 1.00 (0.32, 3.14) 1.00
Type of NRTI backbone
ddl/d4T 1.00 1.00
Other 0.91 (0.21, 3.94) 0.90 0.59 (0.13, 2.70) 0.49
Baseline viral load (copies/mL)
< 500 1.00 1.00
500-10,000 0.86 (0.27, 2.74) 0.80 0.98 (0.30, 3.25)
> 10,000 1.52 (0.68, 3.40) 0.31 1.97 (0.78, 4.97)
Missing 0.82 (0.10, 6.54) 0.85 3.10 (0.33, 29.2)
Nadir CD4 count (per 100 cells/mm3 increase) 1.05 (0.79, 1.40) 0.75 1.09 (0.78, 1.53)
OR, Odds ratio; Cl, confidence Interval; ART, antiretroviral therapy; CNS, central nervous system; ddl, dldanosine; d4T, stavudlne; EFV, efavirenz; 
NRTI, nucleoside analogue reverse transcriptase Inhibitor.
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Factors found to significantly affect whether patients discontinued > 1 drug were 
gender, region of Europe, HBV and HCV status, whether patients had previously 
received ART, the number of drugs in the regimen, the type of NRTI backbone and 
nadir CD4 counts; therefore, these were adjusted for in the multivariable model. No 
significant differences were found in the odds of discontinuation of any of the drugs 
in the regimen between patients with an EFV plasma concentration of <1.5 mg/L 
compared with 1.5-1.9 mg/L (adjusted odds ratio [OR] 1.10, 95% CI: 0.65-1.88, 
p = 0.73), 2.0-2.9 mg/L (adjusted OR: 1.17, 95% CI: 0.74-1.85, p=0.51) or > 3.0 mg/L 
(adjusted OR: 1.09, 95% CI: 0.69-1.74, p=0.70).
A total of 22 patients discontinued EFV within 6 months of starting treatment, 
1 patient (4.5%) because of toxicity in the gastrointestinal tract, 8 (36.4%) because 
of CNS toxicity, 5 (22.7%) with any other toxicity, 4 (18.2%) discontinued as their 
own choice and 4 (18.2%) because of physician’s decision. Factors found to 
significantly affect this were year of starting EFV, age and baseline viral load; 
therefore, these were adjusted for in the multivariable model.
No significant differences were found in the likelihood of discontinuation within 
6 months between patients with an EFV plasma concentration of <1.5 mg/L 
compared with 1.5-1.9 mg/L (adjusted OR: 0.25, 95% CI: 0.03-2.12, p=0.20), 2.0-2.9 
mg/L (adjusted OR: 0.81, 95% CI: 0.23-2.79, p=0.74) or > 3.0 mg/L (adjusted OR:
1.90, 95% CI: 0.62-5.79, p=0.26).
Discussion
The results of our study show no apparent association between EFV plasma 
concentrations and drug discontinuations because of toxicity. Some other 
factors, however, were identified as independent predictors for toxicity-related 
EFV discontinuations.
Patients with an HCV-positive status had an 87% increased odds for toxicity- 
induced EFV discontinuations, which is probably caused by increased hepatotoxicity 
of EFV in patients with HCV co-infection (18-20). The mechanism behind this is not 
fully understood, but several factors might play a role (18;21). One mechanism is 
immune reconstitution. Liver damage in patients with chronic hepatitis C infection 
is predominantly immune-mediated and highly active antiretroviral therapy-induced 
immune restoration could thus result in hypertransaminasemia or even exacerbation 
of chronic hepatitis (21) (22). Another hypothesis is that HCV- coinfected patients
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have impaired drug metabolism, leading to increased drug exposure and 
consequently increased drug toxicity (18). Nonetheless, recent data showed that 
chronic hepatitis C in itself does not modify EFV plasma exposure (23); only patients 
with liver cirrhosis have increased EFV plasma concentrations (24). Because the 
present study did not find a relation between drug exposure and toxicity-related 
EFV discontinuations, this mechanism seems less relevant, at least in this cohort of 
patients.
Another factor that was positively correlated with EFV discontinuations because of 
toxicity was the use of didanosine/stavudine as an NRTI backbone. This result 
should be attributed to the toxicity of this backbone (for example, peripheral 
neuropathy) (25) and is probably not directly related to EFV toxicity.
Because previous reports showed increased EFV plasma concentrations in 
non-Caucasian patients (26-30), we compared EFV plasma concentrations between 
Caucasians and non-Caucasian patients. Indeed, a significantly higher proportion 
of non-Caucasian patients had high EFV plasma concentrations. Median EFV 
plasma concentrations were only borderline statistically different, which is probably 
caused by the low number of non-Caucasian patients included and the consequently 
limited power for this analysis.
EFV is predominantly metabolized by the polymorphic Cytochrome P450 2B6 
(CYP2B6) enzyme (31) (32). Increased EFV plasma exposure in non-Caucasian 
patients is at least partially explained by a higher frequency of certain single 
nucleotide polymorphisms of CYP2B6 (30;32;33). The 516 G>T and the 785 A>G 
polymorphisms, which are both more common among non-Caucasians, together 
characterize the CYP2B6*6 allele (32). Individuals homozygote for CYP2B6*6 were 
shown to have on average 4 times higher plasma exposure to EFV (32) and lowering 
the EFV dose or even starting on a lower dose appeared feasible in *6 /*6  carriers 
(34). In addition, 983T>C polymorphism, which has been only observed in Hispanic 
and African populations, is strongly associated with increased EFV exposure (33).
The clinical consequences of ethnic differences in EFV pharmacokinetics are 
largely unknown. In the large clinical trial ACTG A5095, Gulick et al. observed an 
increased risk of virologic failure among non-Hispanic Black patients. The authors 
speculated that increased EFV-plasma exposure in Black patients might have 
resulted in less tolerability and compromised adherence and thus leading to higher 
rates of virologic failure (35). In the current study, there was no significant difference 
of toxicity-induced EFV discontinuations among patients of non-Caucasian or
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Caucasian ancestry. Given the low number of non-Caucasians included (7.9%), this 
result should be interpreted with caution.
It is important that additional data from other large and diverse cohorts are 
forthcoming to further address the consequence of ethnic differences in EFV 
pharmacokinetics in terms of (CNS) toxicity, adherence and efficacy.
Regardless of race, this analysis did not demonstrate any significant relationship 
between EFV pharmacokinetics and (CNS) toxicity-induced discontinuations. There 
are several explanations for this result.
The first explanation could be that there is no strong relationship between CNS side 
effects and EFV plasma concentrations. Although a number of other studies did 
establish such a relationship (6-9), several other studies did not, including the 2NN 
study (11), the Swiss HIV cohort study (13) and two smaller prospective studies that 
were performed in Sweden (12) and Japan (14). An explanation for the latter results 
might be found in the development of tolerance to CNS toxicity. This phenomenon 
was extensively described in the ACTG A5097s study (36), in which the presence of 
the CYP2B6 516 T/T genotype was associated with EFV CNS toxicity at week 1 
after initiation of EFV therapy, but not at week 24 despite persistently higher EFV 
plasma exposure (30).
Part of the explanation for the observed absence of a relationship between efavirenz 
plasma concentrations and toxicity-driven discontinuations might also be that this 
analysis had limited power because of the low number of patients that were reported 
to have discontinued EFV as a result of CNS toxicity. Of the 3,238 patients who 
started EFV after 1 January 1999, 256 (7.7%) discontinued EFV because of CNS 
toxicity; however, only 30 of those 256 patients had a plasma sample available.
A comparison between these 30 patients and the 226 patients who did not have a 
plasma sample available showed that their characteristics were mostly similar, 
including the proportion of Caucasians in each group. However, patients with a 
sample available were enrolled earlier into the EuroSIDA study (p<0.001) and more 
of these patients were from the north of Europe than patients without a sample 
(p<0.001).
Remarkably, a strong association was found between the geographical EuroSIDA 
region and the risk for CNS toxicity-induced discontinuations, with 23 out of the 
30 patients that discontinued EFV because of CNS toxicity coming from the north 
of Europe. This result suggests that some centres are more aware or more active in
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reporting CNS toxicity as a reason for discontinuation and this phenomenon might 
have also limited the power of this analysis. In an attempt to overcome this lack of 
power, and to ensure that we were not missing any CNS-associated toxicities that 
might have been recorded as physician’s/patient’s choice, we compared patients 
that discontinued EFV within 2 years because of any toxicity (including patient’s/ 
physician’s choice) to those who did not discontinue EFV in our statistical 
analyses.
A third explanation for our results might be found in the population that we have 
been investigating. The majority of our cohort (670 patients, 79.5%) was treatment- 
experienced at the moment of EFV initiation with a median treatment duration of 5-6 
years. Many of these patients might have been using protease inhibitor-based (for 
example, indinavir and nelfinavir) regimens with difficult dosing schedules and 
tedious side effects before initiating EFV. It is imaginable that some of these patients, 
despite CNS toxicity, were motivated to continue EFV therapy.
In conclusion, we observed no apparent association between EFV plasma 
concentrations and toxicity-driven discontinuations among patients in the EuroSIDA 
study. This result questions the designation of EFV concentrations > 4.0 mg/L as 
being ‘toxic’, at least when defined by treatment discontinuation.
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Abstract
Objective: To establish whether efavirenz dose reduction in patients with high 
plasma concentrations prevents toxicity-induced efavirenz discontinuations. 
Methods: HIV-infected patients with a high efavirenz plasma concentration (> 4.0 
mg/L) while using efavirenz 600 mg once-daily as part of their HAART regimen 
were selected from the ATHENA cohort study. These patients were classified into 
two groups. The reduced dose group contained all patients who underwent dose 
reduction following the high plasma concentration measurement; the standard 
dose group consisted of patients who had no dose reduction. Kaplan-Meier and 
Cox proportional hazards analysis were used to assess the impact of dose reduction 
on toxicity-induced efavirenz discontinuations.
Results: 180 Patients with high efavirenz plasma concentrations were included, 
47 of which subsequently had their efavirenz dose reduced from 600 mg to 400 mg 
once-daily, which resulted in a 41% decrease in the median efavirenz plasma 
concentration. At week 48, the Kaplan-Meier estimated cumulative incidence of 
toxicity-induced efavirenz discontinuations was 11.5% in patients who continued 
the standard dose versus 2.3% in patients who had a dose reduction; p=0.066 
(log-rank test). Dose reduction was not associated with loss of virologic 
suppression.
Conclusion: Dose reduction may prevent toxicity-induced discontinuations in 
patients with high efavirenz plasma concentrations, while not compromising 
virologic efficacy.
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Introduction
Therapeutic drug monitoring (TDM) has been advocated as a means to optimize 
the safety and efficacy of antiretroviral therapy. Nevertheless, apart from indinavir 
and nelfinavir in treatment-naive HIV-infected patients (1;2), there is no evidence 
from randomized controlled trials that TDM improves therapeutic outcome (3).
Standard dosing of efavirenz (EFV), a currently preferred first-line antiretroviral 
agent, leads to therapeutic plasma concentrations in at least 80% of the HIV infected 
individuals (4)(5), compared to just 40% for older agents such as nelfinavir (1). As a 
consequence, large and expensive trials, with more than 500 patients per treatment 
arm (6), are required to obtain adequate statistical power to judge the potential 
benefits of the application of TDM as a routine measurement in all patients taking 
EFV. Therefore, we agree with Khoo et al. that in the present situation, the value of 
TDM is best assessed by performing ‘utilitarian’ studies (6). The goal of these 
studies is not to provide evidence for routine use of TDM, but to explore the use of 
TDM in specific clinical situations. These studies should for instance focus on the 
use of TDM during pregnancy or the use of TDM in patients with severe liver 
impairment. In this paper, we describe the use of TDM to manage EFV-related 
toxicity.
Central nervous system (CNS) side effects are a well-known and frequently 
occurring complication of EFV therapy (7). Several reports have demonstrated the 
relationship of these side effects to high EFV plasma concentrations (4;8-11). 
In addition, there is international consensus on a therapeutic window for EFV plasma 
concentrations: 1.0-4.0 mg/L (12).
At our TDM practice, we regularly receive requests for TDM in patients using EFV 
who suffer from CNS side effects. In case these patients are found to have high 
EFV plasma concentrations (> 4.0 mg/L), our advice to the clinicians is to reduce 
the dose of EFV to 400 mg once-daily (QD) under the guidance of TDM. However, 
we have no formal evidence that this intervention improves the clinical outcome of 
these patients.
The objective of the present study was to establish whether EFV dose reduction 
prevents toxicity-induced EFV discontinuations in patients with high plasma 
concentrations. In addition, we aimed to evaluate whether dose reduction affects 
virologic efficacy.
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Methods
Patients
All 25 Dutch hospitals that provide antiretroviral treatment participate in the AIDS 
Therapy Evaluation in The Netherlands (ATHENA) observational cohort study. 
Currently, data from over 15,000 patients have been anonymously recorded in a 
central database that is maintained by the HIV Monitoring Foundation (13).
We selected all patients in ATHENA who had a high EFV plasma concentration 
(i.e., > 4.0 mg/L) recorded within 48 weeks after commencing EFV-based 
antiretroviral combination therapy. This cohort was subsequently classified into two 
groups. The Reduced Dose (RD) group consisted of those who underwent dose 
reduction following the high plasma concentration determination. The date of dose 
reduction was considered baseline. The Standard Dose (SD) group consisted of 
patients who continued the standard EFV dosage (i.e., 600 mg QD). For them, 
baseline was the first documented clinic visit following the high EFV plasma 
concentration measurement.
Statistics
Patient characteristics at the time of starting EFV were tabulated for patients in the 
RD group and the SD group. Differences between groups were compared using 
Chi-squared or Fisher’s exact tests for categorical data and Mann-Whitney tests for 
continuous data. All tests were two-sided and a p-value of less than 0.05 was 
considered statistically significant.
Pharmacokinetics
EFV plasma concentrations before and after baseline were compared by using the 
Wilcoxon matched pairs signed rank sum test. For patients that underwent dose 
reduction, the EFV plasma concentration after baseline had to be taken at least 10 
days after the date of dose reduction in order to have achieved new steady state 
conditions.
Toxicity-induced discontinuations
Reasons for discontinuation of antiretroviral agents are collected in the ATHENA 
database. Kaplan-Meier and Cox proportional hazards analysis were used to 
assess the impact of dose reduction on toxicity-induced EFV discontinuations. 
Patients who discontinued EFV for reasons other than toxicity were censored from 
the moment of discontinuation. Possible effect-measure modification and
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confounding were assessed for the following parameters: gender, region of origin 
(as a surrogate for ethnicity), age, body mass index (calculated as the weight in 
kilograms divided by the square of the height in meters), hepatitis B and C status, 
HIV transmission risk group, CD4 count at the start of EFV, specific NRTI backbone, 
the EFV concentration before baseline and pre-treated status at the start of EFV. 
Pre-treated status was categorized as follows: i) treatment naïve patients that 
started EFV; ii) treatment experienced patients with an undetectectable viral load 
(<50 copies/mL) at the start of EFV; iii) treatment experienced patients with a 
detectectable viral load at the start of EFV.
Virologic response
Multivariable logistic regression modeling was used to investigate the effect of dose 
reduction on virologic response, which was defined as having a viral load below 50 
copies/mL at week 24 after baseline.
We used an observed-failure approach in which patients who discontinued EFV 
due to virologic failure were considered failures at subsequent time points, whereas 
patients who discontinued EFV due to other reasons (e.g., pregnancy wish) were 
censored from that moment onwards. The same factors that we used as independent 
covariables in the Cox regression analysis for toxicity-related discontinuations were 
investigated (see above). In addition, plasma viral load at baseline was used as an 
independent covariable. We used a stepwise selection procedure to identify 
parameters that were significantly (p<0.10) associated with virologic response. The 
EFV dose (reduced dose or standard dose) was a fixed parameter in all models.
Apart from the primary analysis of the virologic response 24 weeks after baseline, 
several sensitivity analyses were carried out to see whether dose reduction affected 
virologic suppression at week 48 after baseline and at week 24 and week 48 after 
starting EFV. In addition, the analyses for the above mentioned four virologic 
efficacy endpoints were repeated stratified for pre-treated status at the start of 
EFV-based antiretroviral therapy. All data were analyzed with SPSS for MS Windows, 
version 16.0.1.
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Results
Baseline characteristics
We identified 180 subjects who had high EFV plasma concentrations following the 
start of an EFV containing antiretroviral regimen. The date of starting EFV ranged 
from July 1998 to February 2007. Forty-nine patients out of the 180 patients (27.2%) 
underwent a dose reduction (RD group) and 131 patients (72.8%) continued the 
standard dosage regimen (SD group).
The patient characteristics between these groups differed significantly with regard 
to gender, HIV transmission risk group, region of origin and EFV plasma 
concentration. The median (interquartile range (IQR)) EFV plasma concentration 
was significantly higher in patients who underwent dose reduction (6.8 (5.7-9.6) 
mg/L), compared to patients that continued the standard dose (5.1 (4.3-6.4) mg/L), 
p<0.001). Furthermore, there were more females, heterosexually-infected patients 
and patients originating from Sub-Saharan Africa in the RD group (see Table 1).
Magnitude of Dose Reduction and pharmacokinetic outcome
The EFV dose was reduced from 600 to 400 mg in 47 out of the 49 patients in the 
RD group. As a result, the median (IQR) EFV plasma concentration decreased from 
6.8 (5.6-9.5) to 4.0 (3.0-5.6) mg/L (p<0.001) in these 47 patients.
Two patients underwent a dose reduction directly from 600 mg QD to 200 mg QD. 
In one of these, the plasma concentration decreased from 6.4 mg/L to 2.7 mg/L. 
In the other patient, the EFV plasma concentration decreased from 27.7 mg/L to
11.4 mg/L. The dosage was further reduced in this latter patient to 100 mg QD 
which resulted in a therapeutic concentration of 2.7 mg/L. Both patients had viral 
loads below 50 copies/mL at all subsequent time points and were included in all 
further analyses.
The EFV plasma concentration remained above the threshold for efficacy (i.e., 1.0 
mg/L) in all 42 patients who had a second plasma concentration available after 
dose reduction. In spite of the significant reduction in EFV plasma concentrations 
in the RD group, 22 patients still had EFV plasma concentrations above 4.0 mg/L. 
Seven of these had their dosage subsequently further reduced to 200 mg QD, 
which resulted in a therapeutic EFV concentration in three patients. Two patients 
still had an elevated EFV plasma concentration of 5.1 mg/L following the dose 
reduction to 200 mg QD and for two patients no measured EFV concentrations 
were available.
Half of the patients (n=68, 52%) that remained on the standard dose had no EFV 
plasma concentration measured after baseline. In the 63 patients who had a second
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EFV plasma concentration available the median (IQR) EFV plasma concentrations 
were 5.3 (4.3-6.4) and 4.6 (3.5-7.3) mg/L before and after baseline, respectively 
(p=0.12).
Toxicity induced discontinuations of efavirenz
At week 48, fourteen patients from the SD group had discontinued EFV due to 
toxicity, compared to 1 patient in the RD group; Figure 1 shows the Kaplan-Meier 
curves for toxicity-induced discontinuations in both groups. At week 48, the 
estimated cumulative incidence of toxicity-induced discontinuations was 11.5% for 
patients in the SD group compared to 2.3% for patients in the RD group; p=0.066 
(log-rank test).
Figure 1 Kaplan-Meier curves for toxicity-induced efavirenz discontinuations.
RD group, reduced dose group; SD group, standard dose group.
71
Ch
ap
ter
 3 
Efa
vir
en
z 
do
se 
red
uc
tio
n 
is 
saf
e 
in 
pa
tie
nts
 w
ith 
hig
h 
pla
sm
a 
co
nc
en
tra
tio
ns
 a
nd 
ma
y 
pr
ev
en
t 
efa
vir
en
z 
di
sc
on
tin
ua
tio
ns
Table 1 Patient characteristics at start of efavirenz treatment.
Total
n
All 180
Gender
Male 111
Female 69 
HIV transmission risk group
IDU1 5
Homosexual 57
Heterosexual 102
Other 16 
Region of origin
Western Europe 72
Sub-Saharan Africa 54
Caribbean /  Latin America 37
Other 17 
Pre-treated status
Treatment naive 80 
Treatment experienced, VL < 50 copies/mL 42 
Treatment experienced, VL > 50 copies/mL 58 
Viral load status at baseline
VL < 50 copies/mL 118
VL > 50 copies/mL 62
%
100.0
61.7 
38.3
2.8
31.7
56.7 
8.9
40.0
30.0 
20.6
9.4
44.4
23.3 
32.2
65.6
34.4
Reduced dose Standard dose P-value
n % n %
49 27.2 131 72.8
0.032f
24 49.0 87 66.4
25 51.0 44 33.6
0.044«
1 2.0 4 3.1
9 18.4 48 36.6
36 73.5 66 50.4
3 6.1 13 9.9
0.022f
13 26.5 59 45.0
20 40.8 34 26.0
8 16.3 29 22.1
8 16.3 9 6.9
0.82f
21 42.9 59 45.0
13 26.5 29 22.1
15 30.6 43 32.8
0.76f
33 67.3 85 64.9
16 32.7 46 35.1
NRTI backbone 0.62f
3TC + AZT 31 17.2 10 20.4 21 16.0
TDF + 3TC 61 33.9 18 36.7 43 32.8
T D F + FTC 19 10.6 6 12.2 13 9.9
Other 69 38.3 15 30.6 54 41.2
Hepatitis B status 0.48f
Negative 111 61.7 28 57.1 83 63.4
Positive 15 8.3 6 12.2 9 6.9
Unknown 54 30.0 15 30.6 39 29.8
Hepatitis C status 0.21ft
Negative 110 61.1 26 53.1 84 64.1
Positive 6 3.3 3 6.1 3 2.3
Unknown 64 35.6 20 40.8 44 33.6
Median IQR2 Median IQR2 Median IQR2
Age (yrs) 37 32-46 36 33-44 38 32-47 0.63*
Date of starting EFV 4/04 2/03-9/05 6/04 10/03-7/05 1/04 12/02-9/05 0.41*
Time between start EFV and baseline (days) 92 56-174 106 66-191 91 53-172 0.35*
Body mass index (kg/m2)3 23.2 21-25 23.0 22-26 23.2 20-25 0.84*
Viral load at baseline (log10 copies/ml) 1.70 1.7-2.3 1.70 1.7-2.1 1.70 1.7-2.3 0.62*
CD4 count (/mm3)4 220 93-410 230 110-415 220 77-400 0.45*
EFV plasma concentration (mg/L) 5.5 4.4-7.2 6.8 5.7-9.6 5.1 4.3-6.4 <0.001*
Time between sampling and latest EFV dose (hours)5 13.2 11.1-15.5 13.3 12.0-16.3 13.2 10.4-15.5 0.17*
f Chi-squared test; ft Fisher's exact test; * Mann-Whitney test; 11DU = intravenous drugs use; 2 IQR = interquartile range;
3 Body mass Index available for 168 patients; 4CD4 count available for 176 patients; 5 Time between sampling and latest EFV dose available for 144 patients.
-s iw
C h a p t e r  3 E f a v i r e n z  d o s e  r e d u c t i o n  is s a f e  in p a t i e n t s  with h i g h  p l a s m a  c o n c e n t r a t i o n s  a n d  m a y  p r e v e n t  e f a v i r e n z  d i s c o n t i n u a t i o n s
Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for patients in 
the reduced dose group achieving virological suppression (VL<50 
copies/mL) at week 24 & 48 after baseline and at week 24 & 48 after 
starting EFV.
Univariable Multivariable
OR 95% CI | p OR 95% CI | p
Week 24 after baseline
Standard dose 1.00 1.00
Reduced dose 3.23 0.71-14.77 0.13 3.76a 0.69-20.49 0.13
Week 48 after baseline
Standard dose 1.00 1.00
Reduced dose 5.09 0.64-40.48 0.12 6.88b 0.67-70.43 0.10
Week 24 after starting EFV
Standard dose 1.00 1.00
Reduced dose 1.24 0.49-3.14 0.65 0.43c 0.12-1.50 0.19
Week 48 after starting EFV
Standard dose 1.00 1.00
Reduced dose 2.21 0.47-10.44 0.32 2.28d 0.38-13.89 0.37
a corrected for pre-treated status and plasma viral load at baseline 
b corrected for pre-treated status and plasma viral load at baseline
c corrected for pre-treated status, CD4 count, efavirenz concentration before baseline and plasma 
viral load at baseline 
d corrected for pre-treated status and plasma viral load at baseline
In a Cox proportional hazards model, patients from the RD group had a lower risk 
(hazard ratio 0.18, 95% CI 0.02-1.40) of toxicity-related EFV discontinuations 
compared to patients from the SD group. Further explorations using multivariable 
Cox proportional hazards models showed that no other parameter was significantly 
associated with the risk of discontinuation of EFV due to toxicity, nor significantly 
(>10%) modified the observed effect of the dose reduction.
Virologic response
Twenty-four weeks after baseline, 95.2% of the patients in the RD group had a viral 
load below 50 copies/mL, compared to 86.1% of the patients who continued the 
standard dose (p=0.15). Univariable logistic regression models showed that the 
pre-treated status, the plasma viral load at baseline, the HIV transmission risk group
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and the EFV concentration before baseline significantly affected whether or not 
patients had virologic response. In the multivariable analysis, pre-treated status 
and plasma viral load at baseline remained significantly associated with virologic 
outcome. Patients who had undergone dose reduction had an adjusted OR of 3.76 
(95% CI: 0.69-20.49, p=0.13) for virologic response when compared to patients that 
continued the standard dose.
Sensitivity analyses
Table 2 shows the adjusted ORs for achieving virologic response at week 48 after 
baseline and at week 24 and week 48 after starting EFV. At most time points, 
patients in the RD group trended towards better virologic response, although 
statistically significant differences were not observed. After stratification for 
pre-treated status, dose reduction still had no negative impact on virologic response 
(data not shown).
Discussion
This study demonstrates that TDM guided EFV dose reduction may prevent toxici­
ty-induced discontinuations in patients with high plasma concentrations. This result 
is conforming our expectations. We hypothesized that by reducing EFV plasma 
concentrations, CNS toxicity would diminish, which would thereupon prevent 
toxicity-induced EFV discontinuations.
In addition, we did not observe any detrimental effect of dose reduction on virologic 
response (see Table 2). Pre-treated status appeared to be the most important factor 
predicting virologic response. Treatment-experienced patients with a detectable 
viral load (>50 copies/mL) performed significantly worse in all virologic analyses, 
compared to either treatment naïve patients or treatment experienced patients that 
had no detectable viral load when switching to EFV. Therefore, we repeated all 
virologic analyses stratifying for pre-treated status at the start of EFV-based 
antiretroviral therapy. Again, dose reduction was not associated with virologic 
response in any of these strata. These results demonstrate that dose reduction is 
safe in patients with high EFV plasma concentrations, regardless of the pre-treated 
status at the start of EFV.
Of importance, no patient decreased to subtherapeutic EFV plasma concentrations 
(i.e., <1.0 mg/L) following dose reduction, which also confirms the safety of the
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dose reduction strategy. It is often stated that EFV trough levels should be at least 
1.0 mg/L, but this is in fact not in line with the work of Marzolini et al., who established 
the therapeutic window of EFV based on mid-dose interval plasma levels which 
were taken during the day, 8 to 20 hours after EFV administration at bedtime (4).
In this study we also used mid-dose interval plasma levels, which were taken on 
average 13 hours post-dose, both before and after baseline.
Patients who underwent dose reduction had higher baseline EFV plasma 
concentrations (median 6.8 mg/L) than patients that continued the standard dose 
(median 5.1 mg/L). This difference may be caused by a tendency of physicians to 
decrease the dose with increasing plasma concentrations, but it may also be 
explained by increased EFV-toxicity at higher plasma concentrations, resulting in a 
higher clinical necessity to adjust the dose. Despite this unbalance at baseline 
favoring the patients who continued the standard dose, the proportion of patients 
who stopped EFV because of toxicity was still higher in the latter group, demonstrating 
the effectiveness of the dose reduction strategy in those who are most in need of it.
Women and patients originating from Sub-Saharan Africa were over-represented in 
the RD group. Previous studies indeed demonstrated higher EFV plasma 
concentrations in women (5) and black African patients (5;14;15). EFV is metabolized 
by the polymorphic Cytochrome P450 2B6 (CYP2B6) enzyme (16)(17) and black 
patients are known to have higher frequencies of certain CYP2B6 polymorphisms 
(e.g., 516 G>T and 983T>C), which are clearly associated with elevated EFV plasma 
concentrations (11 ;17;18). Possible causes for higher plasma concentrations in 
women are differences in body weight (in this cohort, female patients had an 
average weight of 63 kg compared to 73 kg for men), hormonal influences and 
body composition.
The ATHENA cohort study does not collect data on the seriousness of drug toxicity. 
Thus, the only reliable endpoint available to evaluate the pharmacodynamic 
consequence of dose reduction was discontinuation of EFV due to toxicity. Because 
there were only 15 toxicity-induced discontinuations, we had limited statistical 
power, which is a limitation of our analysis. A study in which CNS toxicity had been 
scored systematically before and after dose reduction could have been more 
powerful. Nonetheless, discontinuation of a drug due to toxicity is the ultimate 
consequence of drug-toxicity and we consider this a clinically relevant endpoint.
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Another limitation is the retrospective design of this analysis. The best evidence for 
the dose reduction strategy would come from a controlled trial with a prospective 
design, in which one would randomly assign subjects to a TDM group in which the 
results of EFV concentration measurements plus advice (e.g., dose reduction) were 
reported to the treating physician, or to a control group for whom TDM results were 
not reported. Because it is quite improbable that such a trial will be ever organized, 
we must rely on alternative evaluations of the potential benefits of TDM in HIV-disease 
management.
In conclusion, our study demonstrates that TDM guided dose reduction can be 
considered in patients who have high EFV plasma concentrations. Dose reduction 
does not negatively affect virologic efficacy and may prevent toxicity-induced 
discontinuations.
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Efavirenz dose reduction to 200 mg once-daily 
in a patient treated with rifampicin
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International guidelines suggest that HIV-tuberculosis (TB) co-infected patients are 
treated with efavirenz (EFV)-based antiretroviral regimens, because rifampicin 
decreases EFV plasma concentrations only modestly (22-35%) (1-4). It is 
recommended to use the standard EFV dose in patients weighing <50 kg and to 
consider an increase of the dose to 800 mg in patients weighing >50 kg (1) or >60 
kg (2). In addition, therapeutic drug monitoring (TDM) may aid to ensure adequate 
EFV plasma exposure.
We describe a rifampicin-treated patient who was severely overdosed by using the 
standard EFV dose.
A 46-year-old man from Mauretania, known with Takayashu arteriitis, chronic 
hepatitis C and HIV commenced antiretroviral treatment with nevirapine (NVP), 
emtricitabine and tenofovir in 2004. NVP was used in a dose of 400 mg once-daily 
(QD) and this resulted in average NVP plasma exposure (i.e., 6.6 mg/L four hours 
after the latest drug intake). In March 2007, the 50 kg weighing patient was admitted 
in our hospital because of chest pain. At that time, the HIV viral load was below the 
limit of detection (<40 copies/mL) and the CD4 count was 190 cells/mm3. 
The patient was diagnosed with tuberculosis and treatment was initiated containing 
rifampicin, isoniazid, ethambutol and pyrazinamide. Simultaneously, NVP was 
replaced by EFV in a dose of 600 mg QD. After switching to EFV, our patient had 
complaints such as drowsiness and weariness and was by times very agitated or 
even aggressive. At one and two months after switching therapy, the EFV mid-dose 
levels were measured and both appeared unexpectedly high (7.1 mg/L and 10.6 
mg/L, respectively). Because the patient kept on being agitated, the EFV dose was 
lowered to 400 mg QD, resulting in a plasma level of 5.8 mg/L. Signs of agitation 
were still present and the dose was further decreased to 200 mg QD, which resulted 
in an EFV concentration of 2.2 mg/L (Fig. 1).
After the second dose reduction, patient’s complaints decreased considerably and 
his behaviour became relaxed again. The HIV viral load remained undetectable and 
the patient completed TB treatment without further complications. Afterwards, the 
patient was switched back to his original HAART regimen. Again, the NVP plasma 
concentration was of average value.
In this patient, concomitant use of EFV and rifampicin resulted in unexpectedly 
high EFV plasma exposure and persisting neuropsychiatric side effects. Indeed, 
our patient had some characteristic features that have been related to high EFV 
plasma exposure, such as low body weight and black ethnicity (4). However, these 
factors have also been related to higher NVP exposure (4) (5) and therefore such
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Figure 1 Efavirenz plasma concentrations during concomitant treatment 
with rifampicin. The therapeutic window of efavirenz plasma 
concentrations is 1.0 to 4.0 mg/L (12). EFV denotes efavirenz, 
RIF denotes rifampicin
Start R IF +  600m g  E FV
Time after starting efavirenz + rifampicin (months)
high EFV plasma exposure was not expected, especially given the presence of 
rifampicin. In an attempt to understand this, we performed pharmacogenetic testing 
of the Cytochrome P450 2B6 (CYP2B6) enzyme, which plays a major role in both 
EFV and NVP metabolism, although NVP is also metabolised via CYP3A4 (6;7).
At first, the three most frequently observed polymorphisms related to high EFV 
plasma concentrations were investigated, being the 516 G>T exchange, the 785 
A>G exchange (together characterizing the CYP2B6*6 allele) and the 1459 C>T 
exchange (8). To our surprise, none of these three single nucleotide polymorphisms 
(SNPs) were found. Subsequently, all CYP2B6 exons were sequenced and the 
sample proved homozygote for the 1172 T>A polymorphism in exon 8, which 
characterizes the CYP2B6*15 allele (9).
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Until today, this polymorphism had been only described in 5 patients by Lang and 
colleagues, who demonstrated that 1172 T>A polymorphism results in undetectable 
CYP2B6 enzyme activity (9). Whereas their study comprised Caucasian patients 
heterozygote for 1172 T>A, we describe a black patient with CYP2B6*15 
homozygosity and the phenotypic consequences for NVP and EFV plasma 
concentrations.
The explanation for the observed unexpected high EFV exposure in the presence of 
rifampicin may be as follows. Rifampicin induces CYP2B6 activity by increasing 
CYP2B6 gene transcription (10). Nonetheless, in a patient homozygote for 1172 
T>A, increased formation of CYP2B6 mRNA will merely lead to enhanced production 
of poor-functioning CYP2B6 enzyme, which apparently does not reverse a poor 
metabolizer phenotype into a normal metabolizer phenotype (11).
In spite of poor-functioning CYP2B6, our patient had no high NVP plasma levels. 
However, NVP is also metabolised via CYP3A4 which may serve as an escape 
route for NVP metabolism in patients with poor-functioning CYP2B6 (7).
In conclusion, physicians should be aware of the possibility of high EFV plasma 
exposure and persisting neuropsychiatric side effects in patients that start EFV in 
conjunction with rifampicin, even if former NVP plasma exposure did not indicate 
reduced CYP2B6 metabolism. TDM and pharmacogenetic testing can be valuable 
in such cases.
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Abstract
Several international HIV treatment guidelines recommend therapeutic drug 
monitoring (TDM) for specific clinical scenarios, such as drug interactions or 
pregnancy. The adherence to these recommendations is unknown. We evaluated 
the adherence to the Dutch TDM guideline of 2005. From the ATHENA observational 
cohort study, we selected three scenarios for which the guideline recommended 
TDM: i) start of a combination of lopinavir/ritonavir + efavirenz or nevirapine 
(drug-drug interaction); ii) start of efavirenz (routine TDM), iii) use of nelfinavir during 
pregnancy. The adherence to the TDM guideline was 46.7% in patients who started 
lopinavir/ritonavir plus efavirenz or nevirapine; 9.5% for patients who started 
efavirenz; and 58.5% for patients who used nelfinavir during pregnancy. Patients 
treated in clinics that had a TDM assay locally available and patients treated in 
academic clinics were more likely to receive TDM. A higher baseline HIV viral load 
was another significant predictor for the utilization of TDM.
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Introduction
Therapeutic drug monitoring (TDM), meaning the use of drug plasma concentrations 
in the management of antiretroviral therapy, is frequently utilized in some European 
countries such as The Netherlands, Spain and France. In addition, several 
international treatment guidelines, including the US Department of Health and 
Human Services (DHSS) guidelines, recommend TDM for specific clinical scenarios, 
such as in patients with drug-drug interactions, with drug concentration-dependent 
toxicities or in patients with lack of virologic response (1).
The scientific basis for TDM consists of three observations. First, the importance of 
sufficiently high plasma drug concentrations for adequate suppression of HIV 
replication (2-6). Second, the large inter-individual variability in plasma 
concentrations of protease inhibitors (PIs) and non-nucleoside transcriptase 
inhibitors (NNRTIs) among patients taking the same dose (3;7-9). Third, data from 
two randomized controlled trials which demonstrated better therapeutic outcome in 
treatment-naive patients who received routine TDM of nelfinavir or indinavir (10;11).
Little is known about the adherence of clinicians to TDM recommendations in HIV 
treatment guidelines. In addition, the determinants of adherence to TDM 
recommendations are unknown. For instance, a potential determinant might be the 
local availability of a TDM assay in the hospital of an HIV outpatient clinic. By 
understanding which factors are associated with adherence to TDM guidelines, 
strategies can be developed to improve adherence of clinicians to the guidelines as 
well as to improve the TDM guidelines themselves.
To obtain more insight into the use of TDM and the determinants of its use, we 
evaluated the use of TDM in The Netherlands from January 2004 to December 2008. 
Within this period, in 2005, the Dutch Association of AIDS Physicians (NVAB) issued 
evidence-based guidelines for the treatment of HIV-infected patients, including 
recommendations for TDM (12;13). The guidelines were published (13), they were 
discussed at plenary NVAB meetings and they were distributed by mail to all Dutch 
HIV-physicians. We studied the utilization of TDM in three specific clinical scenarios 
for which TDM was recommended by the Dutch guideline (12;13). In addition, we 
studied whether TDM use was associated with therapeutic outcome.
The first scenario was the use of TDM in the setting of a drug-drug interaction, 
namely patients who started with the combination of the HIV-1 protease inhibitor
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lopinavir/ritonavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI), 
either efavirenz or nevirapine. NNRTIs induce CYP3A-mediated metabolism of 
lopinavir, and it is therefore recommended to increase the dose of lopinavir/ritonavir 
when concomitant use is indicated (14). TDM of lopinavir may be helpful to achieve 
optimal lopinavir plasma exposure in this situation.
The second scenario was the use of routine TDM in patients starting efavirenz in 
combination with two nucleoside analogue reverse transcriptase inhibitors (NRTIs). 
Although there was no formal evidence that routine TDM would benefit patient 
outcome for efavirenz, the scientific committee recommended it because efavirenz 
had similar pharmacological characteristics as indinavir and nelfinavir (i.e. large 
inter-individual variability in pharmacokinetics; and an established relationship 
between the plasma concentration of efavirenz and antiretroviral efficacy and 
toxicity (3)).
The third scenario was in patients who used a nelfinavir-containing regimen during 
pregnancy. At the moment of the introduction of the guideline in 2005, nelfinavir in 
combination with lamivudine and zidovudine was a commonly used regimen for 
HIV-infected pregnant women in the Netherlands (12). Nelfinavir plasma 
concentrations may be decreased during pregnancy (15;16), which may in turn lead 
to an increased risk of virologic failure (17). In order to ensure adequate nelfinavir 
plasma concentrations during pregnancy, the guideline recommended TDM of 
nelfinavir during pregnancy.
Methods
Patients
All Dutch hospitals that provide antiretroviral treatment participate in the AIDS 
Therapy Evaluation in The Netherlands (ATHENA) observational cohort study. 
Currently, data from over 16,000 patients have been anonymously recorded in a 
central database that is maintained by the HIV Monitoring Foundation (18).
Scena rio  1: Drug interaction lopinavir +  efavirenz/nevirapine
From the ATHENA observational cohort study, we selected all adult patients who 
started lopinavir/ritonavir + efavirenz or nevirapine between 1 January 2004 and 
31 December 2008. Adherence to the guideline was defined as the presence of a 
lopinavir plasma concentration in the ATHENA database between week 1 and 12.
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Patients who discontinued the combination of lopinavir + efavirenz or nevirapine 
within three weeks were excluded.
Scena rio  2: Routine TDM of efavirenz
We selected all adult patients who started for the first time efavirenz in combination 
with two NRTIs between 1 January 2004 and 31 December 2008. For efavirenz, the 
guideline recommended to determine plasma concentrations at week 4 and week 
24 after commencing therapy. Therefore, we defined full adherence to the guideline 
as the presence of plasma concentrations of efavirenz in the ATHENA database 
between week 2 and 8, and between week 16 and 32. Patients who discontinued 
efavirenz within 32 weeks were excluded. In addition, we defined ‘partial adherence‘, 
defined as having at least a measurement at week 4. For this analysis, we excluded 
patients who had discontinued efavirenz within 8 weeks.
Scena rio  3: TDM of nelfinavir during p re g n a n cy
For scenario 3, we selected all adult female patients who started nelfinavir during 
pregnancy or who became pregnant while using nelfinavir between 1 January 2004 
and 31 December 2008. We defined adherence to the guideline as the availability 
of at least one plasma concentration of nelfinavir during pregnancy. Patients who 
used nelfinavir for less than 8 weeks during pregnancy were excluded.
Statistics
B a seline cha racteristics
Patient characteristics at the start of one of the three scenarios were tabulated for 
patients who received TDM according to the guideline and those who did not. 
Differences between groups were compared using Chi-squared or Fisher’s exact 
tests for categorical data and Mann-Whitney U tests for continuous data. All tests 
were two-sided and a p-value of less than 0.05 was considered statistically 
significant.
A d h e rence to the g u idelines
We used multivariable logistic regression modeling to investigate the relationship of 
the following factors with the utilization of TDM.
1. Time period of starting therapy i.e.,
i) pre-introduction of guideline (2004);
ii) introduction of guideline (2005-2006);
iii) post-introduction of guideline (2007-2008).
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2. Context of outpatient clinic. Outpatient clinics were categorized as follows:
i) small academic HIV outpatient clinics,
ii) large academic outpatient clinics;
iii) small non-academic outpatient clinics; and 
iiii) large non-academic outpatient clinics.
Outpatient clinics were classified as large or small if they had greater or fewer 
than the median number of patients for academic (n=354) and non-academic 
HIV outpatient clinics (n=221), respectively.
3. Regular presence of a clinical pharmacist at multidisciplinary HIV 
treatment-team meetings.
4. Presence of a TDM assay in the hospital laboratory of the outpatient clinic.
In addition, we evaluated the influence of several patient-related factors, namely 
gender, country of birth (as a surrogate for ethnicity), age, body mass index 
(calculated as the weight in kilograms divided by the square of the height in meters), 
hepatitis B and C status, HIV transmission risk group, CD4 count, HIV viral load at 
the start of the regimen of interest, specific NRTI backbone, and pre-treated status 
at the start of therapy. Pre-treated status was categorized as follows: i) treatment 
naïve patients; ii) treatment experienced patients with an undetectable viral load 
(< 50 copies/mL) at the start of the regimen of interest iii) treatment experienced 
patients with a detectable viral load at the start of the regimen of interest.
Effect of a d h eren ce to the gu id e lin es on virologic re sp o n se  and  
toxicity-driven drug discontinuations
To assess whether adherence to the TDM guideline affected therapeutic outcome, 
we investigated the effect of adherence to the TDM guideline on virologic response 
and toxicity-driven drug discontinuations.
For scenarios 1 and 2, virologic response was defined as a viral load below 50 
copies/mL at week 48. For scenario 3 (nelfinavir use during pregnancy), virologic 
response was a viral load below 50 copies/mL at the last viral load measurement 
before delivery. For the latter scenario, we included the time on nelfinavir as an 
extra independent variable in our logistic regression models.
We used an observed-failure approach in which patients who discontinued their 
regimen due to virologic failure were considered failures at subsequent time points, 
whereas patients who discontinued due to other reasons were censored from that 
moment onwards. Multivariable logistic regression association models were 
constructed to adjust for potential confounders. All patient-related factors which 
were used in the analysis for guideline-adherence were tested for confounding.
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We used a stepwise selection procedure, by which a parameter was identified as a 
confounder if its addition to the model resulted in a >10% change of the regression 
coefficient of TDM on virologic response.
Cox proportional hazards analysis was used to assess the impact of adherence to 
the TDM guideline on drug discontinuations due to toxicity or patient’s choice within 
the first year of therapy. Patients who discontinued the drug of interest for other 
reasons were censored from the moment of discontinuation. Confounding was 
assessed for the same parameters and in the same manner as for the analysis of 
virologic response.
All data were analyzed with SPSS for MS Windows, version 16.0.1.
Results
Table 1 presents some key characteristics of the Dutch HIV outpatient clinics which 
were considered potentially relevant for the uptake of the TDM recommendations. 
Academic outpatient clinics were generally larger than non-academic outpatient 
clinics; in addition academic outpatient clinics had more frequently a TDM assay 
locally available.
Scena rio  1: Drug interaction lopinavir +  efavirenz/nevirapine
Between 2004 and 2008, 304 patients started cART which contained lopinavir/ 
ritonavir plus efavirenz or nevirapine. Within the first three weeks, 47 patients 
discontinued the use of this combination. Thus, 257 patients were included in the 
analysis, of which the majority (158, 61.5%) used efavirenz in combination with 
lopinavir.
A total of 120 of the 257 patients (46.7%) had a lopinavir plasma concentration 
determined as recommended by the guideline. As shown in Table 2, baseline 
characteristics for the TDM and non-TDM group were mostly similar.
The use of TDM increased from 32.4% in 2004 (pre-guideline) to 55.3% during 
introduction of the guideline in 2005-2006. In 2007-2008, the use of TDM remained 
stable (49.0%). Multivariable logistic regression analysis demonstrated that patients 
in large non-academic outpatient clinics were significantly less likely to receive TDM 
compared to patients in academic clinics (see Table 3). Furthermore, treatment- 
experienced patients were more likely to receive TDM compared to treatment naive
95
Ch
ap
ter
 5 
Ad
he
ren
ce
 
to 
the
rap
eu
tic
 d
rug
 
mo
nit
ori
ng
 
gu
ide
lin
es
 
in 
The
 
Ne
the
rla
nd
s
Table 1 TDM-related characteristics of the 24 Dutch HIV outpatient clinics.
Academic Non-academic P-value
n % n 11%
All 8 16
Presence of a clinical pharmacist at multidisciplinary HIV treatment-team meetings
Never 2 25.0 8 50.0 0.39t
Regularly 6 75.0 8 50.0
Presence of a local HIV TDM assay
Present 5 62.5 5 31.3 0.20t
Not present 3 37.5 11 68.8
Median Range Median Range
Number of patients under care 
at 1 January 2006
354 255-1636 221 69-1490 0.032*
t Fisher’s exact test; * Mann-Whitney test
patients, especially those treatment-experienced patients with detectable viral 
loads at baseline (Table 3).
Forty-eight weeks after baseline, 79.6% of the patients who received TDM had a 
viral load below 50 copies/mL, compared to 73.9% of the patients who were not 
monitored by TDM (p=0.50). In the univariable logistic regression analysis, baseline 
CD4 count and baseline viral load were significantly associated with virologic 
response at week 48. After adjusting for these and other factors that confounded 
the effect of adherence to the guideline (namely gender, BMI, hepatitis B status, 
pre-treated status and NRTI backbone), patients who received TDM had an adjusted 
odds ratio (OR) of 1.77 (95% CI 0.36-8.37, p=0.48) for achieving virologic response 
at week 48. At week 24, adherence to the guideline was also not associated with 
virologic response (data not shown).
At week 48, 15 out of the 137 patients who did not receive TDM had discontinued 
lopinavir due to toxicity or patient’s choice (TOXP), compared to 3 out of the 120 
patients who did receive TDM (p=0.008, log-rank test). In bivariable Cox-propor­
tional hazards models, only baseline CD4 count significantly (>10%) modified the 
effect of adherence to the guideline on the risk of TOXP discontinuations. After
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adjusting for this parameter, patients who received TDM still had a significantly 
lower risk of toxicity-induced lopinavir discontinuations (adjusted HR 0.16, 95% CI 
0.036-0.71, p=0.016).
Scena rio  2: Routine TDM of efavirenz
A total of 3,057 patients started antiretroviral treatment with efavirenz in combination 
with two NRTIs between 2004 and 2008. Within the first 36 weeks, 588 patients 
(19.2%) discontinued efavirenz, which left 2,469 patients for the analysis. Of these 
patients, 234 (9.5%) had an efavirenz plasma concentration determined at week 4 
and 24 as recommended by the guideline. As shown in Table 2, patients who 
received TDM had generally lower CD4 counts and higher viral loads at baseline 
compared to patients who did not receive TDM.
The use of TDM of efavirenz decreased significantly from 15.8% in 2004 
(pre-guideline) to 11.5% during introduction of the guideline in 2005-2006. In 
2007-2008, the adherence to the guideline decreased further to 5.7%. As for 
scenario 1, patients treated in non-academic outpatient clinics were less likely to 
receive TDM than patients in academic settings. In addition, large academic clinics 
had lower adherence to the guideline compared to small academic clinics. The 
presence of a clinical pharmacist at multidisciplinary team meetings resulted in 
lower adherence to the 2005 TDM guideline whereas the local availability of a TDM 
assay resulted in greater adherence to the guideline. Finally, patients with higher 
baseline viral loads were more likely to receive TDM of efavirenz (see Table 3).
Partial adherence to the guideline, defined as the presence of an efavirenz plasma 
concentration at week 4, was 30.4%. Partial adherence was stable over time (30.8% 
in 2004, 30.7% in 2005-2006 and 30.0% in 2007-2008). Baseline viral load, 
hospital-type, the presence of a local TDM assay, and the presence of a clinical 
pharmacist at multidisciplinary team meetings predicted partial adherence in the 
same manner as they did for full adherence to the guideline (data not shown).
Forty-eight weeks after baseline, 89.5% of the patients in the group of patients who 
received TDM according to the guidelines had a viral load below 50 copies/mL, 
compared to 93.3% of the patients who did not receive TDM (p=0.054). After 
adjusting for factors that confounded the effect of adherence to the guideline on 
virologic response (BMI and baseline CD4 count), patients who received TDM were 
less likely to achieve virologic response (adjusted OR (95% CI) 0.49 (0.29-0.85), 
p=0.010).
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Table 2 Patient characteristics at the time of starting the regimen of interest.
Lopinavir + NNRTI
TDM No TDM p-value
n % n %
All 120 46.7 137 53.3
Gender
Male 96 80.0 113 82.8 0.61f
Female 24 20.0 24 17.5
Region of origin
Western Europe 86 71.7 78 56.9 0.067f
Caribbean /  Latin America 13 10.8 16 11.7
Sub-Saharan Africa 13 10.8 27 19.7
Other 8 6.7 16 11.7
Pre-treated status
Treatment naive 40 33.3 47 34.3 0.22f
Treatment experienced, VL < 50 copies/mL 19 15.8 32 23.4
Treatment experienced, VL > 50 copies/mL 61 50.8 57 41.6
Median IQR1 Median IQR1
Age (years) 43 37-51 42 36-59 0.37*
Date of starting therapy 06/06 06/05­
10/07
04/06 10/04­
11/07
0.31*
Body mass index (kg/m2) 22.5 20-25 22.9 21-25 0.65*
CD4 count (/mm3) 230 120-463 300 140-440 0.63*
Viral load (log10 copies/ml)2 4.7 3.6-5.8 4.5 3.4-5.5 0.27*
NA = not applicable; f Chl-squared test; * Mann-Whitney test 1 IQR, Interquartile range; 
2 includes only data from patients with a detectable viral load at baseline.
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Efavirenz Nelfinavir
TDM No TDM p-value TDM No TDM p-value
n % n % n % n %
234 9.5 2235 90.5 79 58.5 56 41.5
194 82.9 1827 81.7 0.66f NA - NA - -
40 17.1 408 18.3 79 58.5 56 41.5
145 62.0 1413 63.2 0.75f 15 19 4 7.1 0.065f
28 12.0 247 11.1 13 16.5 5 8.9
41 17.5 349 15.6 45 57.0 44 78.6
20 8.5 226 10.1 6 7.6 3 5.4
161 68.8 1516 67.8 0.034f 66 83.5 44 78.6 0.61f
36 15.4 462 20.7 7 8.9 8 14.3
37 15.8 251 11.2 6 7.6 4 7.1
Median IQR1 Median IQR1 Median IQR1 Median IQR1
40 35-48 41 35-48 0.38* 29 25-32 29 25-33 0.67*
12/05 10/04­
03/07
12/06 07/05­
01/08
<0.001* 06/05 09/04­
02/06
02/05 08/04­
04/06
0.74*
22.7 21-25 23.1 21-25 0.051* 24.7 23-30 26.2 24-28 0.85*
210 100-310 245 160-350 <0.001* 410 283-565 390 281-518 0.51*
5.0 4.6-5.3 4.9 4.4-5.3 0.051 3.9 3.3-4.5 4.0 3.1-4.4 0.96*
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Table 3 Factors predictive of adherence to the Dutch TDM guidelines in multivariable logistic regression analyses
adjusted OR 95% Cl P
Scenario 1: lopinavir + NNRTI drug interaction
Treatment period 0.004
Pre-introduction (2004) 0.24 0.10-0.56 0.001
Guideline-introduction (2005-2006) 1.00
Post-introduction (2007-2008) 0.52 0.23-1.20 0.12
Context of outpatient clinic 0.004
Academic 1.00
Non-academic-small (<221 patients) 0.49 0.18-1.34 0.16
Non-academic-large (>221 patients) 0.24 0.098-0.57 0.001
Patient’s pre-treated status 0.058
Naive 1.00
Treatment experienced, VL <50 copies/mL 1.16 0.42-3.26 0.082
Treatment experienced, VL >50 copies/mL 2.62 1.08-6.40 0.034
Scenario 2: routine TDM o f efavirenz at week 4 and week 24
Treatment period <0.001
Pre-introduction (2004) 1.65 1.15-2.37 0.007
Guideline-introduction (2005-2006) 1.00
Post-introduction (2007-2008) 0.48 0.34-0.67 <0.001
Context of outpatient clinic
Academic-small (<354 patients) 1.00
Academic large (>354 patients) 0.20
Non-academic-small (<221 patients) 0.076
Non-academic-large (>221 patients) 0.13
Presence of a local TDM assay for efavirenz
Not present 1.00
Present 2.06
Presence of a clinical pharmacist at HIV MDT1 meetings
Not present 1.00
Regularly present 0.56
Baseline viral load (copies/mL) (per 10log increase) 1.17
Scenario 3: nelfinavir during pregnancy
Context of outpatient clinic
Academic 1.00
Non-academic-small (<221 patients) 0.39
Non-academic-large (>221 patients) 0.18
Presence of a local TDM assay for nelfinavir
Not present 1.00
Present 3.79
1 MDT, multidisciplinary team.
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<0.001
0.13-0.29 <0.001
0.035-0.17 <0.001
0.089-0.19 <0.001
1.31-3.26 0.002
0.37-0.86 0.009
1.06-1.29 0.003
0.004
0.12-1.24 0.11
0.066-0.49 0.001
1.45-9.87 0.006
Patients who received TDM of efavirenz at week 4 (i.e., partial adherence to the 
guideline) were also less likely to achieve virologic response (adjusted OR 0.59 
(0.39-0.89), p=0.013).
Because there were only a few patients who discontinued efavirenz because of TOXP 
after week 32, we examined the association between partial adherence to the 
guideline (at least a week 4 efavirenz plasma sample available) and TOXP driven 
discontinuations. Within 48 weeks, 11 out of the 836 patients in the TDM group (2.5%) 
had discontinued efavirenz because of TOXP versus 41 out of the 1915 (3.5%) of 
the patients in the non-TDM group (p=0.19, log-rank test). After adjusting for 
confounding factors in a multivariable Cox proportional hazards analysis (baseline 
CD4 count and the NRTI backbone), patients who received TDM had an adjusted HR 
(95% CI) of 0.72 (0.44-1.18) (p=0.19) for TOXP discontinuations of efavirenz.
Scena rio  3: TDM of nelfinavir during p re g n a n cy
A total of 161 patients started antiretroviral treatment with nelfinavir during pregnancy 
or before becoming pregnant. Of these patients, 135 used nelfinavir for more than 
8 weeks during pregnancy. The great majority of these patients (n=130, 96.3%) 
started nelfinavir during pregnancy; 5 patients had already started nelfinavir before 
they became pregnant.
Table 2 shows that most women (n=79, 58.5%) had at least one plasma concentration 
of nelfinavir determined during pregnancy. There were no statistically significant 
differences in baseline characteristics between patients who did or did not receive 
TDM during pregnancy (see Table 2).
The use of TDM slightly increased from 54.9% in 2004 (pre-guideline) to 61.8% 
during introduction of the guideline in 2005-2006. After introduction of the guideline, 
in 2007-2008, the use of TDM decreased (50.0%). In the multivariable logistic 
regression model, patients treated in large non-academic outpatient clinics were 
less likely to receive TDM than patients in academic clinics. In addition, the local 
availability of a TDM assay was associated with more use of TDM during pregnancy 
(see Table 3).
At the last viral load measurement before delivery, 94.2% in the group of patients 
who received TDM during pregnancy had a viral load below 50 copies/mL, 
compared to 94.1% of the patients who did not receive TDM (p=1.00). After 
adjusting for confounders (baseline CD4, baseline viral load and time on nelfinavir), 
the adjusted OR (95% CI) to achieve an undetectable load was 1.45 (0.18-11.73), 
p=0.73 for patients who received TDM. There were 2 TOXP discontinuations of 
nelfinavir during pregnancy in the TDM group, and 2 in the non-TDM group (p=1.00).
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Discussion
The main goal of this study was to evaluate the adherence of clinicians to the Dutch 
TDM guidelines of 2005. The adherence to the recommendations varied from low 
for routine TDM of efavirenz (full adherence 9%; partial adherence 30%), to moderate 
for nelfinavir in pregnancy (59%), and lopinavir concomitantly used with an NNRTI 
(47%).
We cannot compare these results to those of other countries or databases, because 
this is, to our knowledge, the first evaluation of HIV physician adherence to TDM 
guidelines. Part of the explanation for the moderate adherence to the TDM 
recommendations might be that most recommendations were based on expert 
opinion. The only exceptions are nelfinavir and indinavir (10;11). In agreement with 
this, adherence to the TDM recommendations was highest for the nelfinavir 
scenario. HIV therapy is rapidly changing and improving due to continuous drug 
development. Between 2004 and 2008, the antiretroviral armamentarium was 
extended with several potent and relatively well-tolerated drugs. Therefore, 
physicians have increased opportunities for switching therapy instead of managing 
drug-related problems with TDM. This may form a second explanation for the 
moderate adherence to the TDM recommendations.
The adherence to the recommendation to perform routine TDM of efavirenz at week 
4 and week 24 was extremely low, and declined from 16% in 2004 to 6% in the 
period 2007-2008. At present, there is international consensus among clinical 
pharmacologists that TDM should be applied selectively, and not routinely (1; 19-21). 
It is well possible that during our study period, an increasing number of Dutch HIV 
physicians, as well as clinical pharmacists (see Table 3), got convinced that TDM is 
only indicated in selected situations. This may explain the declining rates for routine 
TDM of efavirenz between 2004 and 2008.
A second important goal of this study was to identify determinants of TDM use. 
The data from our study indicate that Dutch HIV physicians are more likely to use 
TDM in patients with a higher baseline viral load (efavirenz scenario) or in treatment- 
experienced patients who start therapy with a detectable viral load (lopinavir 
scenario). TDM is thus used in the most vulnerable patients, who have the highest 
a-priori chance of virologic failure. Other patient-related determinants of TDM use 
were not identified.
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Independent of the context of the outpatient clinic, the local availability of an 
analytical assay for the measurement of antiretroviral drug concentrations was 
associated with increased use of TDM. The availability of a local assay will probably 
ease TDM logistics, thereby shortening the time delay between the moment of 
blood sampling and the TDM result. As a consequence, HIV physicians might 
become more prone to apply TDM, which in turn, will lead to increased experience 
with TDM.
Another health-system related determinant of TDM use was the context of the HIV 
outpatient clinic. Academic centres were more likely to apply TDM than non-academic 
centres for all investigated TDM scenarios. It is difficult to explain this result, which is 
probably caused by multiple factors. One factor might be that academic HIV physicians 
are more willing to adhere to expert opinion based recommendations. A second 
possible explanation might be the presence of trainees who specialize in infectious 
diseases in academic clinics. These trainees were actively educated on the Dutch TDM 
guidelines and they may have propagated the use of TDM in their outpatient clinics. 
Finally, the time period in which therapy was initiated was associated with TDM use 
for efavirenz (discussed above) and for lopinavir. Only for lopinavir in combination 
with efavirenz or nevirapine, the results from our study suggest that the introduction 
of the TDM recommendations led to increased use of TDM.
The ATHENA database offers unique opportunities for TDM research because it 
comprises detailed information on TDM results as well as clinical information. 
Although not the primary goal of our analysis, we were also interested whether 
adherence to the TDM guidelines was associated with virologic response or 
drug-toxicity (the latter being deduced from toxicity or patient’s decision induced 
drug discontinuations).
For the lopinavir scenario, patients who received TDM appeared less likely to 
discontinue lopinavir because of toxicity or patient’s choice. For efavirenz, patients 
who received TDM were less likely to achieve an undetectable viral load at week 48. 
One should cautiously interpret both results, because our study design is 
observational. Thus, patients were not randomized to a TDM or a non-TDM group; 
they may have received TDM for a particular reason, which might be associated 
with the likelihood of achieving the studied outcome. Given the low adherence to 
the efavirenz routine TDM guideline, it is most probable that efavirenz TDM was 
applied selectively, rather than routinely. As described above, TDM was mostly 
applied in those patients who had the highest a-priori chance of virologic failure. In 
our analysis, we attempted to adjust for such a selection bias, (e.g., by including
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baseline viral load in the regression model), but there certainly remains residual 
confounding (e.g., preferential utilization of TDM in patients suspected of 
non-adherence). Confounding by indication is in our view the most likely explanation 
for the worse virologic outcome in patients who received TDM of efavirenz.
The lower discontinuation rate of lopinavir in the TDM group might be caused by 
dose reduction of lopinavir in patients with lopinavir adverse effects and high 
lopinavir plasma concentrations. Five patients in the TDM group had their lopinavir 
dose reduced after initially starting an increased dose, which may have prevented 
some toxicity induced lopinavir discontinuations in the TDM group. High lopinavir 
plasma concentrations have been related to hypercholesterolemia (22) and, anecdotally, 
to gastro-intestinal symptoms, such as nausea and abdominal pain.
Although this study evaluated the adherence to the Dutch TDM guidelines of 2005, 
drug-drug interactions (lopinavir scenario) and pregnancy (nelfinavir scenario) are 
still regarded as valid scenarios for TDM by current international HIV treatment 
guidelines (1;21). Present-day HIV treatment guidelines do not recommend 
unselected, routine use of TDM anymore. However, efavirenz is one of the few 
antiretroviral drugs with a high likelihood of concentration-related adverse effects, 
which is still a valid indication for TDM (3;23).
In conclusion, we have seen moderate to low adherence to the Dutch TDM 
recommendations of 2005. In addition, we have identified multiple determinants of 
TDM use. What can we learn from this study for future implementations of TDM 
guidelines? First, scientific committees that draft TDM guidelines should be cautious 
in making TDM recommendations based on expert opinion, especially if the impact 
is large in terms of time and costs (e.g., routine TDM). This might lead to better 
acceptance of TDM recommendations in clinical practice. Second, the 
implementation of a TDM guideline might be more successful with a more pro-active 
implementation by the clinical pharmacologists of the drafting scientific committee. 
For the Dutch TDM guidelines of 2005, only trainees working in academic clinics 
were actively and continuously educated. Finally, a denser network of laboratories 
with TDM assays might lead to better adherence to TDM guidelines.
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Abstract
Objective: Atovaquone/proguanil is frequently used as malaria prophylaxis by 
HIV-infected travellers. The objective of this study was to compare atovaquone/ 
proguanil pharmacokinetics in healthy volunteers to those in HIV-infected patients 
who were treated with efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
M ethods: This was an open-label, multi-centre, phase-I, single-dose trial. 
On Day 1, a single dose of atovaquone/proguanil was administered during a strictly 
fat-standardized breakfast and blood was collected throughout a 168-hour period. 
Plasma concentrations of atovaquone and proguanil were determined using a 
validated HPLC method. Pharmacokinetic parameters were calculated using 
W inNonLin version 5.2.1.
Results: Seventy-six subjects were available for statistical evaluation: 18 healthy 
volunteers, 20 HIV-infected patients on efavirenz, 19 patients on lopinavir/ritonavir, 
and 19 patients on atazanavir/ritonavir. The geometric mean (95% confidence 
interval (95% CI)) atovaquone AUC0^ t was 103.6 (79-137) h*mg/L in healthy 
volunteers, compared to 29.6 (23-39), 31.7 (24-42), and 64.3 (49-84) h*mg/L 
in patients treated with efavirenz, lopinavir/ritonavir, and atazanavir/ritonavir, 
respectively. The geometric mean (95% CI) atovaquone Cmax was 1.80 (1.4-2.3) 
mg/L in healthy volunteers versus 1.06 (0.84-1.3), 1.13 (0.90-1.4), and 1.02 
(0.81-1.3) mg/L in patients using efavirenz, lopinavir/ritonavir, and atazanavir/ 
ritonavir, respectively. In addition, the AUC0^ t of proguanil was 38-43% lower in the 
three groups of HIV-infected patients versus the healthy controls.
C o n clusio n s: Physicians should be alert for atovaquone/proguanil prophylaxis 
failures in HIV-infected patients treated with efavirenz, lopinavir/ritonavir or, to a 
lower extent, atazanavir/ritonavir. In patients treated with efavirenz or lopinavir/ 
ritonavir, an increase of the dose of atovaquone/proguanil should be considered.
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Introduction
Atovaquone coformulated with proguanil is used for the treatment and prophylaxis 
of malaria. Due to its efficacy and favorable safety profile (1), atovaquone/proguanil 
is frequently used as chemoprophylaxis by HIV-infected patients who travel to 
malaria endemic destinations.
Nevertheless, there are indications for drug interactions of atovaquone with some 
frequently prescribed antiretroviral drugs. Despite a lack of data, the summary of 
product characteristics of lopinavir/ritonavir and ritonavir warn that, theoretically, 
co-administration may lead to decreased atovaquone plasma concentrations (2;3). 
The postulated mechanism for this theoretical drug-drug interaction is enhanced 
glucuronidation of atovaquone (4). Indeed, lop inavir/ritonavir may induce 
glucuronidation (5). O ther ritonavir boosted protease inh ib itors (PIs), such as 
atazanavir/ritonavir, and non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
such as efavirenz, may induce glucuronidation as well (6-7).
The consequences of these theoretical drug-drug interactions are potentially 
serious, since dim inished exposure to atovaquone may result in suboptimal 
prophylaxis of malaria. Therefore, we compared atovaquone/proguanil pharma­
cokinetics in healthy volunteers to those in HIV-infected patients who were on stable 
antiretroviral treatment with regimens that contained either efavirenz, lopinavir/ 
ritonavir or atazanavir/ritonavir.
Methods
This open-label, multi-centre, phase-I, single-dose trial was conducted from May 
2007 until December 2008 at the Erasmus Medical Centre Rotterdam, the Rijnstate 
Hospital Arnhem, the Radboud University Nijmegen Medical Centre, the Leiden 
U niversity Medical Centre, and the Elisabeth Hospital Tilburg, all in the 
Netherlands.
Study design
Participating subjects received one single dose of atovaquone/proguanil 250/100 
mg with breakfast in the morning at their clinic. The breakfast in this study was 
strictly fat-standardized because the absorption of atovaquone is highly dependent 
on the fat content of the meal taken with the drug (8). The Ethical Review Board of
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the Radboud University Nijmegen Medical Centre approved the trial. Local approval 
by the ethical committees of all other participating centres was obtained as well.
Study population
HIV-infected patients with CD4 positive lymphocyte counts higher than 200 cells/^L, 
who were for at least one month stable on antiretroviral regimens containing either 
efavirenz 600 mg once-daily (QD), atazanavir/ritonavir 300/100 mg QD or lopinavir/ 
ritonavir in a dosage of 400/100 mg twice-daily (BD) or 800/200 mg QD, were 
invited to participate in the trial. The main exclusion criteria were: suspicion of 
non-adherence to antiretroviral medication and use of medication known to interfere 
with the pharmacokinetics of atovaquone or proguanil.
The reference group in this study consisted of healthy volunteers, who had to be in 
a good, age-appropriate health condition as established by physical examination, 
medical history, biochemical, hematologic, and urinalysis testing within 4 weeks 
before the single dose. The main exclusion criteria for the healthy volunteers were a 
positive HIV test result; a positive hepatitis B or C test result and therapy with any 
drug (for 2 weeks preceding dosing), except for acetaminophen.
All subjects, both the HIV-infected patients and the healthy volunteers, had to be 
aged 18-65 years on the day of dosing, had to have body mass indexes of 18 to 30 
kg/m2, and had to be willing and able to sign the Informed Consent Form before 
screening evaluations. The main exclusion criteria for all subjects were: sensitivity/ 
idiosyncrasy to atovaquone/proguanil or chemically related compounds, a relevant 
medical history or current condition that might interfere with atovaquone/proguanil 
pharmacokinetics, creatinine clearance less than 60 mL/min (calculated from 
serum creatinine), and pregnant or breast-feeding females. At screening (within 4 
weeks prior to the single dose), eligibility for inclusion was established.
Safety assessments and pharmacokinetic sampling
Blood samples for pharmacokinetics were collected throughout a 168-hour period 
(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 48, 72, and 168 hours (7 days) after atovaquone/ 
proguanil intake (13 samples) to characterize drug absorption, distribution and 
elimination. Serum biochemistry, hematology and urinalysis test results were 
checked on days 1 and 8. Adverse events were assessed during the same visits 
and on days 2, 3, and 4.
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At day 1 and 8 of the study, we determined mid-dose plasma concentrations for 
efavirenz and trough plasma concentrations for lopinavir and atazanavir. In some 
cases, the latter was not possible due to practical reasons. In these cases, plasma 
concentrations were taken at similar (+/- 2 hours) periods after drug-intake on days 
1 and 8.
Bioanalysis
Plasma concentrations of atovaquone and proguanil were analyzed at the 
Department of Clinical Pharmacy of the Rijnstate Hospital (Arnhem, The 
Netherlands). We used a solid-phase extraction (SPE) - high-performance liquid 
chromatography (HPLC) method for the simultaneous quantitative analysis of 
atovaquone and proguanil, which has been described by Lindegardh et al. (9). 
Atovaquone and atovaquone internal standard (IS) (compound 59C80) were kindly 
provided by Glaxo Smith Kline (Hertfordshire, UK); proguanil was kindly provided 
by Astra Zeneca (Cheshire, UK). 1-(2.5)-dichlorophenylbiguanide (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was used as an internal standard for proguanil. 
Briefly, to 500 |iL  plasma, 1,000 |il of atovaquone-IS (2.5 |iM ) in ice-cold acetonitrile 
was added. After vortex-mixing, the tubes were centrifuged at 13,400 G for 10 
minutes. The supernatant was mixed with 1,000 |iL  of proguanil-IS 2.5 |iM in 
phosphate buffer (pH 6.8, 0.01M) and then loaded onto an SPE column (Isolute 
HCX-Q, Biotage, Uppsala, Sweden). The extraction procedure was exactly the 
same as described by Lindegardh et al. (9). The eluate was evaporated to dryness 
under a gentle stream of nitrogen at 60oC. The residue was reconstituted in 100 |iL  
of methanol: water (90:10 v/v). Twenty |iL  of the resulting solution was run on a 
Zorbax SB-CN 250 x 4.6 mm 5 |im  column (Agilent Technologies, Amstelveen, 
The Netherlands) with a flow rate of 1.0 mL/min using the mobile phases elution 
scheme described by Lindegardh (9). Atovaquone and proguanil were detected by 
ultraviolet spectroscopy at 245 nm.
The accuracy values for atovaquone were 107, 103 and 99% at 0.275, 0.573 and 
4.58 mg/L, respectively. At the same concentrations, the precision values (within 
day, coefficient of variation) were 7.9, 3.1 and 3.4%, respectively. The calibration 
curve was linear over a concentration range of 0.183 to 5.50 mg/L. For proguanil, 
the accuracy values were 101, 98 and 96% at concentrations of 0.029, 0.272 and 
0.544 mg/L. The precision values at the same concentrations (within day, coefficient 
of variation) were 4.8, 2.6 and 2.9%, respectively. The calibration curve for proguanil 
was linear over a concentration range of 0.019 to 0.580 mg/L.
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Efavirenz, lopinavir and atazanavir plasma concentrations were analyzed at 
the laboratory of the Department of Clinical Pharmacy of the Radboud University 
Nijmegen Medical Centre by previously described validated HPLC methods (10) (11).
CYP2C19 genotyping
Subjects were tested for the presence of *2 (681G>A, rs4244285), *3 (636G>A, 
rs4986893), and *17 (806C>T, rs12248560) alleles of CYP2C19, which is a key 
enzyme involved in proguanil metabolism. DNA was isolated from EDTA blood 
(Total Nucleic Acid isolation kit (Roche Diagnostics, Mannheim, Germany) on a 
MagnaPure LC (Roche Diagnostics)). Genotyping was performed on 5 ng DNA 
using Taqman allelic discrimination assays (ABI Prism 7000 Sequence Detection 
system, Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
Assay IDs were C_25986767_70 (CYP2C19*2) and C_27861809_10), with thermal 
profiles 50 cycles (15 seconds 92 oC, 90 seconds 60 oC). Genotypes were scored 
by allele-specific fluorescence using SDS 2.2.2 software (Applied Biosystems). 
Assays were validated previously via direct sequencing of wild type, heterozygous 
and homozygous variant samples. Assay performance was monitored by including 
positive and negative controls. After genotyping, subjects were categorized as 
follows: homozygous ultra-rapid metabolizers (*17/*17), heterozygous ultra-rapid 
metabolizers (*1/*17), extensive metabolizers (*1/*1), intermediate metabolizers 
(*1/ * 2 , *1/*3,), and poor metabolizers (*2/*2, *2/*3, *3/*3). There were 6 subjects 
with mixed CYP2C19 *2/*17  genotypes.
Pharmacokinetic analysis
Pharmacokinetic parameters for atovaquone and proguanil were calculated by 
non-compartmental methods using the WinNonlin® software package (version 5.2; 
Pharsight, Mountain View, CA, USA) and the log/linear trapezoidal rule. On the 
basis of the individual plasma concentration-time data, the following pharmacokinetic 
parameters of atovaquone and proguanil were determined: the area under the 
plasma concentration-time curve from t=0 (drug intake) to the last quantifiable 
concentration (AUC0^ t; in hour*milligram/liter), the maximum plasma concentration 
of the drug (C ; in milligrams per liter), the time to reach C (T ; in hours), andmax max max
the apparent elimination half-life (t1/2; in hours). The AUC0^ t was used instead of the 
AUC0^ m because AUC0^ m contained extrapolated areas greater than 20% in the 
majority of subjects for both atovaquone and proguanil.
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Sample size and statistical analysis
The study was powered to detect a 20% difference in atovaquone AUC between the 
healthy controls and each of the other three HIV-1 positive groups. The required 
number of participants was calculated as 20 per study arm.
Patient characteristics at day 1 (baseline) were tabulated for the four groups: the 
healthy volunteers and the HIV-infected patients treated with efavirenz, lopinavir/ 
ritonavir and atazanavir/ritonavir. Differences between groups were compared 
using Chi-squared tests or Fisher’s exact tests where appropriate for categorical 
data and the Kruskal-Wallis test for continuous data. All tests were two-sided and a 
p-value of less than 0.05 was considered statistically significant.
The AUC0^ t, Cmax, and t1/2 were natural log transformed before analysis, and all 
corresponding confidence intervals (CIs) for means (for the difference of two 
means) were constructed on the natural log scale. Exponentiation was performed 
on the means (mean differences and lower and upper limits of these CIs) prior to 
reporting.
We used multiple variable linear regression models to assess the effect of efavirenz, 
lopinavir/ritonavir and atazanavir/ritonavir on the AUC0^ t, Cmax, and t1/2 of atovaquone 
and proguanil. Potential confounding parameters that were assessed were race, 
age, smoking behaviour, body weight, CYP2C19 genotype, and body height. We 
used a stepwise selection procedure, by which a parameter was identified as a 
confounder if its addition to the model resulted in >10% change of the regression 
coefficient of efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
To determine the effect of the CD4 count, the HIV-1 RNA viral load and the specific 
nucleoside analogue reverse transcriptase inhibitor (NRTI) backbone on 
atovaquone/proguanil plasma exposure, we used linear regression models with the 
natural logarithm of the AUC0^ t of atovaquone or proguanil as the dependent 
variable and the CD4 count (per 100 cells/^L increase), the viral load status (using 
a viral load <40 copies/mL as reference) and the NRTI backbone as independent 
variables.
Plasma concentrations of the antiretroviral drugs on days 1 and 8 were compared 
by paired-samples t-tests after natural log transformation of the data.
Statistical evaluations were carried out using SPSS for Windows, version 16.0.1 
(SPSS, Chicago, IL, USA).
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Results
Baseline characteristics
A total of 79 subjects were included: 20 healthy volunteers and 59 HIV-Infected 
patients who were treated with efavirenz (n=20), lopinavir/ritonavir (n=20) or 
atazanavir/ritonavir (n=19). The blood samples of two healthy volunteers were lost 
due to an unfortunate accident. In addition, one patient on lopinavir/ritonavir was 
excluded from statistical evaluations because of unapproved concomitant use of 
phenytoin, a well-known enzyme inducer. Thus, 76 subjects were evaluable for 
statistical evaluation.
In Table 1, baseline characteristics are compared between the healthy volunteers 
and the three groups of HIV-infected patients. Eleven of these patients used 
lopinavir/ritonavir tablets in a dosage of 400/100 mg BD; eight patients used 
lopinavir/ritonavir tablets in a dosage of 800/200 mg QD. Compared to the healthy
Figure 1 Atovaquone plasma concentration-time curves after a single dose 
of atovaquone/proguanil.
Time after intake (h)
Data are presented as arithmetic mean + standard error of the mean.
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volunteers, there were more males and smokers among all categories of HIV-Infected 
patients. In addition, the healthy volunteers were generally younger than the 
HIV-Infected patients.
Pharmacokinetics of atovaquone / proguanil
Because there were no significant differences in any of the pharmacokinetic 
parameters of atovaquone or proguanil between patients who took lopinavir/ 
ritonavir QD or BD, the group of patients who took lopinavir/ritonavir was regarded 
as one single group in the statistical analyses.
Figure 1 and figure 2 show the atovaquone and proguanil plasma concentration­
time curves, respectively, after a single dose of atovaquone/proguanil. The single­
dose pharmacokinetic parameters derived from plasma concentration-time data 
are summarized in Table 2.
Figure 2 Proguanil plasma concentration-time curves after a single dose of 
atovaquone/proguanil.
0,10
Time after intake (h)
Data are presented as arithmetic mean + standard error of the mean.
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120 Table 1 Baseline characteristics.
Total Healthy
volunteers
n % n %
All study participants 76 100.0 18 23.
Gender
Male 61 80.3 10 55.
Female 15 19.7 8 44,
Race
Caucasian 59 77.6 15 83.
Non-Caucasian 17 22.4 3 16.
HIV transmission risk group
Homosexual 39 67.2 NA -
Heterosexual 14 24.1 NA -
IDU 2 3.4 NA -
Other 3 5.2 NA -
NRTI backbone
TDF + FTC 17 29.3 NA -
TDF + 3TC 22 37.9 NA -
AZT + 3TC 7 12.1 NA -
ABC + 3TC 7 12.1 NA -
Other 5 8.6 NA -
Smoking status
Non-smoker 48 63.2 16 88.
Smoker 28 36.8 2 11.
HIV-infected 
patients 
on efavirenz
HIV-infected 
patients 
on lopinavir/ 
ritonavir
HIV-infected 
patients 
on atazanavir/ 
ritonavir
n % n % n % p-value
20 26.3 19 25.0 19 25.0
0.025f
19 95.0 16 84.2 16 84.2
1 5.0 3 15.8 3 15.8
15 75.0 15 78.8 14 73.7 0.93f
5 25.0 4 21.1 5 26.3
16 80.0 12 63.2 11 57.9 0.22f
4 20.0 3 15.8 7 36.8
- - 2 10.5 - -
- - 2 10.5 1 5.3
8 40.0 2 10.5 7 36.8 0.032f
10 50.0 6 31.6 6 31.6
2 10.0 4 21.1 1 5.3
- - 3 15.8 4 21.1
- - 4 21.1 1 5.3
0.028ft
9 45.0 10 52.6 13 68.4
11 55.0 9 47.4 6 31.6
44 75.9 NA - 17 85.0 13 68.4 14 73.7 0.47f
14 24.1 NA - 3 15.0 6 31.6 5 26.3
6 7.9 1 5.6 3 15.0 1 5.3 1 5.3 0.24f
18 23.7 2 11.1 8 40.0 4 21.1 4 21.1
26 34.2 9 50.0 4 20.0 9 47.4 4 21.1
6 7.9 1 5.6 2 10.0 2 10.5 1 5.3
17 22.4 5 27.8 2 10.0 3 15.8 7 36.8
1 1.3 - - 1 5.0 - - - -
2 2.6 - - - - - - 2 10.5
Median IQR Median IQR Median IQR Median IQR Median IQR
46 32-51 23 20-44 47 38-50 48 45-52 49 35-51 0.001’
450 338-655 ND ND 465 318-613 370 260-720 450 400-730 0.57*
73 66-80 70 64-77 78 67-83 73 67-78 70 67-79 0.38*
180 171-184 179 170-181 181 176-186 180 174-185 179 170-181 0.21*
Viral load at screening
<40 copies/mL
>40 copies/mL
CYP2C19 genotype
Ultra-rapid
metabolizers
(*171*17)
Heterozygous ultra­
rapid metabolizers 
{*11*17)
{*11*1)
Mixed genotype 
{*21*17)
Intermediate 
metabolizers 
(*11*2, *11*3)
Poor metabolizers 
{*21*2)
Unknown
Age (years)
CD4 count (/mm3)
Weight (kg)
Height (cm)
f Fisher’s Exact Test; f t Chi-Squared Test; * Kruskai-Wallis Test; IQR, interquartile range; IDU, intravenous drugs use; NA, not applicable; ND, not determined; 
NRTI, nucleoside analogue reverse transcriptase Inhibitor; TDF, tenofovlr; FTC, emtricltabine; 3TC, lamivudlne; AZT, zidovudine; ABC, abacavir.
Chapter 6 Lower a tovaquone/p roguan ll concentra tions In patients taking  efavlrenz, lop lnavir/rltonavir or a tazanavlr/ritonavlr
Table 3 shows the geometric mean ratios of the pharmacokinetic parameters of 
atovaquone and proguanil obtained after adjustment for factors that confounded 
(>10%) the observed effect of efavirenz, lopinavir/ritonavir and atazanavir/ritonavir 
on the pharmacokinetic parameters of atovaquone and proguanil. Compared to the 
healthy volunteers, HIV-infected patients who used efavirenz or lopinavir/ritonavir 
had substantially lower plasma exposure to atovaquone, while patients on 
atazanavir/ritonavir had modestly lower atovaquone exposure. The AUC0^ t of 
proguanil was 38-43% lower in the three groups of HIV-infected patients versus the 
healthy controls (see Table 3).
Effect of HIV-specific parameters
The CD4 count (p=0.030, p = 0.48), nor the viral load status (P= -0.146, p = 0.51) nor 
any of the NRTI backbones were associated with plasma exposure to atovaquone. 
The same analyses for proguanil yielded similar results.
Plasma concentrations of the antiretroviral drugs
There were no patients with undetectable plasma concentrations of efavirenz, 
lopinavir or atazanavir. The geometric mean mid-dose efavirenz concentration was 
2.1 mg/L at both day 1 and day 8 (p=0.52). The geometric mean plasma concentrations 
for lopinavir and atazanavir were 4.1 mg/L and 1.1 mg/L on day 1, respectively, 
compared to 4.3 mg/L (p=0.88) and 1.2 mg/L (p=0.46) on day 8, respectively.
Adverse events and safety assessments
The single dose of atovaquone/proguanil was well tolerated. Six subjects reported 
a total of 8 non-serious adverse events. The majority of these events (n=7, 88%) 
were classified as grade I; the remaining event, namely transient diarrhea on the 4th 
day after the single dose of atovaquone/proguanil, was classified as grade II. 
Only one adverse event was considered possibly or probably related to the single 
dose of atovaquone/proguanil: a patient who was treated with lopinavir/ritonavir, 
zidovudine and lamivudine had a transient headache in the afternoon of study 
day 1, which did not require additional treatment.
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Table 2 Pharmacokinetic parameters of atovaquone and proguanii after a single dose of atovaquone/proguanil (250/1 OOmg)
Pharmacokinetic Healthy volunteers HIV-infected patients HIV-infected patients HIV-infected patients
parameter (n=18) on efavirenz on lopinavir/ritonavir on atazanavir/ritonavir
(n=20) (n = 19) (n = 19)
Atovaquone GM 95% Cl GM 95% Cl GM 95% Cl GM 95% Cl
AUCM (h*mg/L) 103.6 (79,137) 29.6 (23,39) 31.7 (24,42) 64.3 (49,84)
Cma, (mg/L) 1.80 (1.4, 2.3) 1.06 (0.84,1.3) 1.13 (0.90,1.4) 1.02 (0.81,1.3)
T1/2 (h) 93.6 (74,118) 48.2 (38,62) 47.7 (37,62) 90.6 (72,114)
Tmax (h)a 4.0 3-5 4.0 3-5 4.0 2-5 4.0 3-5
Proguanii GM 95% Cl GM 95% Cl GM 95% Cl GM 95% Cl
AUCM (h*mg/L) 0.62 (0.44,0.87) 0.32 (0.23,0.44) 0.38 (0.27,0.53) 0.39 (0.28,0.55)
Cmax (mg/L) 0.09 (0.08,0.11) 0.07 (0.05,0.08) 0.07 (0.06,0.07) 0.07 (0.06,0.09)
T1/2 (h) 5.4 (3.9, 7.6) 4.5 (3.4, 6.0) 6.0 (4.3, 8.4) 3.8 (2.7, 5.2)
T (h)a 3.0 2-4 3.0 2-4 2.0 1-3 3.0 2-4max v 1
n, number of subjects; GM, geometric mean; Cl, confidence interval; 
“ Median and Interquartile range reported fo rT ma,
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Table 3 Unadjusted and adjusted geometric mean ratios (GMRs) of the pharmacokinetic parameters of atovaquone
and proguanii in HIV-infected patients treated with efavlrenz, loplnavir/rltonavir, or atazanavlr/ritonavlr versus those 
obtained In healthy volunteers.
Pharmacokinetic
parameters
HIV-infected patients 
on efavirenz
HIV-infected patients on lopinavir/ 
ritonavir
HIV-infected patients 
on atazanavir/ritonavir
Atovaquone GMR
(95% Cl)
Adjusted GMR
(95% Cl)
GMR
(95% Cl)
Adjusted GMR
(95% Cl)
GMR
(95% Cl)
Adjusted GMR
(95% Cl)
AUCm  (h*mg/L) 0.29
(0.20-0.42)
0.25a
(0.16-0.38)
0.31
(0.21-0.45)
0.26a
(0.17-0.41)
0.62
(0.42-0.91)
0.54a
(0.35-0.83)
c _  (mg/L) 0.59(0.43-0.82)
0.56b
(0.39-0.80)
0.63
(0.45-0.88)
0.56b
(0.39-0.82)
0.57
(0.41-0.79)
0.51b
(0.36-0.73)
T1/2(h) 0.51
(0.37-0.72)
0.58°
(0.41-0.83)
0.51
(0.36-0.72)
0.53°
(0.36-0.78)
0.97
(0.70-1.34)
1.05'
(0.75-1.48)
Proguanii GMR
(95% Cl)
Adjusted GMR
(95% Cl)
GMR
(95% Cl)
Adjusted GMR
(95% Cl)
GMR
(95% Cl)
Adjusted GMR
(95% Cl)
AUCM (h*mg/L) 0.51
(0.32-0.82)
0.57d
(0.35-0.93)
0.61
(0.38-0.99)
0.62d
(0.39-0.99)
0.64
(0.40-1.03)
0.59d
(0.38-0.93)
Cma,.(mg/L) 0.73
(0.58-0.92)
0.89e
(0.70-1.14)
0.79 
(0.62-1.00)
0.88e
(0.70-1.10)
0.79
(0.66-1.00)
0.83e
(0.66-1.05)
T1/2(h) 0.83
(0.54-1.30)
0.90'
(0.55-1.48)
1.11
(0.69-1.79)
1.12'
(0.67-1.88)
0.69
(0.43-1.12)
0.60'
(0.36-0.99)
GMR, geometric mean ratio; a adjusted for age; b adjusted for age and body weight; adjusted for age, body weight and gender; d adjusted for CYP2C19 genotype, 
body height and smoking status; e adjusted for CYP2C19 genotype, body height, body weight and gender; f adjusted for CYP2C19 genotype, age, race, and gender.
Discussion
The objective of our study was to compare atovaquone/proguanil pharmacokinetics 
in healthy volunteers to those in HIV-infected patients who were treated with 
efavirenz, lopinavir/ritonavir or atazanavir/ritonavir, respectively. The differences in 
atovaquone exposure appeared to be substantial. HIV-infected patients who used 
efavirenz or lopinavir/ritonavir had on average 75% lower exposure to atovaquone 
compared to the healthy controls, while patients on atazanavir/ritonavir had 40-50% 
lower exposure to atovaquone.
It is not possible to establish from our study the exact mechanism behind the lower 
atovaquone plasma concentrations in the three groups of HIV-infected patients. 
The mechanism might be increased atovaquone glucuronidation (4), although there 
are only indirect data that suggest that atovaquone may be metabolized by 
glucuronidation (12-14). The lower atovaquone exposure in patients treated with 
lopinavir/ritonavir compared to those treated with atazanavir/ritonavir is in line with 
such a mechanism, because lopinavir/ritonavir seems to have stronger inductive 
effects on glucuronidation enzymes than atazanavir/ritonavir (5;7;15).
Another potential mechanism might be a pharmaceutical interaction in the gastro­
intestinal tract, caused by simultaneous intake of the antiretroviral agents and 
atovaquone/proguanil. However, this is unlikely because atovaquone/proguanil 
peak plasma concentrations did not differ significantly in patients who took 
atovaquone/proguanil and antiretroviral medication simultaneously (within a time 
frame of 3 hours) and those who did not (e.g., patients who took atazanavir/ 
ritonavir in the evening) (data not shown).
Plasma exposure to proguanil was on average 38-43% lower in the three groups of 
HIV-infected patients. Proguanil, which bolsters atovaquone activity (16), is 
predominantly metabolized by CYP2C19. Lopinavir/ritonavir and efavirenz may 
induce CYP2C19 (17;18), which may explain the lower proguanil exposure in these 
groups. In addition, patients treated with atazanavir/ritonavir had reduced proguanil 
exposure, which might be due to CYP2C19 induction by ritonavir, atazanavir or both.
Despite the substantially lower atovaquone plasma exposure observed in our study, 
no clinical reports have been published so far that describe atovaquone/proguanil 
chemoprophylaxis failure in HIV-infected travellers treated with ritonavir boosted 
PIs or NNRTIs. In addition, there are no established minimum effective atovaquone 
plasma concentrations in the setting of malaria prophylaxis, which makes it difficult
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to assess the precise clinical relevance of decreased atovaquone plasma 
concentrations. Nevertheless, the difference in atovaquone plasma exposure with 
the healthy volunteers was substantial. Therefore, physicians should be alert for 
atovaquone/proguanil prophylaxis failures in HIV-infected patients treated with 
efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
We did not choose for a design in which therapy naïve HIV-infected patients served 
as a reference group, because the HIV-physicians at our clinics felt it would be very 
difficult to motivate this group of patients to participate in our trial. Because of the 
chosen design, it remains unknown whether HIV-infection itself resulted in lower 
atovaquone plasma concentrations, which is a limitation.
On the other hand: our study mimics the ‘real world situation’. HIV-infected patients 
treated with antiretroviral regimens travel to malaria endemic areas like healthy 
people do, and phase 3 trials of atovaquone/proguanil for malaria prophylaxis were 
only conducted in healthy subjects (1).
Another potential limitation of our study is that we used a single dose design for 
atovaquone/proguanil. However, as shown by Thapar et al. (19), the AUC0^ m of 
atovaquone after a single dose of Malarone® was predictive of the AUC0^ t of 
atovaquone at steady state (19). Therefore, we judged it would be possible to obtain 
our main objectives using a single dose design, which appeared to be safe and 
convenient for the participating subjects.
In summary, our study shows considerably lower plasma exposure to atovaquone 
in HIV-infected patients treated with efavirenz or lopinavir/ritonavir, and modestly 
lower plasma exposure to atovaquone in those treated with atazanavir/ritonavir, 
compared with a group of healthy volunteers. In addition, plasma concentrations of 
proguanil, which bolsters atovaquone activity, were modestly reduced in patients 
treated with efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Therefore, physicians should be alert for atovaquone/proguanil prophylaxis failures 
in HIV-infected patients treated with efavirenz, lopinavir/ritonavir or atazanavir/ 
ritonavir. We recommend emphasizing adherence to atovaquone/proguanil in 
HIV-infected travellers treated with these drugs, i.e., strict daily intake during the 
main meal. In addition, an increase of the dose of atovaquone/proguanil should be 
considered in patients treated with efavirenz or lopinavir/ritonavir.
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Abstract
We studied the effect of raltegravir on the pharmacokinetics of the anti-epileptic 
agent lamotrigine. Twelve healthy volunteers (group A) received 400 mg of raltegravir 
tw ice-daily from day 1-5. On day 4, a single dose of 100 mg of lamotrigine was 
administered. After a wash-out period, subjects received a second single dose of 
100 mg of lamotrigine but now without raltegravir (day 32). In group B, 12 subjects 
received the same treatment as in group A but in reverse order. On days 4 and 32, 
48-hour pharmacokinetic curves were drawn. Geometric mean ratios (+90% 
confidence intervals (CIs) of lamotrigine area under the plasma concentration-time 
curve (AUC0^ 48) and peak plasma concentration (Cmax) for raltegravir + lamotrigine 
versus lamotrigine alone were 0.99 (0.96-1.01) and 0.94 (0.89-0.99), respectively. 
The mean ratio of the AUC0^ 48 of lamotrigine-2N-glucuronide to lamotrigine was 
similar when lamotrigine was taken alone (0.35) or when taken with raltegravir 
(0.36). Raltegravir does not influence the glucuronidation of lamotrigine.
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Introduction
Raltegravir is a newly developed antiretroviral drug that acts by targeting the HIV-1 
Integrase, thereby preventing the integration of HIV-DNA into the genome of the 
human host-cell. Raltegravir has demonstrated potent antiretroviral efficacy and is 
generally well tolerated (1;2). Raltegravir is metabolized in the liver by UDP- 
glucuronosyltransferase 1A1 (UGT1A1). As a consequence, its pharmacokinetics 
can be influenced by inhibitors (e.g., atazanavir) or inducers (e.g., etravirine, 
tipranavir, rifampicin) of UGT1A1 (3-6).
In contrast to protease inhibitors and non-nucleoside transcriptase inhibitors, 
raltegravir does not inhibit or induce Cytochrome P450 (CYP450) enzymes (7). Limited 
data are available on the influence of raltegravir on substances that share raltegravir’s 
metabolic pathway: glucuronidation. In vitro studies suggest that raltegravir does 
not potently inhibit (IC50 >50 |iM ) UGT1A1 and UGT2B7 enzymes (8). However, 
other UGT sub enzymes, such as UGT1A4, have not been evaluated and there are 
no clinical studies that support the in vitro data.
An example of a UGT-substrate which may be prescribed to HIV-infected patients 
is the anti epileptic agent lamotrigine, which is hepatically metabolized to lamotrig- 
ine-2N-glucuronide (9). Lamotrigine is one of the recommended anti-epileptic 
agents for the management of seizures in HIV-infected patients (10). Seizures are 
not rare in HIV-infected patients: retrospective studies indicate that 2-20% of the 
HIV-infected patients will have seizures at some time during their illness (11). In 
addition, lamotrigine is one of the few drugs with proven efficacy in the treatment of 
HIV-associated neuropathic pain (12).
In previous studies, we demonstrated that lopinavir/ritonavir reduces plasma 
exposure to lamotrigine, by approximately 50% (13). The combination of atazanavir/ 
ritonavir is also able to induce glucuronidation of lamotrigine as demonstrated in a 
subsequent trial (14). The decrease in lamotrigine exposure (32%), however, was 
less pronounced as with lopinavir/ritonavir; in addition, this trial showed that 
atazanavir alone did not influence lamotrigine pharmacokinetics, suggesting that 
the effect from atazanavir/ritonavir is mainly caused by ritonavir.
These two trials demonstrate that the conversion of lamotrigine to lamotrigine-2N- 
glucuronide is an appropriate marker to evaluate the effect of concomitant 
medications on the glucuronidation of lamotrigine. Given the unknown effect of
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raltegravir on the glucuronidation of UGT-substrates in vivo, we studied the effect of 
raltegravir on the pharmacokinetics of lamotrigine.
Methods
Study design
This open-label, randomized, two-period, cross-over, single-centre, phase-I, 
multiple-dose trial was conducted in March and April 2008 at the Radboud 
University Nijmegen Medical Centre (Nijmegen, The Netherlands). The study was 
designed to investigate the effect of raltegravir on the pharmacokinetics of 
lamotrigine and lamotrigine-2N-glucuronide as determined by intrasubject 
comparison. Secondary objectives were to assess the effect of lamotrigine on the 
pharmacokinetics of raltegravir when compared to historical controls and to 
evaluate the safety of combined use of lamotrigine and raltegravir.
Twenty-four male subjects were randomized to either group A or group B. In group 
A, 12 subjects received 10 oral doses of 400 mg of raltegravir twice daily (BD) 
during the first period of 5 days. On day 4 (together with the 7th dose of raltegravir), 
a single dose of 100 mg of lamotrigine was administered. After a wash-out period 
of 26 days (study days 6 to 31), all subjects received a second single dose of 100 
mg of lamotrigine (day 32). In group B, 12 subjects received the same treatments 
in reverse order.
The trial was approved by the Review Board of the Radboud University Nijmegen 
Medical Centre.
Study population
The trial was conducted in healthy young men aged between 18 and 55 years on 
the day of first dosing. For inclusion in the trial, subjects had to be in a good, age- 
appropriate health condition as established by physical examination, medical 
history, electrocardiography and biochemical, hematologic, and urinalysis testing 
within 4 weeks before the first dose. Subjects had to be able and willing to sign the 
Informed Consent Form before screening evaluations.
The main exclusion criteria were as follows: a history of sensitivity or idiosyncrasy to 
medicinal products or excipients; a positive HIV, hepatitis B or C test result and 
therapy with any drug (for 2 weeks preceding dosing), except for acetaminophen.
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Study drug and dosing
The raltegravir dosage that was used in this trial (400 mg twice-daily with or without 
food) is the recommended dosage for raltegravir (8;15). At the days of pharmacoki­
netic sampling, both raltegravir and lamotrigine were taken on an empty stomach 
because at the time of study design, available data on raltegravir pharmacokinetics 
were obtained in the absence of food (5). Fasting (no food, no fluid) was continued 
until 2 hours after dosing, followed by a standardized breakfast. Previous work 
demonstrated that steady-state conditions for raltegravir are present after 2 to 3 
days of chronic dosing (16). Therefore, the single dose of lamotrigine was 
administered on the fourth day of raltegravir administration. We used single doses 
of lamotrigine to minimize the risk of rash (13; 14).
Safety assessments and pharmacokinetic sampling
Blood samples for pharmacokinetics were collected throughout a 48-hour period 
(0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 24 and 48 hours) after dosing on day 4 and 32 
for lamotrigine and lamotrigine-2N-glucuronide to characterize drug absorption, 
distribution and elimination. Blood samples for pharmacokinetics of raltegravir 
were collected during an 8-hour period (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours) after 
dosing raltegravir on day 4 (group A) or day 32 (group B). In addition, blood samples 
were collected to determine trough levels of raltegravir, just before intake of the 
drug on day 1, 2, and 4 (group A); or day 29, 30 and 32 (group B).
Serum biochemistry and hematology test results were checked on days 1, 2, 4, 6, 
29, 30, 32 and 34. Adverse events were assessed during the same visits and on 
days 5 and 33. Screening for drugs of abuse was performed in urine on days 1 and 
29; urinalysis was carried out on days 4 and 32.
Compliance
Study personnel supervised all intake of medication at the clinical trial unit. The 
exact times of dosing were recorded. Drug intake at home was monitored by use of 
microelectronic monitoring system (MEMS) caps (Aardex Ltd, Zug, Switzerland), 
which record the opening of the medication bottle. Furthermore, pill counts and 
trough level measurements at days 2, 4, 30, and 32 were used to assess adherence. 
Finally, subjects were asked to write down the exact times of medication intake in a 
booklet.
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Bioanalysis of raltegravir, lamotrigine and lamotrigine-2N-glucuronide 
in plasma
Plasma concentrations of lamotrigine and lamotrigine-2N-glucuronide were 
analyzed by use of a validated reversed-phase high-performance liquid 
chromatography method (13). The accuracy values for lamotrigine were 103%, 
103%, and 104% for concentrations of 0.358, 1.79, and 11.94 mg/L, respectively. At 
these same concentrations, the precision values (within-day, coefficient of variation) 
were 2.34%, 1.82%, and 1.87%, respectively. For lamotrigine-2N-glucuronide, the 
accuracy values were 99%, 100%, and 99% at concentrations of 0.218, 1.09, and
7.25 mg/L, respectively. The precision values (within-day, coefficient of variation) 
were 4.08%, 2.43%, and 1.06%, respectively, for the same concentrations.
Plasma concentrations of raltegravir were analyzed by means of liquid-liquid 
extraction followed by reversed-phase HPLC with fluorescence detection. In brief, 
to 500 |aL of plasma was added: 500 |iL  acetate buffer (pH 4.0, 0.2 M); 5 mL 
hexane:dichloromethane 1:1 (v/v); and 50 |iL  of internal standard (lormetazepam in 
methanol: water 1:1 (v/v)). The sample was mixed on a vortex mixer for 5 minutes, 
followed by centrifugation at 11,000 rpm for 5 minutes. Afterwards, the organic 
phase was evaporated at 370C under a gentle stream of nitrogen gas, and 
reconstituted in 200 |iL  of eluens (acetonitrile: phosphate buffer (pH 4.80, 20 mM) 
(35:65 v/v)). Forty |iL  of the resulting solution was run on a 10-cm Symmetry Shield 
reversed phase C18 column (flow rate 1.5 mL/min) and raltegravir was detected by 
use of a fluorescence detector (X ,, 240 nm, X 412 nm).' excitation ’ emission >
The accuracy values for raltegravir were 99%, 101% and 97% at 0.050, 0.140 and
0.500 mg/L, respectively. At the same concentrations, the precision values (within 
day, coefficient of variation) were 2.4%, 2.5% and 1.9%, respectively. The calibration 
curve was linear over a concentration range of 0.014 to 1.40 mg/L.
Pharmacokinetic analysis
Pharmacokinetic parameters for lamotrigine, lamotrigine-2N-glucuronide and 
raltegravir were calculated by non-compartmental methods using the WinNonlin 
software package (version 4.1; Pharsight, Mountain View, CA) and the log/linear 
trapezoidal rule. Based on the individual plasma concentration-time data, the 
following pharmacokinetic parameters of lamotrigine were determined: the area 
under the plasma concentration-time curve from 0 to 48 hours after intake (AUC0^ 48; 
in hour*milligram/liter), the maximum plasma concentration of the drug (Cmax; in 
milligrams per liter), the time to reach Cmax (tmax; in hours), and the apparent 
elimination half-life (t1/2; in hours).
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For raltegravir the same pharmacokinetic parameters were calculated. To be able 
to compare raltegravir AUC with historical data, we calculated steady state AUC0^ 12 
by extrapolation to 12 hours.
Sample size and statistical analysis
The study was powered to detect a 20% difference in lamotrigine AUC. In our 
previous single dose lamotrigine trial, the intersubject coefficient of variation in 
lamotrigine AUC was 22.2% (14). With a conservative approach, we assumed 
intrasubject variability to be equal to intersubject variability and we calculated the 
required number of participants as 20. With an estimated dropout rate of 15%, 24 
subjects were included in the trial to ensure complete data from 20 subjects.
For the identification of a clinically relevant drug interaction, we used the 
bioequivalence approach (17). Geometric mean ratios (GMRs) with 90% confidence 
intervals (CIs) were calculated for A U C  „„, C and after log transformation of' > 0^ 48’ max 1/2 ^
within-subject ratios. GMRs with 90% CIs falling entirely within the range of 0.80 to
1.25 were considered to indicate no significant interaction.
We calculated AUC ratios of lamotrigine-2N-glucuronide vs. lamotrigine obtained 
by use of lamotrigine alone and by use of lamotrigine in combination with raltegravir 
to determine the effect of raltegravir on the glucuronidation of lamotrigine. To check 
whether auto induction of lamotrigine metabolism might have influenced our results, 
we also compared the AUC ratios of lamotrigine-2N-glucuronide and lamotrigine in 
subjects who took lamotrigine alone on day 32 (group A) to those obtained in 
subjects who took lamotrigine alone on day 4 (group B).
Statistical evaluations were carried out using SPSS for Windows, version 16.0.1 
(SPSS, Chicago, IL, 1989-2005).
Results
Baseline characteristics
Twenty-four healthy male subjects were included in this trial. The mean (range) age, 
body weight and body mass index were 34 (20-52) years, 79 (63-94) kg and 24 
(20-28) kg/m2, respectively. There was one black subject and one hispanic subject; 
the other subjects were Caucasians. There were no dropouts: all subjects completed 
the trial and were available for statistical analyses.
Ch
ap
ter
 7 
The
 
eff
ec
t 
of 
ra
lte
gr
av
ir 
on 
the
 
glu
cu
ro
nid
ati
on
 
of 
lam
otr
igi
ne
Compliance
The compliance of all 24 subjects was good, as indicated by their statements about 
the intake of the drug doses, the number of tablets in the returned vials, the 
raltegravir trough concentrations, the booklets, and the MEMS caps (data not 
shown).
Pharmacokinetics
All included subjects completed day 34 of the trial and were included for statistical 
evaluation. Figure 1 shows the lamotrigine and lamotrigine-2N-glucuronide plasma 
concentration versus time curves obtained in the presence and absence of 
steady-state raltegravir. The mean pharmacokinetic parameters of lamotrigine are 
shown in Table 1. Raltegravir did not appear to influence the pharmacokinetics of 
single-dose lamotrigine. The geometric mean ratios of lamotrigine AUC0^ 48, Cmax
Figure 1 Arithmetic mean plasma concentrations of lamotrigine and
lamotrigine-2N-glucuronide following the administration of a single 
dose of 100 mg of lamotrigine in the presence and absence of 
raltegravir.
Error bars represent the standard error of the mean.
Time after intake of lamotrigine (h)
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Table 1 Comparison of lamotrigine pharmacokinetics following
administration of a single dose of 100 mg of lamotrigine in the 
presence or absence of co-administration of multiple doses of 
400 mg raltegravir twice daily to healthy male subjects.
Pharmacokinetic
parameter
Lamotrigine alone Lamotrigine +  
Raltegravir
Lamotrigine 
+ Raltegravir: 
Lamotrigine alone
G eom etric
m ean
95%  CI for 
g eom etric  
m ean
G eom etric
m ean
95%  CI for 
geom etric  
m ean
GM R 90%  CI for 
G M R
A U C 0^  (h*m g /L) 33.1 (31.3, 35.0) 32.6 (30.7, 34.7) 0.99 (0.96, 1.01)
Cmax (m g/L) 1.28 (1.20, 1.37) 1.20 (1.13, 1.28) 0.94 (0.89, 0.99)
11/2 (h) 35.0 (31.0, 39.5) 36.0 (31.9, 40.7) 1.03 (0.97, 1.09)
AUC, area under the plasma concentration-time curve; Cmax , peak plasma concentration; 
t1/2 elimination half-life; GMR, geometric mean ratio; CI, confidence interval.
and t for lamotrigine + raltegravir vs. lamotrigine alone were are all close to 1.0 
and the corresponding 90% CIs were within the predefined interval of 0.80 - 1.25, 
indicating no interaction occurred (see Table 1). In agreement with this observation, 
the mean (SD) ratio of the AUC0^ 48 of lamotrigine-2N-glucuronide /  lamotrigine was 
similar when lamotrigine was taken alone or when taken with raltegravir.
The geometric mean (95% CI) AUC0^ 48 of lamotrigine-2N-glucuronide was 11.0 
(10.1-12.0) h*mg/L after intake of 100 mg of lamotrigine alone, leading to a mean 
(SD) AUC ratio of metabolite vs. parent compound of 0.35 (0.08). The mean (SD) 
ratio was 0.36 (0.10) when lamotrigine was taken in the presence of steady state 
raltegravir (p=0.35, paired samples t-test).
The mean (SD) AUC ratios of lamotrigine-2N-glucuronide vs. lamotrigine were 0.37 
(0.07) and 0.32 (0.08) in subjects who took lamotrigine alone on day 4 and day 32, 
respectively (p = 0.16, independent samples t-test), indicating no period effect 
occurred. In addition, the elimination half-life of lamotrigine was not significantly 
different in subjects who took lamotrigine alone on day 4 vs. on day 32: the mean 
elimination half-lives were 37.0 and 36.0 hours, respectively (p=0.83, independent 
samples t-test).
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Table 2 Pharmacokinetic parameters of raltegravir when compared to 
historical controls.
Pharmacokinetic
parameter
This study 
(n = 23c)
Wenning et al.(18) 
(n=9)
Anderson et al.(6) 
(n = 19)
AUCM2 (h*mg/L) 3.9 (2.7, 5.7)a 5.0b 3.4 (2.4, 4.7)b
Cmax (m9/L) 1.2 (0.8, 1.8) 1.4 (0.8, 2.3)b 0.8 (0.6, 1.2)b
Tmax (h) 1.5 (0-8) 1.5 1.5 (0-12)
AUC, area under the plasma concentration-time curve; Cmax , peak plasma concentration;
Tmax, time to reach Cmax.
Data are geometric means + 95% confidence intervals, except for Tmax (median + range)
a The raltegravir AUCM2 was obtained by extrapolation from the raltegravir AUC0^ 8
b Data for AUC and Cmax from historical controls were converted from h*|iM and |iM to 
h*mg/L and mg/L, respectively, using the molecular weight of raltegravir (482.51 g/mol)(8).
c One subject was excluded from the pharmacokinetic analyses of raltegravir because 
raltegravir's half-life and thus AUCM2 could not be determined reliably in this individual.
The arithmetic mean plasma raltegravir concentration-time curve following 
administration of raltegravir with lamotrigine is shown in Figure 2. One subject was 
excluded from the pharmacokinetic analyses of raltegravir, because raltegravir’s 
half-life and thus AUC0^ 12 could not be determined reliably. The geometric mean of 
the AUC0^ 8 of raltegravir was 3.70 h*mg/L. Extrapolation in Winnonlin to the AUC0^ 12 
resulted in a slightly higher (4.6%) geometric mean: 3.87 h*mg/L. The pharma­
cokinetic parameters of raltegravir, which are presented in Table 2, were similar to 
those of historical controls (6;18).
Raltegravir pharmacokinetics displayed large inter-individual variability: the 
coefficient of variation (CV) for raltegravir AUC0^ 8 was 77%. In addition, we observed 
that steady state raltegravir trough levels in the morning were 3 to 4 times higher 
than raltegravir levels obtained 8 hours after dosing (see Figure 2).
Adverse events and safety assessments
Study medication was generally well tolerated. Thirteen subjects reported a total of 
37 non-serious adverse events. The majority of these events (n=25, 68%) were 
classified as grade I; the remaining 12 events were classified as grade II (n=11, 
30%), or grade III (n=1, 3%).
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Three adverse events were considered possibly or probably drug-related. One 
subject reported transient nausea on the first day of raltegravir administration, 
which disappeared within 6 hours without need of additional treatment. The other 
two adverse events were reported in one subject who developed a grade III ASAT 
elevation (385 U/L) and a grade II ALAT elevation (101 U/L) on day 6, following five 
days of raltegravir administration. The subject reported no complaints and ALAT 
and ASAT values returned to normal values within 10 days.
Figure 2 Arithmetic mean plasma raltegravir concentration profile following 
the administration of multiple doses of 400 mg raltegravir twice 
daily.
1.8
0 1 2 3 4 5 6 7 8
Time after intake of raltegravir (h)
Error bars represent the standard error of the mean.
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Discussion
The primary objective of this study was to determine the effect of raltegravir on the 
pharmacokinetics of single-dose lamotrigine. The lamotrigine pharmacokinetics 
clearly met the predefined bioequivalence criteria for no clinically relevant interaction. 
In addition, the mean ratio of the AUC0^ 48 of lamotrigine-2N-glucuronide to 
lamotrigine was similar when lamotrigine was taken alone (0.35) or when taken with 
raltegravir (0.36), which indicates that raltegravir does not inhibit or induce the 
glucuronidation of lamotrigine.
In our previous single dose lamotrigine study, the AUC ratio of lamotrigine-2N- 
glucuronide vs. lamotrigine was slightly higher (0.45) after the same dose of 
lamotrigine (14). This is probably caused by the longer sampling period in that 
study (120 hours vs. 48 hours in the current study) (14). Lamotrigine-2N-glucuronide 
has a longer elimination half-life than lamotrigine (see Figure 1). As a consequence, 
determining the AUC0^ m for both lamotrigine and lamotrigine-2N-glucuronide 
instead of the AUC0^ 48 which we did in the current study, will increase the absolute 
value of the AUC of lamotrigine-2N-glucuronide relatively more when compared to 
the AUC of lamotrigine, which results in a higher ratio of lamotrigine-2N-glucuronide 
versus lamotrigine.
Because raltegravir and lamotrigine share a common metabolic pathway, we 
hypothesized that raltegravir might inhibit lamotrigine glucuronidation, although 
results from in vitro experiments had indicated that raltegravir did not potently inhibit 
(IC50 >50 |iM) UGT2B7-mediated glucuronidation. However, as explained by Kiang 
and colleagues (19), one must be cautious when predicting in vivo effects of UGT 
enzymes based on data obtained from in vitro experiments.
Moreover, there are several examples of drug-drug interactions between drugs that 
are both metabolized via glucuronidation, potentially based on hepatic competition 
for glucuronidation (20;21). Therefore, and because of the importance of drug-drug 
interactions in the management of seizures in HIV-infected patients (10), we felt it 
was appropriate to investigate raltegravir’s influence on the glucuronidation of the 
UGT substrate lamotrigine in a clinical study.
In our previous lamotrigine study, we considered lamotrigine a phenotypic probe 
for UGT1A4 and possibly UGT2B7 substrates (14). Based on this view, we originally 
designed the current study as a ‘phenotypic probe’ study to investigate the influence
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of raltegravir on UGT1A4 and UGT2B7 enzymes in vivo. Meanwhile, lamotrlgine 
metabolism by UGT1A4 and UGT2B7 has become in part controversial: a recent 
publication suggests that lamotrigine is metabolized by UGT1A3 and UGT 1A4, but 
not by UGT2B7 (22). Thus, it is possible that lamotrigine is metabolized by at least 
three different UGT enzymes, which questions the appropriateness of using 
lamotrigine as a selective probe for UGT phenotyping. For instance, if raltegravir 
inhibits UGT1A4 enzymes and not UGT1A3 or UGT2B7, it is possible that lamotrigine 
is still glucuronidated at a similar velocity by using UGT1A3 and/or UGT2B7 as 
escape routes.
As depicted in Table 2, pharmacokinetic parameters of raltegravir were comparable 
to those of healthy volunteers in other studies, indicating no significant effect of a 
single dose of lamotrigine on raltegravir pharmacokinetics. Because assessing the 
effect of a single dose of lamotrigine on the pharmacokinetics of raltegravir was a 
secondary objective of our trial, we did not include a 12-hour pharmacokinetic 
sample in our study. We extrapolated the raltegravir AUC0^ 8 to AUC0^ 12 in order to 
compare our data to historical controls. Because the percentage of the AUC 
extrapolated was smaller than 5%, we do not expect the extrapolation to confound 
the comparison to the historical controls.
The pharmacokinetics of raltegravir were characterized by large interindividual 
variability (CV 77%), which was reported by others as well (23). Proposed 
explanations for large interindividual variability are differences in co-administration 
with food and concomitant medications (8). Nonetheless in our study, raltegravir 
was taken on an empty stomach and concomitant medications, except for 
lamotrigine, were not allowed. Since omeprazole increases raltegravir exposure by 
321% (15), differences in gastric pH might have contributed to interindividual 
variability. Another contributing factor may be genetic polymorphism of UGT1A1, 
the enzyme that metabolizes raltegravir. Genetic polymorphism of UGT1A1 is 
relatively common: 7-19% of the Caucasian population is homozygous for 
UGT1A1*28, which leads to decreased UGT1A1 expression and reduced elimination 
of UGT1A1 substrates, such as irinotecan and raltegravir (19).
Raltegravir trough concentrations taken in the morning of study day 4 (i.e., around 
8 AM), before drug intake for pharmacokinetic sampling, were on average 3 to 4 
times higher than raltegravir concentrations obtained 8 hours after dosing (see 
Figure 2). Because this might have been caused by too late intake of the raltegravir 
evening dose before the day of pharmacokinetic sampling, we checked our MEMS 
data thoroughly. However, according to MEMS, all subjects opened the medication
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bottle between 7:42 PM and 8:56 PM in the evening of day 3 or 31 (scheduled intake 
time 8:00 PM).
Further investigation learned that the same phenomenon can be noted in the work of 
Anderson et al. (6) In their paper, raltegravir (morning) trough concentrations were 
about 2-fold higher than C8h or C12h raltegravir concentrations. A possible explanation 
for these findings could lie in circadian variations in pharmacokinetics (24). 
For instance, acetaminophen glucuronidation occurs at a higher rate in the daytime 
compared to the night (25). Glucuronidation rates of raltegravir might vary in a 
similar way, although this hypothesis requires further investigation. Another factor 
that may have contributed to this phenomenon is that raltegravir morning Ctrough 
levels may have been increased in subjects who took raltegravir with food at the 
evening before pharmacokinetic sampling days. The food effect on raltegravir is 
substantial (35% decrease in Cmax and 8.5-fold increase in Cmin), although not 
considered clinically relevant (26). Unfortunately, we cannot test this hypothesis, 
because we did not note whether subjects took raltegravir with or without food 
at home.
Combined use of single-dose lamotrigine and raltegravir was generally well 
tolerated. However, there was one subject with a reversible grade III ASAT and 
grade II ALAT elevation after 5 days of raltegravir administration. Lamotrigine as the 
causal agent seems unlikely in this case, because ASAT had already risen from 16 
to 190 U/L between day 1 and day 4, i.e., before intake of lamotrigine. Indeed, 
hepatitis is among the serious drug-related adverse events of raltegravir, although 
its frequency is defined as ‘uncom mon’ (> 1/1,000 to <1/100) (8;15).
This is the third study in which we studied the influence of antiretroviral drugs on 
the glucuronidation of lamotrigine. In the first trial we encountered a relatively high 
incidence (25%) of lamotrigine-related rashes (13), especially among women (42%). 
Therefore, we decided to include only male subjects in future trials with lamotrigine. 
In an attempt to further reduce the incidence of rash, we used single doses of 
lamotrigine instead of chronic dosing. The effect of these measures is satisfactory: 
rash occurred in only one subject in the second trial (4.8%) and it did not occur in 
the present trial.
In the first study that used single doses of lamotrigine, we used a sequential design,
i.e., all subjects received a single dose of lamotrigine on day 1 (reference) and 
again on days 13 and 27, after administering atazanavir without and with ritonavir, 
respectively. In this situation, it could not be excluded that auto-induction of 
lamotrigine metabolism had confounded our results (9;14). Therefore, we modified
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the design of the current study and used a randomized cross-over design with a 
wash out period of 26 days. In addition, we were now able to check whether our 
data were confounded by lamotrigine auto-induction, which clearly did not occur. 
Therefore, we consider the current study design optimal for testing whether drugs 
influence the glucuronidation of lamotrigine.
In conclusion, our study shows that raltegravir does not affect exposure to the UGT 
substrate lamotrigine.
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Abstract
Background: To evaluate the potential drug-drug interaction between raltegravir 
and pravastatin.
Methods: This was an open-label, randomized, 3-period, cross-over, single-centre 
trial in 24 healthy volunteers. Subjects received the following treatments: pravastatin 
40 mg q.d. for 4 days, raltegravir 400 mg b.d. for 4 days, and pravastatin 40 mg 
q.d. + raltegravir 400 mg b.d. for 4 days. The treatments were separated by wash­
out periods of 10 days. On day 4 of each treatment period, blood samples for 
pharmacokinetics were collected throughout a 24-hour period.
Results: Geometric mean ratios (GMRs) (90% confidence interval (90% CI)) for 
pravastatin + raltegravir versus pravastatin alone were 0.96 (0.83-1.11) for AUC0^ 24 
and 1.04 (0.85-1.26) for Cmax. The mean low-density lipoprotein cholesterol 
decrease after 4 days of pravastatin was 0.42 mmol/L both in the presence and the 
absence of raltegravir. The GMR (90% CI) AUC0^ 12, Cmax, and C12 for raltegravir + 
pravastatin versus raltegravir alone were 1.13 (0.77-1.65), 1.31 (0.81-2.13), and 0.59 
(0.39-0.88), respectively.
Conclusion: Raltegravir did not influence the pharmacokinetics or the short­
term lipid-lowering effects of pravastatin, whereas pravastatin increased the 
Cmax but decreased the C12 of raltegravir. The effects of pravastatin on raltegravir 
pharmacokinetics are not likely to be clinically relevant.
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Introduction
Highly active antiretroviral therapy (HAART) has changed HIV Infection from a fatal 
disease to a manageable chronic medical condition. As a result, the HIV-infected 
population is becoming older (1). Among this aging population, risk factors for the 
development of cardiovascular disease are highly prevalent. These include HIV 
itself and the relatively high number of males and smokers (2;3).
In addition, the use of HIV-protease inhibitors and certain nucleoside analogue 
reverse-transcriptase inhibitors, i.e. abacavir and didanosine, seems to be 
associated with an increased risk of myocardial infarction (4;5). The mechanism by 
which HIV and some antiretroviral drugs increase the risk of cardiovascular events 
is not entirely understood, although it may be partly explained by HIV- and HAART- 
induced dyslipidemia (4;6). A common strategy to manage dyslipidemia is the use 
of lipid-lowering drugs, such as 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG- 
CoA) reductase inhibitors (statins) and flbrates (7).
A complicating factor in the concomitant use of antiretroviral agents and lipid­
lowering drugs is the occurrence of drug-drug interactions. Most statins are 
metabolized by Cytochrome P450-3A isoenzyme (CYP450-3A), while protease 
inhibitors are strong inhibitors of this enzyme. Drug-drug interaction studies 
on the co-administration of statins and protease inhibitors have demonstrated 
significant increases in plasma concentrations of simvastatin (8), atorvastatin (8), 
and rosuvastatin (9;10), and cases of rhabdomyolysis in HIV-infected patients 
have been attributed to these interactions (11;12). Pravastatin is not metabolized 
by CYP450 and protease inhibitors do not elevate its plasma concentration (8;13). 
Therefore, and because of pravastatin’s well-established benefit in the prevention 
of cardiovascular events (14;15), pravastatin is considered a first-choice statin for 
HIV-infected patients (13;16).
The newly developed HIV-1 integrase inhibitor raltegravir is likely to be used by 
patients that suffer from HIV or HAART-associated dyslipidemia. Hence, co­
administration of pravastatin and raltegravir can be expected in the HIV-infected 
population.
Raltegravir is glucuronidated by uridine diphosphate (UDP)-glucuronyltransferase 
1A1 (UGT1A1) (17). Pravastatin metabolism is complex and involves multiple oxidative 
pathways and glucuronidation (18). Because both agents share glucuronidation as 
a common metabolic pathway, there is a potential for a pharmacokinetic drug-drug
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interaction. In addition, raltegravlr use has been associated with myopathy and 
rhabdomyolysls in heavily pre-treated HIV-infected patients (17;19). Although the 
causal relationship to raltegravir has not been clearly established, the Summary 
of Product Characteristics of raltegravir warns that raltegravir must be taken with 
caution in patients receiving statins (17).
In the context of this warning and the potential for a pharmacokinetic drug interaction 
between raltegravir and pravastatin, there was a clear need to perform a formal 
drug-drug interaction study. The primary objective of this study was to determine 
the effect of raltegravir on pravastatin pharmacokinetics and vice versa. Secondary 
objectives were to evaluate the safety of the combined use of pravastatin and 
raltegravir, and to investigate the effect of raltegravir on the short-term lipid-lowering 
effects of pravastatin.
Methods
Study design
This open-label, randomized, three-period, cross-over, single-center, phase I, 
multiple-dose trial was conducted from June to September 2008 at the Radboud 
University Nijmegen Medical Centre (Nijmegen, the Netherlands).
Twenty-four healthy volunteers (12 females, 12 males) were stratified according to 
gender and the presence of a fasting elevated serum total cholesterol at screening 
> 6.5 mmol/L. The 24 participants were subsequently divided into 6 groups of 4 
participants. In group 1, participants received pravastatin 40 mg q.d. for 4 days. 
After a wash-out period of 10 days, participants received raltegravir 400 mg b.d. 
for 4 days. After a second wash-out period of 10 days, participants received both 
pravastatin 40 mg q.d. and raltegravir 400 mg b.d. for 4 days. The other 5 groups 
were exposed to exactly the same drug regimens, but each in a different order to 
prevent bias that might result from period effects.
The trial was approved by the Review Board of the Radboud University Nijmegen 
Medical Centre.
Study population
The trial was conducted in healthy men and women aged between 18 and 55 years. 
For inclusion in the trial, participants had to be in a good, healthy condition for their
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age, as established by physical examination, medical history, electrocardiography, 
and biochemical, hematologic, and urinalysis testing conducted within 4 weeks 
before the first dose. Participants had to be able and willing to sign the Informed 
Consent Form before screening evaluations were carried out.
The main exclusion criteria were: a history of sensitivity or idiosyncrasy to medicinal 
products or excipients; a fasting triglyceride level >8.0 mmol/L (see below); a 
positive HIV test result; a positive hepatitis B or C test result; and therapy with any 
drug (for 2 weeks preceding dosing), except for acetaminophen.
Study drug and dosing
The raltegravir dosage that was used in this trial (400 mg b.d. with or without food) 
is the recommended dosage for raltegravir (17;20). On the days of pharmacokinetic 
sampling, both raltegravir and pravastatin were taken on an empty stomach because 
pravastatin’s systemic bioavailability is reduced by food (21), and because, at the 
time of study design, available data on raltegravir pharmacokinetics were obtained 
in the absence of food (22). Fasting (no solids or fluids) was continued for 2 hours 
after dosing, followed by a standardized breakfast.
Safety assessments and pharmacokinetic sampling
Blood samples for pharmacokinetics were collected just before dosing and at 0.5, 1, 
1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours after dosing on day 4 of each treatment period 
to characterize drug absorption and elimination. After administration of raltegravir 
alone, no sample was taken at 24 hours after dosing. In addition, blood samples 
were collected to determine trough levels of either raltegravir or pravastatin or both, 
just before intake of the drug on days 1 and 2 of each treatment period.
Serum biochemistry, hematology, and urinalysis test results were checked at 
screening and on days 1, 2, 4, and 5 of each treatment period. Adverse events 
were assessed during the same visits. Special attention was paid to myopathy. 
Screening for drugs of abuse was performed at screening and on day 1 of each of 
the three treatment periods.
Compliance
At visits to the clinical trial unit, study personnel supervised the intake of medication 
and recorded the exact times of dosing. Drug intake at home was monitored by 
the use of microelectronic monitoring system (MEMS) caps (Aardex Ltd, Zug, 
Switzerland), which record the opening of the medication bottle. Furthermore,
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pill counts and plasma trough level measurements on days 2 and 4 were used to 
assess adherence. Finally, participants were asked to write down the exact times of 
medication intake in a booklet.
Bioanalysis of pravastatin and raltegravir in plasma
Plasma concentrations of raltegravir were analyzed at the Department of Clinical 
Pharmacy at the Radboud University Nijmegen Medical Centre by means of 
a validated reversed-phase high-performance liquid chromatography (HPLC) 
method, which has been described previously (23).
Plasma concentrations of pravastatin were measured at the Analytical Biochemical 
Laboratories (Assen, the Netherlands). In the assay procedure, pravastatin, 
along with its internal standard, d3-pravastatin, were extracted from the plasma 
samples by protein precipitation followed by on-line solid-phase extraction using 
C18 cartridges on a Symbiosis Pharma system (Spark, Emmen, the Netherlands). 
Separation of pravastatin and d3-pravastatin was performed on the same 
system, equipped with a C8 HPLC column (75 x  4.6 mm, 3.5 |um). Detection and 
quantification of pravastatin and d3-pravastatin was carried out using an API 4000 
tandem mass spectrometry (MS/MS) detector (MDS Sciex, Concord, ON, Canada). 
The accuracy values for pravastatin were 106%, 105%, and 103% at 1.50, 15.0, and 
400 jug/L, respectively. At the same concentrations, the precision values (within day, 
coefficient of variation) were 3.7%, 1.6%, and 3.2%, respectively. The calibration 
curve was linear over a concentration range of 0.500 to 500 ug/L.
Pharmacokinetic analysis
Pharmacokinetic parameters for pravastatin and raltegravir were calculated by 
non-compartmental analysis of the plasma-concentration data using WinNonlin 
software version 5.2.1 (Pharsight Corporation, Mountain View, CA, USA). 
On the basis of the individual plasma concentration-time data, the following 
pharmacokinetic parameters of pravastatin were determined: the area under 
the plasma concentration-time curve from 0 to 24 hours after intake (AUC0^ 24; 
in ug-hour/L); the maximum plasma concentration of the drug (Cmax; in ug/L), the 
time to reach Cmax (Tmax; in hours); the apparent oral clearance (CL/F) (in L/hour); 
the volume of distribution (V/F) (in liters); and the apparent elimination half-life 
(t ; in hours). For raltegravir, the same pharmacokinetic parameters were calculated, 
except that the trough concentration in plasma 12 hours after intake (C12; in mg/L) 
was also calculated and the AUC was calculated over the dosing interval from 0 
to 12 hours.
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Lipid-lowering effects: low-density lipoprotein cholesterol
On days 1 and 5 of each treatment period, serum total cholesterol, triglycerides, 
and high-density lipoprotein cholesterol concentrations were obtained under 
fasting conditions (> 12 hours from last food ingestion). The Friedewald equation 
was used to calculate LDL cholesterol (24). Because this equation cannot be 
applied in subjects with triglyceride levels above 8.0 mmol/L, we excluded those 
who had higher fasting triglyceride levels. We used paired t-tests to compare LDL 
changes during the 4 days of treatment with pravastatin, raltegravir, and pravastatin 
+ raltegravir, respectively.
Sample size and statistical analysis
The required number of participants was calculated to be 20 (to detect 20% 
differences in the AUCs of pravastatin and raltegravir). To account for a dropout 
rate of 15%, 24 participants had to be included.
For the identification of a clinically relevant drug interaction, we used the 
bioequivalence approach (25). Geometric means were calculated for the AUC, Cmax, 
C12, CL/F, V/F, and t GMRs with 90% CIs were calculated after log transformation 
of within-patient ratios. GMRs with 90% CIs falling entirely within the range of 0.80 
to 1.25 were considered to indicate no significant interaction.
Statistical evaluations were carried out using SPSS for Windows, version 16.0.1 
(SPSS, Chicago, IL, 1989-2005).
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Results
Baseline characteristics
Twenty-four healthy volunteers (12 females and 12 males) were Included In the 
trial. The mean (range) age, body weight, and body mass Index were 34 (20-53) 
years, 70 (49-103) kg and 23 (18-29) kg/m2, respectively. There were two Hispanic 
participants; the other 22 participants were Caucasian. There were no dropouts: all 
participants completed the trial and all were available for statistical analyses.
Compliance
The compliance of all 24 participants was good, as indicated by their statements 
about the intake of the drug doses, the MEMS caps, the number of tablets in the 
returned vials, the plasma trough concentrations of raltegravir, and the booklets 
(filled in by the participants) recording intake of medication.
Figure 1 Geometric mean plasma pravastatin concentration profile In
the presence and absence of raltegravir (note the semilog scale 
on the inset).
60,0
Time after intake of pravastatin (h)
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Table 1 Comparison of steady-state pravastatin pharmacokinetics with or 
without co-administration of multiple doses of 400 mg of raltegravir 
twice daily to healthy volunteers.
Pharmacokinetic Pravastatin alone Pravastatin + Pravastatin +
parameter Raltegravir Raltegravir:
Pravastatin
alone
Geometric 95% CI Geometric 95% CI GMR 90% CI 
mean for geometric mean for geometric for GMR
mean mean
AUC0^ 24 (h-MS/L) 157 (127, 194) 150 (121, 187) 0.96 (0.83, 1.11)
Cmax (M9/L) 58.4 (45.1, 75.6) 60.5 (47.6, 77.0) 1.04 (0.85, 1.26)
tmax 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
CL/F (L/h) 255 (206, 315) 266 (214, 331) 1.04 (0.90, 1.21)
V/F (L) 1048 (788, 1394) 1026 (672, 1566) 0.98 (0.67, 1.42)
11/2 (h) 2.85 (2.14, 3.80) 2.68 (1.93, 3.70) 0.94 (0.68, 1.30)
CI, confidence interval; GMR, geometric mean ratio; AUC, area under the plasma concentration­
time curve; Cmax, peak plasma concentration; Tmax, time to reach Cmax, CL/F, apparent oral clearance; 
V/F, volume of distribution; t1/2, elimination half-life. *For Tmax, median + interquartile range is reported.
Pharmacokinetics
Figure 1 shows the geometric mean pravastatin plasma concentration versus 
time curves obtained in the presence and absence of raltegravir. The mean 
pharmacokinetic parameters of pravastatin are described in Table 1. Raltegravir did 
not influence the pharmacokinetics of pravastatin. For pravastatin co-administered 
with raltegravir relative to pravastatin alone, the GMR (90% CI) was 0.96 (0.83-1.11) 
for AU C  „, 1.04 (0.85-1.26) for C and 0.94 (0.68-1.30) for t„.0^ 24’ ' > max ' 1 1/2
The geometric mean plasma raltegravir concentration-time curves following 
administration of raltegravir with and without pravastatin are shown in Figure 2. 
The mean pharmacokinetic parameters of raltegravir are presented in Table 2. 
Pravastatin increased the Cmax but decreased the C12 of raltegravir. For raltegravir 
co-administered with pravastatin relative to raltegravir alone, the GMR (90% CI) 
was 1.13 (0.77-1.65) for AUC0^ 12, 1.31 (0.81-2.13) for Cmax, 0.59 (0.39-0.88) for 
C12, and 0.99 (0.88-1.22) for t1/2. At days 2 and 4, the GMR (90% CI) Ctrough for 
raltegravir + pravastatin versus raltegravir alone were 0.70 (0.48-1.02) and 0.90
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(0.60-1.33), respectively. Of note, steady-state plasma trough concentrations of 
raltegravlr obtained in the morning were approximately 10 times higher than plasma 
concentrations obtained 12 hours after dosing in the evening (see Figure 2).
Lipid-lowering effects: low-density lipoprotein cholesterol
Table 3 summarizes the changes in low-density lipoprotein (LDL) cholesterol 
observed in the three treatment regimens. After short-term administration (8 doses) 
of raltegravir alone, serum LDL cholesterol levels were not significantly altered. 
Short-term administration (4 doses) of pravastatin alone resulted in a statistically 
significant decrease of the mean serum LDL cholesterol concentration. The mean 
LDL decrease after 4 days of pravastatin administered with raltegravir was similar 
to the effect of pravastatin alone, indicating no influence of raltegravir on the short­
term lipid-lowering effects of pravastatin.
Figure 2 Geometric mean plasma raltegravir concentration profile In
the presence and absence of pravastatin (note the semilog scale 
on the inset).
Time after intake of raltegravir (h)
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Table 2 Comparison of steady-state raltegravir pharmacokinetics with or
without co-administration of multiple doses of 40 mg of pravastatin 
once-daily to healthy volunteers.
Pharmacokinetic
parameter
Raltegravir alone Raltegravir +  
Pravastatin
Raltegravir +  
Pravastatin: 
Raltegravir 
alone
Geometric 95% CI Geometric 95% CI GMR 90% CI
mean for geometric 
mean
mean for geometric 
mean
for GMR
AUCM 2  (irmg/L) 6.93 (5.24, 9.16) 7.83 (5.39, 11.4) 1.13 (0.77, 1.65)
Cmax (mg/L) 2.05 (1.43, 2.94) 2.69 (1.71, 4.23) 1.31 (0.81, 2.13)
t (h)*max v ' 1.52 (1.00, 2.44) 1.50 (0.89, 2.00)
C,2 (mg/L) 0.061 (0.038, 0.098) 0.036 (0.021, 0.060) 0.59 (0.39, 0.88)
CL/F (L/h) 57.7 (43.7, 76.4) 51.1 (35.2, 74.2) 0.88 (0.60, 1.29)
V/F (L) 178 (124, 256) 156 (93.7, 261) 0.88 (0.52, 1.48)
11/2 (h) 1.99 (1.72, 2.30) 1.96 (1.53, 2.52) 0.99 (0.80, 1.22)
CI, confidence interval; GMR, geometric mean ratio; AUC, area under the plasma concentration-time 
curve; Cmax, peak plasma concentration; Tmax, time to reach Cmax, C12, plasma concentration 12 hours 
after intake of raltegravir; CL/F, apparent oral clearance; V/F, volume of distribution; t1/2, elimination 
half-life. *For Tmax, median + interquartile range is reported.
Adverse events and safety assessments
There were no discontinuations due to adverse events, and no serious adverse 
events were reported. The 24 study participants reported a total of 91 adverse 
events. The most common adverse event was headache, which was reported by 5 
different participants (4 reports on raltegravir, 2 on pravastatin, and 2 on pravastatin 
+ raltegravir). Twenty adverse events (22%) were considered to be possibly drug- 
related. The great majority of these events (n=19, 95%) were classified as grade 1; 
one adverse event (i.e. transient headache on raltegravir) was classified as grade 2. 
There were no creatinine kinase (CK) elevations or cases of myopathy that were 
considered to be possibly related to the study drugs.
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Table 3 Changes in fasting serum LDL cholesterol (mmol/L) after 4 doses 
of 40 mg of pravastatin.
Mean 95% CI P
Change in LDL after 4 doses of 40 mg of 
pravastatin taken alone (day 5 - day 1)
-0.42 (-0.61; -0.24)t <0.001«
Change in LDL after 4 doses of pravastatin taken 
with raltegravir (day 5 - day 1)
-0.42 (-0.59; -0.25)t <0.001«
Change in LDL after 8 doses of raltegravir alone 
(day 5 - day 1)
+ 0.12 (-0.02; +0.26)t 0.10«
Differences in pravastatin - induced LDL change: 
change without raltegravir (day 5 - day 1) minus 
change with raltegravir (day 5 - day 1)
-0.002 (-0.24; +0.23)t 0.98«
LDL, low-density lipoprotein; CI, confidence interval. 
t 95% confidence interval around the mean.
«  paired-samples t-test.
Discussion
In this study, raltegravir did not increase pravastatin plasma concentrations and 
no drug-related myopathy or CK elevations occurred during the short-term co­
administration of pravastatin with raltegravir. In addition, raltegravir had no influence 
on the short-term lipid-lowering efficacy of pravastatin.
On the other hand, concomitant use of pravastatin and raltegravir resulted in a 
mean 30% increase of the raltegravir Cmax, and a slightly increased raltegravir mean 
AUC0^ 12 (13%). The elimination half-life of raltegravir was unaffected, because both 
raltegravir clearance and volume of distribution decreased to a similar degree 
after the addition of pravastatin (see Table 2). Therefore, the higher raltegravir Cmax 
in the presence of pravastatin is probably not caused by inhibition of raltegravir 
metabolism, but rather by a change in the bioavailability of raltegravir.
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It is tempting to speculate about the potential mechanism for the increased 
raltegravir peak plasma concentration in the presence of pravastatin. Raltegravir 
is a P-glycoprotein (P-gp) substrate; P-gp inhibition might thus have increased the 
bioavailability of raltegravir (26). However, this is not a likely mechanism because 
pravastatin is not an inhibitor or a substrate of P-gp (27). Pravastatin is a substrate of 
the organic anion-transporting polypeptide (OATP) 1B1, formerly known as OATP2 
or OATP-C (28-30). OATP1B1 is a transporter which is located at the basolateral 
membrane of hepatocytes (31). If OATP1B1 also mediates raltegravir uptake into 
hepatocytes, which is currently unknown, competition for OATP1B1 may have 
resulted in decreased raltegravir hepatic uptake and increased raltegravir peak 
plasma concentrations.
The increase in raltegravir plasma concentrations with pravastatin is smaller than 
observed with tenofovir (raltegravir AUC +49%, Cmax +64%) (32) or atazanavir 
(raltegravir AUC +41%, Cmax +24%) (33). Clinical data from phase II and phase III 
trials showed that the combined use of raltegravir with these drugs did not raise any 
safety issues (34;35). In addition, no dose- or pharmacokinetic parameter-related 
toxicities have been identified for raltegravir so far. A phase I trial, in particular, 
showed that a raltegravir dosage as high as 800 mg b.d. was as well tolerated 
as the standard dosage of 400 mg b.d. (36). Therefore, the modest increase in 
raltegravir peak plasma concentrations in the presence of pravastatin is not likely to 
cause any safety concerns.
Raltegravir C12 was approximately 40% decreased in the presence of pravastatin. 
Because we encountered considerable variability in raltegravir Ctrough and C12 values 
(coefficient of variation: 50%), this finding may be caused by chance. Another 
explanation would be induction of raltegravir metabolism by pravastatin. Nonetheless, 
this is not a likely scenario. First, pravastatin had no effect on the elimination half-life 
of raltegravir (see Table 2). Second, enzyme induction is known to increase with time, 
which is in contrast with our data (the GMR Ctrough for raltegravir + pravastatin versus 
raltegravir alone were 0.70 and 0.90 on day 2 and day 4, respectively). Finally, there 
are no indications of pravastatin being an enzyme inducer (37).
When interpreting the results of our study, it is important to realize which 
pharmacokinetic parameter of raltegravir is associated with antiviral efficacy. 
Intensive investigations of pharmacokinetic-pharmacodynamic data obtained in 
phase II and phase III trials did not find any relationship between raltegravir C12 and 
raltegravir efficacy (38;39).
161
C
h
a
p
te
r 
8 
D
ru
g
-
d
ru
g
 
in
te
ra
c
ti
o
n
s
 
b
e
tw
e
e
n
 
ra
lt
e
g
ra
v
ir
 
an
d 
p
ra
va
s
ta
ti
n
 
in 
h
e
a
lt
h
y 
v
o
lu
n
te
e
rs
These relationships were established for raltegravlr plasma concentrations which 
were randomly taken during the dosing interval, which indicates that raltegravir 
AUC is the pharmacokinetic parameter related to efficacy (39). In agreement with 
this, in vitro data provided evidence that the AUC/EC50 ratio of raltegravir is the 
pharmacokinetic variable that explains viral inhibition by raltegravir (40). Because 
the AUC of raltegravir was 13% increased in our study, we do not expect diminished 
raltegravir efficacy when combined with pravastatin.
Plasma trough concentrations of raltegravir obtained on the morning of study day 4, 
before drug intake for pharmacokinetic sampling, were on average 10 times higher 
than raltegravir C12 concentrations (see Figure 2). This finding is consistent with 
previously published results (23;41). Possible explanations are circadian variations 
in glucuronidation (42;43) and the effect of food on raltegravir pharmacokinetics. 
The food effect on raltegravir is considerable (e.g. 8.5-fold increase in Cmin (44)). 
Therefore, raltegravir morning Ctrough levels may have been increased in participants 
who took raltegravir with food on the evening before the pharmacokinetic sampling 
days. In this study, participants were free to take raltegravir at home with or without 
food, and the intake of food was not recorded.
In conclusion, short-term co-administration of raltegravir and pravastatin was well 
tolerated in healthy volunteers and did not result in altered pravastatin plasma 
exposure. In accordance with this, raltegravir did not influence the short-term 
lipid-lowering effects of pravastatin. The effects of pravastatin on raltegravir 
pharmacokinetics are not likely to be of clinical importance. The data from our 
study support the co-administration of raltegravir and pravastatin without dose- 
adjustments.
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Abstract
Objective: To manage the interaction between fosamprenavir/ritonavir and 
posaconazole, we hypothesized that ritonavir could be replaced by posaconazole 
as an alternative booster of fosamprenavir with no significant influence on 
posaconazole pharmacokinetics.
Methods: This was an open-label, randomized, 3-period, cross-over, single-centre 
trial in 24 healthy volunteers. All subjects received the following three treatments for
10 days, separated by washout periods of 17 days: posaconazole 400 mg twice 
daily; fosamprenavir/ritonavir 700/100 mg twice daily; fosamprenavir 700 mg twice 
daily with posaconazole 400 mg twice daily.
Results: Twenty subjects completed the trial. Geometric mean ratios (GMR; +90% 
CI) of posaconazole AUC and Cmax when taken with fosamprenavir versus 
posaconazole alone were 0.77 (0.68-0.87) and 0.79 (0.71-0.89), respectively. 
The GMRs of amprenavir AUC and Cmax when taken as fosamprenavir and 
posaconazole versus fosamprenavir/ritonavir were 0.35 (0.32-0.39) and 0.64 
(0.55-0.76), respectively. No serious adverse events were reported during the trial. 
Conclusion: Unboosted fosamprenavir should not be used concomitantly with 
posaconazole.
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Introduction
Infections with fungi and yeasts frequently occur in patients infected with HIV. Since 
the introduction of combination antiretroviral therapy (cART), the incidence and 
prevalence of most opportunistic infections has decreased (1;2) but they can still 
pose a problem in, for instance, resource limited settings or in non-compliant 
patients.
Azole antifungal drugs are first line therapy in the prophylaxis and treatment of 
invasive fungal infections. Posaconazole is a second generation triazole with a 
broad antifungal spectrum against yeasts and moulds. It has proven to be effective 
in the prevention and treatment of invasive fungal infections in high-risk patients, 
including those who are immunosuppressed (3-5). Once absorbed, 76.9% of the 
administered dose of posaconazole is excreted with feces. 14% of the administered 
dose is retrieved in the urine as a glucuronide metabolite (6). UDP-glucuronyltrans- 
ferase 1A4 (UGT1A4) has been identified as the key enzyme responsible for 
posaconazole glucuronidation (7). Posaconazole is a potent inhibitor of the 
cytochrome P450 isoform 3A4 (CYP3A4) (8).
Fosamprenavir is a protease inhibitor that is used to treat HIV-infection (9). Once 
hydrolysed to amprenavir, this substance is both a substrate and an inhibitor of 
CYP3A4. Fosamprenavir is given concomitantly with ritonavir which serves as a 
booster of the pharmacokinetics of amprenavir (10). Although ritonavir is capable of 
potent CYP3A4 inhibition, ritonavir induces other metabolic pathways including glu­
curonidation and CYP2C19 (11-14).
The combination of antiretroviral drugs with azole antifungal drugs is not without 
risk. First, combining fosamprenavir/ritonavir with posaconazole may lead to 
subtherapeutic posaconazole exposure due to induction of UGT by ritonavir. 
Second, inhibition of CYP3A4 by posaconazole may (further) increase exposure to 
amprenavir with an increased risk of fosamprenavir toxicity.
To manage the interaction between fosamprenavir/ritonavir and posaconazole, we 
hypothesized that ritonavir could be replaced by posaconazole as an alternative 
booster of the pharmacokinetics of fosamprenavir, with the additional advantage of 
eliminating the potential negative effect of ritonavir on posaconazole. Based on 
these theoretical considerations, we performed a trial to determine the effect of 
unboosted fosamprenavir on posaconazole and vice versa.
171
C
h
a
p
te
r 
9 
E
ff
e
c
t 
of
 
p
o
s
a
c
o
n
a
z
o
le
 
on
 
th
e 
p
h
a
rm
a
c
o
k
in
e
ti
c
s
 
of
 
fo
s
a
m
p
re
n
a
v
ir
 
an
d 
vi
ce
 
ve
rs
a
 
in 
h
e
a
lt
h
y 
v
o
lu
n
te
e
rs
Methods
Study design
This open-label, 3-period, cross-over, single-centre, phase-I, multlple-dose trial was 
conducted from March to May 2009 in the Clinical Research Centre of the Radboud 
University Nijmegen Medical Centre, The Netherlands. The study was designed to 
examine the effect of fosamprenavir on the pharmacokinetics of posaconazole and 
vice versa by intrasubject comparison. The secondary objective of this trial was to 
evaluate the safety of combined administration of posaconazole and fosamprenavir. 
The trial (ClinicalTrials.gov Identifier NCT00817765) was approved by the review 
board of the Radboud University Nijmegen Medical Centre and conducted 
according to the declaration of Helsinki.
Study population
This trial was conducted in healthy male and female volunteers, aged 18-55 years 
with a body mass index of 18 to 30 kg/m2. Subjects who were included had to be 
able and willing to sign the Informed Consent Form prior to screening evaluations. 
Subjects had to be in a good age-appropriate health condition as established by 
medical history, physical examination, electrocardiography, biochemistry, hematology 
and urinalysis testing within 4 weeks prior to the first day of dosing. The main 
exclusion criteria were a history of sensitivity / idiosyncrasy to any of the study 
drugs, a HIV positive test, a positive hepatitis B / C test or therapy with any drug 
(two weeks preceding dosing), except for acetaminophen. Other exclusion criteria 
were: participation in a drug trial or donation of blood within 60 days prior to the first 
dose. Pregnant females were also excluded.
Study drug and dosing
In this cross-over design three treatment arms were investigated. Subjects were 
randomized to start with different treatment arms (6 different treatment sequences in 
total) (Table 1). Each period consisted of 10 days of treatment with either one of the three 
regimens. After each treatment period, there was a wash-out period of 17 days. The 
interaction arm contained fosamprenavir 700 mg twice daily together with posaconazole. 
Posaconazole was dose escalated from 200 mg once daily on day 1, 200 mg twice daily 
on day 2 and 400 mg twice daily from day three onward. In the first comparator arm, 
posaconazole was given in a similar fashion as in the interaction arm. In the second 
comparator arm, subjects used fosamprenavir 700 mg twice daily with ritonavir 100 mg 
twice daily. The chosen dose escalation for posaconazole, which is not listed in the 
label, was chosen to minimize toxicity since this regimen had never been tested.
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Table 1 Study Design
Arm Period 1 
(Days 1 -  10)
Washout 
(Days 11-28)
Period 2 
(Days 29-38)
Washout Period 3 
(Days 39-56) (Days 57-66)
1 POS* FPV / RTV POS +  FPV
2 POS POS +  FPV FPV / RTV
3 FPV / RTV# POS POS +  FPV
4 FPV/ RTV POS +  FPV POS
5 POS +  FPV$ POS FPV / RTV
6 POS +  FPV FPV / RTV POS
* POS = POS 200 mg QD on day one, 200 mg BID on day two, 400 mg BID from days 3-10.
# FPV / RTV = FPV 700 mg BID + RTV 100 mg BID from days 1-10.
$ POS + FPV = POS 200 mg QD on day one, 200 mg BID on day two, 400 mg BID from days 3-10 
+ FPV 700 mg BID from days 1-10.
Fosamprenavir, ritonavir and posaconazole were taken with food at approximately 
8 AM and 8 PM. Subjects visited the trial centre approximately every other day 
during the treatment periods for supervised dosing and blood sampling. On every 
visit day of each treatment period, subjects received a standardized breakfast at 
around 8 AM followed by the supervised intake of an oral dose of posaconazole, 
fosamprenavir/ritonavir or fosamprenavir/posaconazole (depending on the 
treatment arm). Fosamprenavir tablets and ritonavir capsules were swallowed 
whole with 200 mL of water. The posaconazole suspension was swallowed with 200 
mL water. The breakfast consisted of 2 slices of wheat bread (one slice with 48+ 
cheese and one with luncheon meat or cervelat) and one glass of full milk or full 
chocolate milk. This breakfast contained, depending on the choice of topping and 
milk, 488 - 553 kcal and 26-28 gram fat (43-50% fat).
Pharmacokinetic sampling and safety assessments
Blood samples for pharmacokinetics were collected throughout a 12-hour period at
11 pre-deflned time points (0, 1, 2, 3, 4, 5, 6, 7, 8, 10 and 12 hours after dosing) at 
day 10 of every treatment period to characterize drug absorption and elimination. 
Trough concentrations, just before intake of the drugs, were collected on study 
days 1, 3, 5, and 8 of each treatment period.
Serum biochemistry and hematology were checked at screening and on days 
1,3,5,8 and 10 of each treatment period. Adverse events assessment, blood glucose 
and urinalysis were performed at screening and on days 1 and 5 of each treatment
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period. A pregnancy test for women was conducted at screening and a screening 
for drugs of abuse was conducted before dosing on day 1 of each treatment period. 
Electrocardiogram and blood pressure / pulse rate (supine) were checked at 
screening and on days 1 and 5 of each treatment period.
Compliance
Study personnel supervised all medication intakes at the clinical trial unit on visit 
days. The times of dosing were recorded. Drug intake of subjects at home was 
monitored by the use of MEMS caps (Aardex Ltd., Zug, Switzerland), which record 
the opening of the medication bottle. Furthermore, subjects were asked to write 
down exact times of medication intake in a diary.
Pharmacokinetic analysis
Pharmacokinetic parameters for posaconazole, amprenavir and ritonavir were 
calculated by non-compartmental methods using the WinNonLin software package 
(version 5.2.1; Pharsight, Mountain View, CA) and the log/linear trapezoidal rule.
On the basis of the individual plasma concentration-time data, the following 
pharmacokinetic parameters were determined: the area under the plasma 
concentration-time curve from 0 to 12 hours after intake (AUC0^ 12; in mg*hour per 
liter), the maximum plasma concentration of the drug (Cmax; in mg per liter), the time 
to reach Cmax (Tmax; in hours), the apparent clearance after oral administration (CL/F) 
(in liters per hour), the apparent volume of distribution (V/F) (in liters), the trough 
concentration in plasma (C12 [12 hours after intake]) and the apparent elimination 
half-life (t1/2; in hours).
Analytical procedure
All plasma samples were analyzed at the Department of Clinical Pharmacy, 
Radboud University Nijmegen Medical Centre.
Amprenavir and ritonavir were determined by a validated High Performance Liquid 
Chromatography method with UV-detection (15). Samples were pre-treated using a 
liquid-liquid extraction from plasma. The dynamic range of the amprenavir assay 
was 0.10 - 30 mg/L and for ritonavir 0.045 - 30 mg/L. The assay had an accuracy 
range (five replicates of three concentrations of QC samples), dependent on the 
concentration, from 102-105% for amprenavir and 101-104% for ritonavir, respectively. 
Intraday precision (n=15) for amprenavir varied between 2.55 - 4.05% and 0.89 - 
3.22% for ritonavir. The interday precision (n = 3) for amprenavir was 1.18 - 5.04% 
and 1.10 - 3.64% for ritonavir, respectively.
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Posaconazole samples (total and free fraction) were measured by a validated High 
Performance Liquid Chromatography method with fluorescence detection. Samples 
were pretreated using a protein precipitation procedure. The dynamic range of the 
assay was 0.05 - 10 mg/L. The assay had an accuracy range (five replicates of three 
concentrations of QC samples), dependent on the concentration, from 97.9 - 
104.1%. Intraday precision varied between 1.56 - 3.03% and interday precision was 
between 1.37 - 4.11%.
To determine the free fraction of posaconazole, we used plasma samples drawn at 
or around Tmax. This plasma was then transferred into Centrifree Centrifuge tubes 
(30 kDa). Samples were centrifuged during 10 minutes at 2000 RCF (rpm 3310) 
(Rotante 46 R, radius 164 mm, angle 45 degrees, temperature 25 C). The analysis 
was modified to be able to determine very low concentrations of unbound 
posaconazole and had a lower limit of quantification of 0.01 mg/L without loss of 
accuracy and precision. Both assays are externally validated by an international 
proficiency testing program (16-18).
Sample size calculation and Statistical Analysis
To determine bioequivalence with sufficient power, the sample size calculation was 
performed on posaconazole since this drug has the highest estimated degree of 
intrasubject variation (19-21). The study was powered (power of 80%) to detect a 
20% difference in posaconazole AUC. The required number of participants was 16 
and compensating for drop-outs, 24 subjects were included.
For the identification of a clinically relevant drug interaction, we used the 
bioequivalence approach “Guidance for Industry: Statistical Approaches to 
Establishing Bioequivalence” (22). Geometric mean ratios (GMRs) with 90% 
confidence intervals (CIs) were calculated for AUC  „  and C after log' > 0—>12 max ^
transformation of within-subject ratios. GMRs with 90% CIs falling entirely within the 
range of 0.80 to 1.25 were considered to indicate no significant interaction.
To assess the carry-over and period effect of concomitant administration of 
posaconazole on the pharmacokinetics of fosamprenavir, linear mixed model 
analyses were performed on the log(AUC0-12) of amprenavir. Similar analysis were 
performed on fosamprenavir. In this approach, treatment, period, and a carry-over 
variable were treated as fixed factors and patients effects as random.
Statistical evaluations were carried out using SPSS for Windows, version 16.0.1 
(SPSS, Chicago, IL, 1989-2005).
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Results
Baseline characteristics
Twenty-four healthy volunteers (10 females and 14 males) were included. The mean 
(range) age, body weight and body mass index were 36 (18-54) years, 73 (44-104) 
kg and 23 (18-29) kg/m2, respectively. Twenty-one participants were Caucasian, 
three participants were from Hispanic ethnicity. Three subjects prematurely 
withdrew from the study due to adverse events and a fourth subject withdrew at 
own request, not related to treatment. Twenty participants completed the trial 
(9 female and 11 male) and were available for pharmacokinetic analyses.
Figure 1 Arithmetic mean plasma posaconazole concentration profile 
following the administration of multiple doses of 400 mg 
posaconazole twice daily alone versus posaconazole 400 mg 
twice daily with fosamprenavir 700 mg twice daily.
Error bars represent the standard error of the mean.
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Compliance
The compliance of all participants was good, as indicated by their statements about 
the intake of the drug, the number of tablets in the returned vials, the trough drug 
concentrations, and the MEMS caps (data not shown).
Pharmacokinetics
Figure 1 shows the posaconazole plasma concentration versus time curves 
obtained in the absence and the presence of fosamprenavir. The mean pharma­
cokinetic parameters of posaconazole are described in Table 2. Fosamprenavir 
reduced the exposure to posaconazole. For posaconazole co-administered with 
fosamprenavir relative to posaconazole alone, the GMR (90% CI) was 0.77 
(0.68-0.87) for AUC0^ 12, and 0.79 (0.71-0.89) for Cmax (Table 2; Figure 2).
Figure 2 Individual changes in area under the concentration time curve 
of posaconazole alone versus posaconazole combined 
with fosamprenavir and of fosamprenavir / ritonavir versus 
fosamprenavir combined with posaconazole
Geometric mean free posaconazole concentration in the posaconazole arm was 
0.029 mg/L (95% CI: 0.023-0.036) and 0.029 mg/L (95% CI: 0.022-0.038) in the 
combination arm. There was no statistically significant difference in geometric
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mean (range) free fractions of posaconazole (n=20) in the posaconazole alone arm 
versus in the combination arm: 0.988% (0.63 - 1.64%) versus 1.10% (0.63 - 1.74%) 
(p=0.18, paired samples T-test).
The amprenavir plasma concentration-time curves following administration of 
fosamprenavir with ritonavir versus fosamprenavir with posaconazole are shown in 
Figure 3. The mean pharmacokinetic parameters of amprenavir are presented in 
Table 2. Posaconazole did not increase the AUC and C of amprenavir to themax r
same extent as ritonavir did. For fosamprenavir with posaconazole relative to 
fosamprenavir with ritonavir, the GMR (90% CI) was 0.35 (0.32-0.39) for AUC0^ 12, 
and 0.64 (0.55-0.76) for Cmax (Table 2, Figure 2,3).
Figure 3 Arithmetic mean plasma amprenavir concentration profile following 
the administration of multiple dose of 700 mg of fosamprenavir 
twice daily with 100 mg ritonavir twice daily versus fosamprenavir 
700 mg twice daily with posaconazole 400 mg twice daily.
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Table 2 Steady state pharmacokinetic parameters as determined on day 10 of treatment; geometric mean ratios of area under 
the concentration time curve and maximum concentration of posaconazole and amprenavir.
Steady-state plasma pharmacokinetic parameter estimates, Treatment comparisons,
geometric mean (95% Cl) geometric mean ratio (90% Cl)
Posaconazole Amprenavir
Pharmacokinetic
Parameter
POS POS + FPV FPV/RTV FPV + POS POS + FPV vs 
POS alone
FPV + POS vs 
FPV/RTV
AUCM2 (mg*h/L) 30.4 (25.2-36.7) 23.5 (19.7-27.9) 42.0 (36.7-47.9) 14.8 (12.4-17.7) 0.77 (0.68 - 0.87) 0.35 (0.32-0.39)
C (mg/L)max 3.0 (2.5-3.6) 2.4 (2.0-2.8) 5.8 (5.0-6.6) 3.7 (3.0-4.5) 0.79 (0.71 - 0.89) 0.64 (0.55-0.76)
T (h)max v > 5 (4-5) 5 (4-5) 3 (2-4) 2(1-3) - -
Cmin (mg/L) 2.2 (1.8-2.7) 1.6 (1.4-2.0) 2.1 (1.8-2.5) 0.3 (0.2-0.4) - -
CL/F (L/h) 13.2 (10.9-15.9) 17.1 (14.4-20.3) 16.7 (14.6-19.1) 47.2 (39.5-56.4) - -
WF (L) 609 (489-759) 471 (385-576) 173 (137-218) 241 (171-341) - -
M h ) 32.1 (26.0-39.7) 19.1 (16.3-22.5) 7.2 (6.1-8.5) 3.5 (2.7-4.7) - -
AUC0_ r„ area under the plasma concentration-time curve over the 12 hour dosing Interval; Cma: , peak plasma concentration; Tma: , time to reach Cma: ;
Cmin, plasma concentration 12 hours after Intake of study drug; CL/F, apparent oral clearance; V/F, volume of distribution; ti;„, elimination half-life; Cl, confidence Interval 
* For Tma median + Interquartile range Is reported
Chapter 9 Effect of posaconazole on the pharmacokinetics of fosam prenavir and vice versa in healthy volunteers
There was no carry-over effect of fosamprenavir on posaconazole as assessed by 
the contribution of the variable defined to be 1 respectively 0 in case a treatment 
with fosamprenavir preceded or did not precede the treatment with posaconazole 
(p = 0.9). Likewise, there was no carry-over effect of posaconazole on fosamprenavir 
(p = 0.6). For both outcome variables there was no indication of a period effect to 
be present (p=0.5 for posaconazole and p=0.9 for fosamprenavir, respectively).
A regression analysis was performed to determine if there was a concentration 
dependent inhibition of amprenavir metabolism by posaconazole. No significant 
correlation was found between posaconazole exposure and amprenavir exposure 
(p=0.099; r2=0.144).
Adverse events and safety assessments
A total of 141 adverse events were reported by a total of 23 subjects. The severity of 
28 adverse events was grade 2; two adverse events were grade 3 and two grade 4 
(three occasions of increased CK in one subject and one grade 4 occasion of 
increased CK in a second subject, all were judged not to be related to the study 
medication); all other (109) adverse events were grade 1. No serious adverse events 
were reported. There was no notable difference in adverse events in the different 
treatment arms.
The relation to the study drug was judged to be definite in eight occasions reported 
by three subjects: a grade II rash occurred in two subjects (one on fosamprenavir / 
ritonavir and one on posaconazole / fosamprenavir) and one subject experienced 
a grade III rash on posaconazole / fosamprenavir treatment. All three subjects 
discontinued treatment after which they recovered from the rash. Other side effects 
definitely related to the study drug were reported by a single subject: loose stool 
(2 occasions), flatulence (2 occasions) and pruritus. Seventeen adverse events 
were judged to be probably related and 36 possibly related.
Discussion
This trial showed a significant, bidirectional effect on the pharmacokinetics of 
posaconazole and fosamprenavir. Exposure to both posaconazole (-23%) and 
fosamprenavir (-65%) were significantly lower than in the comparator arms.
We could think of four possible explanations for the decrease in exposure of 
posaconazole by fosamprenavir: 1) induction of UGT1A4; 2) induction of P-glycoprotein; 
3) decreased absorption of posaconazole 4) protein displacement of posaconazole.
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It is generally thought that ritonavir Is responsible for Induction of glucuronldation 
(12;13) although an effect of the boosted protease inhibitor cannot be ruled out 
(12;13;23). Fosamprenavir has been shown to significantly reduce plasma raltegravir 
exposure, likely through UGT1A1 induction (24), however the effect on UGT1A4 
remains unknown (10;25). Based on the average 23% decrease in posaconazole 
exposure, fosamprenavir may be a less potent UGT1A4 inducer than efavirenz and 
phenytoin, which have shown a reduction of 50% in exposure to posaconazole 
(26;27).
Posaconazole is a substrate for P-glycoprotein. Fosamprenavir has been shown to 
induce intestinal expression of P-glycoprotein in rats (28). This mechanism could 
be an additional explanation for an increase in intestinal efflux of posaconazole with 
subsequent lowered exposure.
Posaconazole absorption is significantly influenced by gastric pH, prandial state 
and timing of intake relative to the meal (29). In the literature there are no reports of 
an effect of fosamprenavir on the absorption of other drugs by, for instance, 
alterations in gastric pH. The Tmax of posaconazole was not changed after addition 
of fosamprenavir, indicating that at least the rate of absorption was not influenced.
In general, an increased free fraction due to protein displacement, will result in a 
lower total plasma concentration (30). Posaconazole is >98% bound to serum 
albumin (27) while amprenavir is 90% bound to alpha-1-acid glycoprotein and 
albumin (31); hence an interaction based on protein displacement is possible. 
In our study posaconazole free drug fraction was unaltered. Therefore, protein 
displacement can be ruled out as an explanation.
In a recent study the AUC and Cmax of atazanavir combined with posaconazole 
were comparable to the AUC and C of atazanavir boosted with ritonavirmax
(33.4 mg*h/L and 3.57 mg/L versus 35.4 mg*h/L and 3.93 mg/L, respectively) (26). 
This suggests that posaconazole may be an equipotent inhibitor of CYP3A4 when 
compared to ritonavir.
In our study, the AUC and Cmax of amprenavir after intake of fosamprenavir with 
posaconazole were 2.9 and 1.6 fold lower compared with administration of 
fosamprenavir with ritonavir. Yet, when compared with a historical control group, an 
effect on the pharmacokinetics of fosamprenavir by posaconazole can be noted 
compared with unboosted fosamprenavir 700 mg twice daily: AUC0^ 12 14.82 mg*h/L 
(95% CI 12.41-17.70; this study) versus AUC0^ 12 9.51 mg*h/L (95% CI 7.81-11.6) (32).
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The extent of boosting of fosamprenavir by posaconazole is an indication that there 
might be a moderate effect of posaconazole on fosamprenavir pharmacokinetics, 
but clearly not to an extent similar to ritonavir. In fact, the exposure of amprenavir 
given as fosamprenavir 700 mg twice daily with posaconazole approximates that of 
unboosted fosamprenavir 1400 mg twice daily, which is a FDA-licensed dose for 
the treatment of therapy naive patients (10;33). However, unboosted fosamprenavir 
dosed 1400 mg twice daily dose is considered a non-favorable regimen according 
to the Panel on Antiretroviral Guidelines for Adults and Adolescents (9).
No serious adverse events were reported during this trial and none of the included 
subjects experienced irreversible damage due to the use of trial medication. Three 
subjects dropped out because of a rash, but the other adverse events during 
this trial were mild or moderate. We expected rash to be an adverse event of 
fosamprenavir, as it is described as “common” in the Summary of Product 
Characteristics (SPC) of fosamprenavir (10).
Once again our study demonstrates the complexity of combined use of antiretroviral 
and antifungal drugs. From the results of our study we conclude that combined use 
of fosamprenavir with posaconazole results in subtherapeutic amprenavir 
concentrations compared to ritonavir boosted fosamprenavir and therefore this 
combination should not be used in this way. Future studies must reveal whether 
ritonavir boosted fosamprenavir can be safely combined with posaconazole. 
With regard to posaconazole, concentrations must be monitored by means of 
therapeutic drug monitoring to assure adequate exposure in order to warrant 
efficacy.
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General Discussion
The first section of the general discussion will discuss the history and the present 
role of TDM and TDM research. The second section will focus on drug-drug 
interaction studies which are performed during phase 4 drug development, thus 
after introduction into clinical care. Which studies should be performed? How 
should these studies be performed? These questions are addressed in the second 
section of the general discussion. Finally, the general discussion will conclude with 
future research agendas for TDM and drug-drug interaction studies.
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1. Therapeutic Drug Monitoring
1.1 Therapeutic drug monitoring: from 1996 to 2010
The drugs that were used in the early era of combination antiretroviral therapy 
(cART) had unfavorable pharmacokinetic properties. This resulted in numerous 
problems, such as frequent daily intake of pills with strict food requirements, high 
interindividual variability in plasma concentrations (1;2) and high rates of virologic 
failure (3). These problems led to strong interest for TDM, which had the potential of 
ameliorating HIV treatment by providing the optimal dose for the individual patient.
Before TDM can be applied, drugs need to fulfil a number of criteria, such as the 
existence of a relationship between the plasma concentration of the drug and its 
effect and/or adverse effects (4). Intensive research learned that protease inhibitors 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs), but not nucleoside 
analogue reverse transcriptase inhibitors (NRTIs), met these criteria (5-9).
The next question in the development of TDM was to find out which patients would 
most likely benefit from it. Two prospective randomized controlled trials investigated 
whether routine and unselected use of TDM would benefit patient outcome. In 2002 
and 2003, the results of these trials were published, demonstrating less virologic 
failures and less toxicity-induced drug discontinuations in patients in whom therapy 
was monitored by TDM (1;10). These results led to increased enthusiasm for TDM. 
Typical for the enthusiasm those days, the Dutch HIV treatment guideline of 2005 
recommended TDM of all available protease inhibitors and NNRTIs in all patients 
who started a new antiretroviral regimen (see chapter 5).
It is important to realize however, that HIV therapy is rapidly changing and improving 
due to continuous drug development. The randomized controlled trials that 
demonstrated improved therapeutic outcome with TDM were performed with 
indinavir- and nelfinavir-based cART in treatment naive patients, a scenario which 
has almost completely vanished from current clinical practice.
Currently preferred antiretroviral drugs, such as efavirenz, possess much better 
pharmacokinetic profiles. As mentioned in chapter 3, standard dosing of efavirenz 
leads to therapeutic plasma concentrations in at least 80% of the HIV infected 
individuals (6;11), compared to just 40% for nelfinavir (1). As a consequence, it 
would require large randomized controlled trials (with more than 1,000 patients (12)) 
to have sufficient statistical power to investigate the value of unselected routine use
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of TDM for efavirenz. For most clinical research groups, the organization of such 
trials is not feasible, also because it is difficult to obtain the financial resources for 
the conductance of such trials.
To give a rough idea of the use of routine TDM of efavirenz, it is interesting to 
estimate the number needed to treat with TDM in order to prevent virologic failure 
or discontinuation of efavirenz because of CNS toxicity.
A close look at the landmark study of efavirenz TDM, conducted by Marzolini and 
colleagues, learns that 7.7% of the patients had efavirenz plasma concentrations 
below 1.0 mg/L. Half of these patients developed virologic failure. The majority of 
patients, 79.2%, had efavirenz plasma concentrations in the therapeutic range. 
Virologic failure occurred in 22.3% of these patients. Finally, 13% of the patients had 
efavirenz plasma concentrations above 4.0 mg/L, associated with an increased risk 
of central nervous system (CNS) toxicities. The risk of virologic failure in this group 
was 17.6% (6).
Without TDM, the risk of virologic failure in a randomly selected patient would 
therefore be: (0.077*0.500) + (0.792*0.223) + (0.13*0.176)= 0.238; 23.8%. Assuming 
that the application of TDM would result in therapeutic concentrations for all 
patients, the risk of virologic failure would be reduced to 22.3%. Therefore, the 
number of patients ‘needed to TDM’ in order to prevent one patient from virologic 
failure would be 1/(0.238-0.223) = 67.
In addition, routine TDM of efavirenz may prevent toxicity-induced efavirenz discon­
tinuations. The data presented in chapter 3 show that patients with efavirenz 
plasma concentrations above 4.0 mg/L who continued the standard efavirenz dose 
had a risk of 11.5% of toxicity-induced efavirenz discontinuations. Patients who had 
their dose reduced had a 2.3% risk of efavirenz discontinuation. According to 
Marzolini, patients who had a plasma concentration below 1.0 mg/L had 0% risk of 
persistent CNS toxicity. Assuming that patients with a therapeutic plasma 
concentration would also have a risk of 2.3% for efavirenz discontinuations because 
of toxicity, like patients with high plasma concentrations who had their dose 
reduced, the risk for a randomly selected patient for efavirenz discontinuations 
would be: (0.077*0) + (0.792*0.023) + (0.13*0.115) = 0.033; 3.3%. With TDM, all 
patients would ideally get the risk of patients with a therapeutic plasma concentration, 
namely 2.3%. Therefore, the number ‘needed to TDM’ to prevent a randomly 
selected patient from virologic failure or from discontinuing efavirenz because of 
toxicity can be estimated to be 1/((0.238-0.223) + (0.033-0.023)) = 40.
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It should be realized that this is merely an estimation with data from two observational 
studies. In the absence of evidence from randomized controlled trials that 
demonstrate benefits of routine TDM of efavirenz, it seems rational to restrict TDM 
to those patients who are suspected of non-compliance, who take medication 
which may interact with efavirenz, who experience persistent CNS toxicities and to 
treatment-experienced patients with limited treatment-options (9;13).
1.2 Therapeutic drug monitoring research
Current international HIV treatment guidelines recommend TDM for selected 
scenarios, such as in patients with drug-drug interactions (9;13). The adherence of 
clinicians to these recommendations is unknown. In order to improve the 
implementation of future guidelines and to adapt TDM guidelines, it is important to 
understand which factors are associated with adherence to TDM guidelines. 
Therefore, we evaluated the clinicians’ adherence to the Dutch TDM recommenda­
tions of 2005 (chapter 5).
As described in chapter 5, the adherence to the TDM guidelines in The Netherlands 
appeared to be low to moderate, depending on the indication for TDM. Part of the 
explanation for the moderate implementation of the TDM guidelines might be that 
most indications for TDM were based on expert opinion. In order to improve the 
level of evidence for TDM recommendations, TDM research should focus on 
demonstrating its use in specific clinical situations. Studies should, for instance, 
investigate the use of TDM in pregnant women or in patients with renal dysfunction. 
In this thesis, we performed one such study, in which we investigated the use of 
TDM to manage efavirenz related CNS disturbances in patients with high plasma 
concentrations (chapter 3).
In principle, the best design for investigating the use of TDM in a specific clinical 
situation would be a prospectively randomized controlled design, in which one 
group would receive TDM and the other group would not. Unfortunately, there are 
some problems that hinder the performance of such trials. First, most accepted 
clinical scenarios for TDM are relatively seldom. Therefore, it would require large 
multi-centre trials to recruit a sufficiently high number of patients, which complicates 
the organization of these trials. Second, TDM has entered into the hearts and minds 
of numerous European HIV-physicians. Despite the fact that the TDM indications in 
international guidelines are predominantly based on expert opinion, it is questionable 
whether HIV physicians would, for instance, be willing to withhold TDM from 
randomly selected pregnant women. This illustrates how treatment guidelines
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based on expert opinion may unintentionally hamper the conductance of prospective 
randomized controlled trials. Third, it is doubtful whether funding can be obtained 
for the multi-centre trials described above. After all, there is no commercial interest 
for performing these kind of studies. In addition, it is questionable whether 
governmental organizations would give this type of TDM studies a high enough 
priority rating for funding them.
In conclusion, it seems not feasible to perform prospective studies of TDM. An 
alternative would be to perform retrospective studies at TDM services with data 
from the own laboratory. Our research group, for instance, used data from our own 
TDM service to study determinants of plasma exposure to lopinavir (14). Nonetheless, 
if the dependent variable of an analysis is a relatively seldom categorical variable, 
such as discontinuation of efavirenz because of toxicity, large datasets are needed 
in order to have sufficient statistical power.
Fortunately, we have the availability of such datasets in the Netherlands. In 1996, 
the Dutch Minister of Health, Els Borst, made several new antiretroviral drugs 
accelerated available through a subsidized early-access program. Two years later, 
a large investigation was started to measure the effects of cART in all patients who 
had commenced antiretroviral therapy from 1996. This study, which was conducted 
between 1998 and 2001, became known as the ATHENA (AIDS Therapy Evaluation 
in the Netherlands) cohort study. Once ATHENA was finished, it was decided that 
the research should be continued. This led to the establishment of the HIV Monitoring 
Foundation in 2001. Although officially incorrect, the HIV monitoring Foundation still 
refers to the ‘ATHENA cohort study’ in its scientific publications (15;16). Almost all 
Dutch HIV-infected patients are included in ATHENA. Currently, the central database, 
maintained by the HIV Monitoring Foundation, contains data from 16,715 patients 
(16). As can be noted from Table 1, the ATHENA database contains much of the 
information that is needed to evaluate the use of TDM in specific clinical situations. 
ATHENA has one limitation. The reason for performing TDM is not collected in 
ATHENA. It would, for instance, be relevant to know whether a TDM sample is taken 
because a patient is suspected of non-adherence. This thesis comprises two 
studies with data from ATHENA (chapters 3 and 5).
In addition, this thesis contains one retrospective study with data from another 
database, called EuroSIDA. Like ATHENA, EuroSIDA is a prospective observational 
cohort study. The EuroSIDA database contains over 16,000 patients followed in 103 
hospitals in 32 European countries plus Israel and Argentina (17). Table 1 compares
192
Table 1 Comparison of the EuroSIDA and the ATHENA database
EuroSIDA ATHENA
General features
Number of patients in database (2009) 16,505 16,715
Number of participating hospitals (2009) 103 25
Number of participating countries (2009) 34 1
Important features for TDM studies
Database contains viral load data Yes Yes
Database collects reasons for 
discontinuation of antiretroviral drugs
Yes Yes
Database contains information on dosages 
of antiretroviral drugs
No Yes
Database contains TDM results No1 Yes2
Database contains information on 
co-medication
Partially3 Complete
1 At 6 monthly Intervals, a blood sample Is taken and stored for each patient, which has led to the 
accumulation of a large sample repository which can be used to determine plasma concentrations 
of antiretroviral drugs. However, the time between the last intake of the patient's antiretroviral drugs 
and time of sampling is not noted.
2 The time between sampling and intake of the antiretroviral drug is included in the database.
3 EuroSIDA collects data on drugs which are used for the treatment and prophylaxis of opportunistic 
infections, and drugs being used for cardiovascular disease. EuroSIDA does not collect data on all 
drugs that patients may be taking, such as anti-depressants or anti-convulsants.
EuroSIDA and ATHENA. Because of the manner that EuroSIDA collects Its data 
(see Table 1), this database Is not suitable to evaluate TDM-drIven Interventions.
Nonetheless, the half-yearly blood samples that are taken In EuroSIDA can be used 
to explore relatIonshIps between plasma concentratIons of antIretrovIral drugs and 
pharmacodynamIc endpoInts. Such studIes are only approprIate for antIretrovIral 
drugs wIth long elImInatIon half lIves. Because EuroSIDA does not collect the tIme 
between samplIng and the latest Intake of the antIretrovIral drug, the Influence of 
this factor on the drug plasma concentratIon should be neglIgIble. ThIs Is only the 
case for drugs wIth long elImInatIon half lIves (6).
There Is another problem though, when performIng retrospectIve studIes In 
EuroSIDA. SInce plasma samples are only taken on a half-yearly basIs, It wIll be 
hard to detect correlatIons between plasma concentratIons and clInIcal endpoInts
■
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that have the highest incidence just after starting therapy. All patients who 
discontinue the drug before their half-yearly plasma sample has been taken are not 
included in such analyses. This problem was encountered in chapter 2.
In conclusion, the EuroSIDA database can be used to explore relationships between 
plasma concentrations of antiretroviral drugs and pharmacodynamic endpoints. 
Studies should only be performed on clinical endpoints that occur with a stable 
incidence in time. In addition, only drugs with long-elimination half lives can be 
appropriately studied.
2. Drug-Drug Interactions
In a general sense, the effects of a drug are related to its concentration at the sites 
of action, which is a function of the administered dose and the drug's absorption, 
distribution and elimination. The latter three processes can be influenced by food 
and other drugs, potentially resulting in diminished drug-efflcacy or increased 
drug-toxicity.
For antiretroviral drugs, diminished drug efficacy may have serious consequences, 
such as drug (-class) resistance and virologic failure. Validly, the evaluation of 
potential drug-drug interactions has become an important part of the drug approval 
process (18).
Notwithstanding this, drug-drug interactions involving antiretroviral drugs are 
frequently not unraveled until after introduction into clinical care (19). There are 
several explanations for this phenomenon. First, new antiretroviral drugs often 
receive accelerated drug-approval, which obviously benefits HIV-infected patients 
with limited treatment-options, but decreases the available information on potentially 
hazardous drug-drug interactions. A recent example is the drug-drug interaction of 
raltegravir and rifampicin. After accelerated FDA approval of raltegravir in October 
2007 (20), it lasted until January 2009 before the summary of product characteristics 
recommended to double the raltegravir dose when combined with rifampicin (21).
A second explanation for the discovery of relevant drug-drug interactions during 
the post-marketing phase is that polypharmacy is common among HIV-infected 
patients. For instance, HIV-infected subjects are known to have a high incidence of 
psychotropic agent use (22;23). With the increasing age of the HIV-infected 
population (24), the use of concomitant drugs will probably increase even more, for 
instance to treat cardiovascular disease or cancer (25).
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Because of this polypharmacy, it is not realistic to expect all potentially relevant 
drug-drug interactions to be elucidated before marketing approval. Two recent 
examples of clinically relevant drug-drug interactions that were discovered long 
after introduction into clinical care are the effect of ginkgo biloba on efavirenz (26) 
and the effect of lopinavir/ritonavir on the anticancer drug irinotecan (27).
For academic researchers who want to perform pharmacokinetic drug-drug 
interaction studies in the post-marketing phase, the challenge is to identify those 
combinations that are the most useful to be studied. To be able to do this, close 
collaboration with HIV-physicians is essential. Drug-drug interaction questions which 
arise in clinical HIV practice can be used to identify relevant research questions. To 
identify interesting topics, it may be helpful to register pharmacological questions 
and answers in a database. By regularly evaluating the registered questions, the 
pharmacological researcher may identify drug-drug interactions that need to be 
studied. Naturally, the clinical pharmacologist should use his or her pharmacological 
knowledge to predict the probability of the occurrence of a hypothetical drug-drug 
interaction. Furthermore, he or she should assess, in consultation with the clinician, 
the potential clinical relevance of a drug-drug interaction. Finally, if an interaction can 
be easily bypassed for instance by replacing a drug for a suitable alternative drug, it 
is unnecessary to perform a drug-drug interaction study. The former reasoning can 
be expressed in the algorithm depicted in Figure 1.
The study described in chapter 6, which aimed to describe the effect of two 
boosted protease inhibitors and efavirenz on the pharmacokinetics of atovaquone/ 
proguanil, is an example of a study that was undertaken after proceeding the steps 
depicted in the algorithm.
Another way to come to a relevant research question is to think ahead of clinical 
practice. By attending scientific clinical pharmacology meetings, ideas for 
interesting drug-drug interaction studies may come up. This is especially true for 
new antiretroviral drugs, or new drugs that are expected to be used frequently 
by HIV-infected patients. In this scenario, one can enter the algorithm in step 3 
(is a significant drug interaction imaginable...). The studies described in chapters 8 
and 9 fit into this scenario.
The drug-drug interaction study described in chapter 7 does not entirely fit into the 
algorithm, since frequent combined use of raltegravir and lamotrigine is not 
expected in the HIV-infected population. The original goal of this study was broader
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Figure 1 Decision tree to decide whether it is useful to perform a drug-drug 
interaction study.
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than investigating the influence or raltegravir on lamotrigine pharmacokinetics. 
Based on previous studies (28), we had designed this study as a ‘phenotypic probe’ 
study (see below and see chapter 7).
2.1 Study designs of drug-drug interaction studies
2.1.1 Cross-over design or parallel design?
Most drug-drug interaction studies employ a crossover design. This allows for a 
within-subject comparison between treatments because each subject serves as 
his or her own control, eliminating the bias introduced by intersubject variability 
(29). The pitfall of this approach is carry-over effects. For instance, a long wash-out 
period may be required to prevent bias resulting from enzyme induction. The study 
described in chapter 7 (raltegravir/lamotrigine trial) illustrates this. In this study, we 
used a wash-out period of 26 days to prevent bias which could have resulted from 
auto-induction of lamotrigine metabolism.
A parallel study design can be considered when drugs cannot be stopped or 
repeatedly administered. This is the case if there is a risk for the development of 
resistance in HIV-infected patients after drug withdrawal. Thus, it would be 
undesirable to utilize a crossover design with mono therapy of efavirenz or nevirapine 
in HIV-infected patients. Because the intersubject pharmacokinetic variability of 
most drugs is considerably higher than the intraindividual variability, the sample 
size of studies with parallel designs must be higher, which is a clear disadvantage 
of parallel designed drug-drug interaction studies.
2.1.2 Study population: HIV-infected patients or healthy volunteers?
Most drug interaction studies of antiretroviral drugs are performed in healthy 
volunteers, because it allows to control for as many factors as possible. A major 
disadvantage of conducting drug interaction studies in HIV-infected patients is the 
use of co-medication, which may bias the assessment of the interaction between 
two drugs. Another disadvantage of conducting these trials in HIV-infected patients 
is the risk of lowered plasma concentrations of antiretroviral drugs, which might 
lead to the development of resistant virus.
An obvious disadvantage of conducting drug interaction studies in healthy 
volunteers is that healthy people are exposed to (antiretroviral) drugs, and potential 
concomitant toxicities. Before designing a drug interaction trial, one should therefore 
carefully balance the importance of the information that a trial may provide against 
the risk for the participating subjects.
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If the risk of adverse events is disproportionally high, one should seek for a design 
with HIV-infected patients who have a true indication for the drug combination of 
interest. Such a scenario should for instance be preferred for drug-drug interaction 
studies between antiretroviral drugs and anticancer drugs. In addition, studies of 
drug-drug interactions between rifampicin or rifabutin and protease inhibitors 
should preferably have HIV-infected patients as study population. For both drugs, 
toxicity appears to be more prevalent among healthy volunteers than in HIV-infected 
patients.
Rifampicin is a strong inducer of Cytochrome P450 (CYP) 3A mediated metabolism 
of protease inhibitors. Three recent drug-drug interaction studies which aimed to 
study combined use of rifampicin with the protease inhibitors atazanavir, saquinavir, 
and lopinavir in healthy volunteers were prematurely terminated because of high 
incidences of gastro intestinal intolerance and hepatotoxicity (30-32). Hepatotoxicity 
of this magnitude has not been reported in HIV-infected populations who used 
protease inhibitors concomitantly with rifampicin (33-36).
Rifabutin can be used as an alternative for rifampicin in the treatment of 
HIV-associated tuberculosis, because CYP3A enzyme induction is lower than with 
rifampicin. However, combined use with protease inhibitors is complex, since 
protease inhibitors inhibit CYP3A-mediated metabolism of rifabutin. This may lead 
to higher rifabutin plasma concentrations and an increased risk of rifabutin 
associated neutropenia and uveitis.
Clinical trials that included both HIV-infected and non-HIV-infected individuals 
reported a significantly higher frequency of rifabutin-associated neutropenia among 
HIV-negative study participants (37;38). In addition, recent drug-drug interaction 
studies of rifabutin with lopinavir and atazanavir in healthy volunteers reported high 
incidences (57-72%) of neutropenia and other rifabutin associated adverse reactions 
(39;40). Meanwhile, a drug interaction study of rifabutin and lopinavir in HIV-infected 
subjects, which used the same dosage of rifabutin, found a 40% lower rifabutin Cmax 
and better tolerance as compared to the healthy volunteer trial. Based on the latter 
data, the authors recommended a higher dose of rifabutin for HIV-infected patients 
than the originally recommended rifabutin dose that was based on healthy volunteer 
trials (41). From above, it becomes clear that further drug-drug interactions studies 
of rifabutin or rifampicin in healthy volunteers are undesirable.
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It is unclear why some adverse effects seem to occur at a higher rate in HIV-negative 
subjects. An obvious explanation would be an immune mediated mechanism. 
However, there are no clear data to support this hypothesis. In addition, little is 
known about the potential differences in pharmacokinetics between HIV negative 
and HIV positive subjects (42).
What is, apart from rifabutin, rifampicin, and other highly toxic drugs, the optimal 
design for a drug interaction study of antiretroviral drugs? In my opinion, a drug-drug 
interaction study with a crossover design in healthy volunteers is still best capable 
of assessing whether two drugs influence each other’s pharmacokinetics. However, 
the pharmacokinetic behaviors and in some cases toxicities of drugs, might differ 
as a result of HIV-disease (42). Therefore, one should be cautious when making firm 
dose recommendations based on healthy volunteer data alone. If data in HIV-infected 
patients are lacking, TDM should be used to support the management of drug-drug 
interactions.
Figure 2 displays an algorithm for the choice of the study population of drug-drug 
interaction trials involving antiretroviral agents. The drug-drug interaction studies 
performed described in chapters 7 to 9 fit into this algorithm, whereas the study 
described in chapter 6, does not. The latter study aimed to determine the effect of 
lopinavir/ritonavir, atazanavir/ritonavir and efavirenz on the pharmacokinetics of a single 
dose of atovaquone/proguanil. The chosen design was a comparison of single dose 
atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected 
patients who were using lopinavir/ritonavir, atazanavir/ritonavir or efavirenz.
The reason to choose for this design was that we wanted to prevent healthy 
volunteers from taking antiretroviral drugs for 10 days to obtain enzyme induction. 
According to the algorithm in Figure 2, it would have been appropriate to conduct 
this trial in healthy volunteers using a cross over design. After all, there was a highly 
relevant research question and the administration of a boosted protease inhibitor 
alone is not expected to result in disproportional toxicity.
In fact, the atovaquone study is not a pure drug-drug interaction study, but a parallel 
comparison of single dose atovaquone/proguanil pharmacokinetics in healthy 
volunteers and HIV-infected patients who were taking antiretroviral drugs that 
may have influenced the metabolism of the two anti malaria drugs. However, the 
pharmacokinetics of the anti malaria drugs may have been altered by HIV-infection 
as well.
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Figure 2 Decision tree for selecting the most appropriate study population 
for a drug-drug interaction trial.
This does not make the data useless: the study mimics the ‘real world situation’. 
The manufacturer of atovaquone/proguanil does not recommend to adjust the 
atovaquone/proguanil dose for people with HIV-infection, while phase 3 trials for 
malaria prophylaxis were conducted in healthy subjects (43).
2.2 Probe Studies
Based on in vitro data, an antiretroviral drug can be suspected to affect the 
metabolism of other drugs. In that case, a sensitive and specific probe can be used 
to investigate the drug-drug interaction potential of that antiretroviral drug in vivo 
(44). For instance, a method to assess CYP2C19 activity is by calculating the 5-OH 
omeprazole / omeprazole ratio in plasma after administration of omeprazole (45).
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There are several requirements for phenotypic probes. First, it is essential that 
individual enzyme or transporter activity is stable. Second, it must be validated that 
the phenotypic metric that is used reflects enzyme/transporter activity under various 
circumstances. Thus the metric should change when patients are treated with 
inhibitors or inducers of the enzyme/transporter, there should be proven in vitro 
specificity of the metabolic step/transport, there should be a low coefficient of 
variation for repeated tests and the metric should not depend on other factors not 
related to enzyme activity (44).
Instead of using one probe at a time, a combination of probes may also be used, 
provided that no drug interactions occur between the probes. There are several 
examples of these so called phenotypic cocktails, such as the Leiden cocktail, the 
Pittsburgh cocktail, the Cologne cocktail and the Cooperstown (5+1) cocktail (44). 
The latter cocktail includes validated metrics and has been used extensively (46). 
An excellent example of the use of this cocktail was given by Yeh and colleagues, 
who demonstrated that the administration of 10 days of lopinavir/ritonavir resulted 
in significant enzyme induction of CYP1A2, CYP2C9 and CYP2C219 (45).
There are no widely validated phenotypic methods in use for most phase II metabolic 
enzymes, such as glucuronyltransferases, sulfotransferases and glutathione 
transferases (44).
In the past, our research group had evaluated the effect of lopinavir/ritonavir and 
atazanavir on the glucuronidation of lamotrigine. In this thesis, we studied the effect 
of raltegravir on the glucuronidation of lamotrigine (chapter 6).
Although these studies provide important information of the inductive potential of 
ritonavir on the glucuronidation of the UDP-glucuronyltransferase (UGT) substrate 
lamotrigine, and the lack of such an effect of unboosted atazanavir and raltegravir, 
these data cannot be straightaway extrapolated to other UGT substrates. Lamotrigine 
has not been validated as a phenotypic probe for specific UGT enzymes in vitro or 
in vivo. In fact, it has become unclear whether lamotrigine is metabolized solely by 
UGT1A4, or by a UGT1A4 and UGT2B7, or by UGT1A4 and UGT1A3 (28;47;48). 
Therefore, lamotrigine cannot be considered a selective phenotypic UGT probe.
2.3 Funding of drug-drug interaction studies after marketing approval
The algorithm depicted in Figure 1 ignores the funding which is required for 
performing drug-drug interaction studies after marketing approval. In our experience, 
it is difficult to require funding from non-commercial organizations for clinically 
oriented pharmacology research. Consequently, investigator-driven clinical
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pharmacology research is often funded by the pharmaceutical industry. This does 
not mean that the quality of such research is at stake, but this may have implications 
for the choice of the drug-drug combinations that are studied.
Obviously, funding of clinical pharmacology HIV research by an unbiased expert 
committee would be preferable. For the topic of drug-drug interactions, such 
committees should collect data and questions arising from the clinical field and 
congresses, in order to decide which drug-drug combinations would need to be 
studied after marketing approval. In addition, academic researchers who want to 
perform investigator initiated drug interaction studies should be able to submit 
study proposals to such expert committees.
The United States have the Aids Clinical Trials Group (ACTG). The ACTG is funded 
by the US Department of Health and Human Services, the National Institute of 
Allergy and Infectious Diseases and by the National Institutes of Health, division of 
AIDS (http://www.aactg.org). The ACTG has published many high-impact papers, 
such as the recent comparison of the efficacy between the NRTI backbones 
lamivudine/abacavir and tenofovir/emtricitabine (49). In addition, several key 
drug-drug interaction studies of antiretroviral drugs with statins were funded by the 
ACTG (50-52). Since 2007, Europe has the European Aids Treatment Network 
(NEAT). The future must learn whether NEAT will provide funding for drug-drug 
interaction studies in the way ACTG does.
3. Future Perspectives
3.1 Therapeutic Drug Monitoring
As explained in section 1 of the general discussion, TDM research should now 
focus on demonstrating its use in specific clinical scenarios. As can be noted from 
Table 1, the ATHENA database contains much of the information that is needed to 
evaluate the use of TDM in those specific situations.
A scenario that could be investigated in ATHENA would be the drug-drug interaction 
between efavirenz and rifampicin (see chapter 4). It would be of interest to 
investigate whether clinicians use TDM in this situation. In addition, the study could 
describe the number of subtherapeutic efavirenz plasma concentrations and the 
number of successful TDM-driven dose increases of efavirenz. Another example of 
a study that could be conducted in ATHENA would be to investigate the use of TDM
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in patients who receive lopinavir in a once-daily dosage. A third potential study 
would be to describe the use of TDM of all protease inhibitors and NNRTIs during 
pregnancy, including the number of subtherapeutic drug concentrations in the third 
trimester and the number of successful TDM-driven interventions in this situation.
A complete other part of future TDM research should focus on new antiretroviral 
drugs, such as raltegravir, darunavir and etravirine. For none of these drugs, a lower 
threshold concentration for efficacy has been established and the role of TDM 
seems therefore limited at this moment. However, a minimum trough concentration 
for efficacy has been suggested for maraviroc (9) and raltegravir efficacy seems to 
be related to the raltegravir AUC (53;54).
As noted above, EuroSIDA cannot be used to evaluate the use of TDM. Nonetheless, 
some interesting research questions on potential correlations between plasma 
concentrations and clinical endpoints could be investigated in this database. Given 
the short elimination half-lives of most antiretroviral drugs, only tenofovir, nevirapine 
and efavirenz would be suitable agents for future pharmacokinetic research in 
EuroSIDA.
Future EuroSIDA studies could for instance investigate the potential relationship 
between tenofovir plasma concentrations and nephrotoxicity, which can be 
expressed in a continuous variable (e.g., serum creatinine) and which develops 
gradually in time (55). A second idea would be to explore the potential correlations 
between plasma concentrations and age, which may provide important information 
in the context of the aging HIV-infected population (24). A third idea, which we are 
currently working out, is to measure plasma concentrations of protease inhibitors in 
patients who had virologic failure on protease inhibitor-based cART in the absence 
of documented resistance. The goal of this study is to assess the role of 
non-adherence in this specific situation.
3.2 Drug-Drug Interactions
Looking at the future, several aspects need to be addressed. First, there is an 
ageing population of HIV-infected patients. Therefore, increased use of anticancer 
drugs and cardiovascular drugs can be expected in the HIV-infected population. 
Especially for anticancer drugs, studies aimed at investigating the potential 
drug-drug interactions with antiretroviral drugs are lacking (56). Alternative study 
designs, using HIV-infected patients who need treatment for cancer, are required to 
study these interactions. An elegant example of a study with an alternative design
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is given by Corona and colleagues. They studied HIV-infected patients with Kaposi’s 
sarcoma who were treated with irinotecan. The researchers managed to perform a 
crossover design to investigate the pharmacokinetics of irinotecan and its active 
metabolite SN-38 in the presence and the absence of lopinavir/ritonavir (27).
A second development that needs our attention is the great number of new drugs 
for the treatment of the hepatitis C virus (HCV) (57). Treating HIV-HCV co-infected 
patients is challenging, and there will be a clinical need for information on drug-drug 
interactions between antiretroviral drugs and the new anti-HCV drugs.
Third, there is very little information available on the potential differences between 
healthy volunteers and HIV-infected patients with regards to the pharmacokinetics 
of (antiretroviral) drugs. This subject deserves more attention.
Fourth, the use of phenotypic probe studies has the promise of decreasing the 
number of required subjects for drug interaction trials. However, phenotypic 
measures need to be validated thoroughly. This is another subject that deserves 
more attention.
Finally, it would be valuable to evaluate the adoption of dose recommendations coming 
from drug-drug interaction trials with data from ATHENA or other databases.
4. Conclusions
Clinical pharmacology continues to be highly relevant for HIV treatment. Data from 
drug-drug interaction trials, pharmacological knowledge, and TDM are essential 
input factors for the decision-making process in the management of drug-drug 
interactions. Although the role of TDM has become smaller (i.e., selected use rather 
than routine use), chapters 3 and 4 once more demonstrate the important role that 
TDM can have in individual patient management.
TDM of protease inhibitors and NNRTIs should be employed in vulnerable patient 
populations (children, pregnant women) and in complex situations, such as with 
drug-drug interactions. Future TDM research should provide evidence for TDM in 
these scenarios. In the context of the HIV-infected population, studies aimed at 
investigating the potential drug-drug interactions between antineoplastic agents 
and antiretroviral drugs are highly required. Other aspects that need to be explored 
are the use of phenotypic probes and the adherence to dose recommendations 
coming from drug-drug interaction studies.
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Summary

Introduction
This thesis has presented a variety of clinical pharmacology studies of HIV therapy. 
Part I of the thesis focuses predominantly on therapeutic drug monitoring (TDM) in 
HIV-infected adults. Part II contains four drug-drug interaction studies of antiretroviral 
drugs with drugs that are used for the prevention and treatment of co-morbidities in 
HIV-infected patients.
I. The rapeu tic  D rug M on ito ring
Chapter 1 contains a brief review which discusses the role of TDM in present-day 
antiretroviral therapy. The review discusses the main arguments in favor and against 
the use of TDM. The most important arguments in favor of TDM are the correlation 
of plasma concentrations with virologic response and the high interindividual 
variability in plasma concentrations among patients taking the same dose. 
An important argument against the implementation of routine TDM is the lack of 
randomized controlled trials demonstrating that TDM improves therapeutic 
outcomes. Therefore, it is concluded that TDM should be used for specific 
indications, such as in patients with manifestations of concentration-dependent 
toxicities, patients suspected of non-adherence, pregnant women and children.
The central theme of chapters 2 to 4 is TDM of efavirenz. Efavirenz is a 
non-nucleoside reverse-transcriptase inhibitor (NNRTI) that is used as a first line 
agent in the treatment of HIV infection. A well-known disadvantage of efavirenz are 
its central nervous system (CNS) side effects, like insomnia, dizziness and 
headache. More than 50% of the patients treated with efavirenz experience CNS 
adverse effects after starting efavirenz. These adverse effects are usually transient. 
Nonetheless, some patients experience persistent CNS toxicity.
A number of studies have described a relationship between persistent CNS toxicity 
and high efavirenz plasma concentrations (i.e., >4.0 mg/L). However, there is 
controversy on this subject, because several other studies did not establish an 
increased risk of CNS toxicity in patients with high efavirenz plasma 
concentrations.
Given these conflicting data, we performed a large retrospective study with data 
from the EuroSIDA study (chapter 2). The goal of this study was to determine 
whether patients with high efavirenz plasma concentrations had an increased 
likelihood of toxicity-driven efavirenz discontinuations. A total of 843 patients were
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included in the study. Of these patients, 138 patients (16.4%) discontinued efavirenz 
due to toxicity or patient’s/physician’s choice (TOXPC) and 705 (83.6%) patients 
continued EFV for > 2 years. A total of 20 (14.5%) patients in the TOXPC group had 
high EFV plasma concentrations (>4.0 mg/L) compared to 99 (14.0%) of the 
patients in the no toxicity group, p=0.89. A positive hepatitis C status (p=0.026), 
but not the EFV plasma concentration, was an independent predictor of toxicity- 
driven EFV discontinuations. Part of the explanation for this result might have been 
limited power, since most patients who discontinued efavirenz because of CNS 
toxicity had no plasma sample available. Nonetheless, the results of this study 
suggest that there is a large number of patients with high efavirenz plasma 
concentrations that do not experience CNS toxicity to such an extent that they have 
to stop taking the drug.
Despite the conflicting data described above, pharmacists at our TDM practice 
advise dose reduction of efavirenz in patients with plasma concentrations above 
4.0 mg/L who suffer from persistent CNS toxicity. Anecdotally, this has been 
reported to be an effective intervention, but the outcome of this intervention had 
never been formally evaluated.
The retrospective analysis with data from the ATHENA cohort study, described in 
chapter 3, evaluates the effect of this intervention. The analysis included 180 
patients with high plasma efavirenz levels. Of these patients, 49 (27.2%) had their 
efavirenz dose reduced. After one year, the Kaplan-Meier estimated cumulative 
incidence of toxicity-induced efavirenz discontinuations was 11.5% in patients who 
continued the standard dose versus 2.3% in patients who had a dose reduction 
(p=0.07). As expected, dose reduction was not associated with loss of virologic 
suppression. Therefore, we concluded that dose reduction of efavirenz in patients 
with high plasma concentrations is safe with regards to maintenance of virologic 
efficacy. In addition, the results of this study suggest that dose reduction may 
prevent toxicity-induced discontinuations of efavirenz.
International guidelines suggest that HIV-tuberculosis (TB) co-infected patients are 
treated with efavirenz -based antiretroviral regimens, because rifampicin decreases 
efavirenz plasma concentrations only modestly (22-35%). It is recommended to use 
the standard efavirenz dose (600 mg QD) in patients weighing <50 kg and to 
consider an increase of the dose (800 mg QD) in patients weighing >50 kg. Chapter
4 describes a 50 kg weighing rifampicin-treated HIV-TB co-infected patient who 
had high efavirenz plasma concentrations (10.6 mg/L), and concomitant CNS
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toxicities on the standard dosage of efavirenz. Despite concomitant use of 
rifampicin, the efavirenz dose was decreased to 200 mg once-daily under the 
guidance of TDM, which resulted in an alleviation of CNS symptoms.
In an attempt to understand this, we performed pharmacogenetic testing of the 
Cytochrome P450 2B6 (CYP2B6) enzyme, which plays a major role in efavirenz 
metabolism. The patient turned out to be homozygote for CYP2B6*15, which results 
in very little CYP2B6 enzyme activity. Although rifampicin induces CYP2B6 activity 
by increasing CYP2B6 gene transcription, increased formation of CYP2B6 mRNA in 
this patient merely led to enhanced production of poor-functioning CYP2B6 enzyme. 
Apparently, this does not reverse a poor metabolizer phenotype into a normal 
metabolizer phenotype. This chapter illustrates the value that TDM and pharmaco­
genetic testing can have in individualized patient management.
In 2005, the Dutch Association of AIDS Physicians (NVAB) issued guidelines for the 
treatment and management of HIV-infected patients, including recommendations 
for TDM. Chapter 5 provides an evaluation of the uptake of these recommenda­
tions in the Netherlands. We selected three scenarios for which the guideline 
recommended TDM from the ATHENA observational cohort study: i) start with a 
combination of lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 
ii) start with efavirenz (routine TDM), iii) use of nelfinavir during pregnancy. The 
adherence to the TDM guideline was low for routine TDM in patients who started 
efavirenz (10 to 30%, depending on the definition), and moderate (45-60%) for the 
two other scenarios. Patients treated in clinics with the local availability of a TDM 
assay, and patients treated in academic clinics were more likely to receive TDM. A 
higher baseline HIV viral load was also predictive for the use of TDM. A potential 
explanation for the moderate adherence to the guidelines is that most recommen­
dations were based on expert opinion.
II. D rug-drug In te ractions
The second part of this thesis contains four drug-drug interaction studies between 
antiretroviral drugs and drugs being used for the prevention and treatment of 
co-existing medical conditions.
Atovaquone co-formulated with proguanil is frequently used by western HIV-infected 
patients who travel to malaria-endemic destinations. Atovaquone is considered a 
substrate for glucuronidation. Chronic use of protease inhibitors and NNRTIs may 
induce glucuronidation. Therefore, HIV-infected patients who use protease inhibitors
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or NNRTIs might have diminished atovaquone plasma concentrations when taking 
atovaquone/proguanil, which might in turn lead to suboptimal malaria prophylaxis. 
The study described in chapter 6 compares single dose atovaquone/proguanil 
pharmacokinetics between 18 healthy volunteers and 58 HIV-infected patients, who 
were using efavirenz (n=20), lopinavir/ritonavir (n=19), or atazanavir/ritonavir (n=19) 
as part of their antiretroviral regimens. After a single dose of atovaquone/proguanil, 
the geometric mean (95% confidence interval (95% CI)) atovaquone AUC0^ t was 
104 (79-137) h*mg/L in healthy volunteers, compared to 30 (23-39), 32 (24-42), and 
64 (49-84) h*mg/L in patients treated with efavirenz, lopinavir/ritonavir, and 
atazanavir/ritonavir, respectively. The AUC0^ t of proguanil was 38-43% lower in the 
three groups of HIV-infected patients versus the healthy controls. The study 
concludes that physicians should be alert for atovaquone/proguanil prophylaxis 
failures in HIV-infected patients who are treated with efavirenz, lopinavir/ritonavir or, 
to a lower extent, atazanavir/ritonavir.
Chapter 7 and chapter 8 contain two drug-drug interaction studies with the recently 
approved HIV-1 integrase inhibitor raltegravir. Raltegravir is metabolized by UDP 
glucuronyltransferase (UGT) 1A1 and hence its pharmacokinetics can be influenced 
by inhibitors (e.g., atazanavir) or inducers (e.g., etravirine, tipranavir, rifampicin) of 
UGT1A1. The influence of raltegravir itself on UGT substrates had not been evaluated 
in clinical studies. Therefore, we undertook the study described in chapter 7 to 
investigate the influence of raltegravir on the UGT substrate lamotrigine. The results 
of this study, which was conducted in 24 healthy male volunteers, show no effect of 
raltegravir on the glucuronidation of lamotrigine.
Dyslipidemia is a common complication during chronic HIV infection. Pravastatin is 
considered a preferred lipid-lowering drug for HIV-infected patients. As a 
consequence, frequent combined use of raltegravir and pravastatin can be 
expected in the ageing HIV-infected population. Therefore, and because both drugs 
share a common metabolic pathway, we studied the effect of raltegravir on pravastatin 
pharmacokinetics and vice-versa in 24 healthy male and female volunteers (chapter 
8). The results of this study show no effect of raltegravir on the pharmacokinetics or 
the short-term lipid-lowering effects of pravastatin. On the other hand, pravastatin 
increased the Cmax (+31%) and the AUC of raltegravir (+13%), whereas the raltegravir 
C12 was 41% decreased in the presence of raltegravir. Because the AUC of raltegravir 
appears to be related to virologic efficacy, and not the raltegravir Cmin, the effects of 
pravastatin on raltegravir pharmacokinetics are not likely to be clinically relevant.
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Finally, chapter 9 contains a drug-drug interaction study of the combined use of 
the protease inhibitor fosamprenavir and the antifungal agent posaconazole. 
Fosamprenavir is normally used with ritonavir, which serves as a booster of the 
pharmacokinetics of amprenavir through inhibition of CYP3A. Combining 
fosamprenavir/ritonavir with posaconazole may lead to a bidirectional drug-drug 
interaction. First, inhibition of CYP3A4 by posaconazole (above that already caused 
by ritonavir) may further increase exposure to amprenavir with an increased risk of 
fosamprenavir toxicity. Second, ritonavir might induce posaconazole glucuronida- 
tion. Thus, combined use of fosamprenavir/ritonavir with posaconazole might lead 
to subtherapeutic posaconazole exposure.
To manage the interaction between fosamprenavir/ritonavir and posaconazole, we 
hypothesized that ritonavir could be replaced by posaconazole as an alternative 
booster of the pharmacokinetics of fosamprenavir, with the additional advantage of 
eliminating the potential negative effect of ritonavir on posaconazole. Therefore, we 
performed a clinical trial in 24 healthy volunteers to determine the effect of unboosted 
fosamprenavir on posaconazole and vice versa. The geometric mean ratios (GMR; 
90% CI) AUC0^ 12 and Cmax for posaconazole + fosamprenavir versus posaconazole 
alone were 0.77 (0.68-0.87) and 0.79 (0.71-0.89), respectively. In addition, 
posaconazole was not capable of boosting the amprenavir pharmacokinetics in a 
similar way as ritonavir: the GMR (90% CI) of the amprenavir AUC0^ 12 and C12 for 
fosamprenavir + posaconazole versus fosamprenavir + ritonavir were 0.35 
(0.32-0.39) and 0.64 (0.55-0.76), respectively. Therefore, the conclusion of this 
study was that the combination of posaconazole and unboosted fosamprenavir 
should not be used in HIV-infected patients.
D iscuss ion
The discussion starts with a short description of the history of TDM in HIV therapy. 
Whereas there is evidence that routine TDM benefits patient outcome for indinavir 
and nelfinavir, the evidence is lacking for current first-line antiretroviral drugs. 
Therefore, it is concluded that TDM should not be used routinely, but for specific 
indications, such as with drug-drug interactions or in patients with manifestations of 
concentration-dependent toxicities. Because there is also little evidence for TDM in 
these situations, TDM research should be aimed at investigating the potential 
benefits of TDM for these specific clinical scenarios. It seems most feasible to 
perform these studies retrospectively, for instance by using data from the ATHENA 
cohort study.
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The second part of the discussion focuses on drug-drug interaction studies during 
phase 4, thus after marketing approval. The general discussion presents an 
algorithm for phase 4 drug-drug interaction studies, which may help to decide 
whether a potential drug-drug interaction should be studied.
The study design of drug-drug interaction studies is also discussed. In principle, 
the optimal design would be a cross-over trial in healthy volunteers. However, there 
are several situations in which another design, for instance in HIV-infected patients, 
seems preferable. Other subjects in the second part of the general discussion are 
the use of phenotypic probe studies and the funding of drug-drug interaction 
studies. Finally, the general discussion concludes with recommendations for future 
research. For instance, given the ageing HIV-infected population, more knowledge 
will be required on drug-drug interactions between antineoplastic agents and 
antiretroviral drugs.
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Inleiding
Dit proefschrift bevat negen hoofdstukken. Alle hoofdstukken zijn gewijd aan de 
behandeling van HIV, waarbij steeds voor een klinisch farmacologische invalshoek 
is gekozen. Deel 1 van het proefschrift gaat voornamelijk in op de rol van ‘therapeutic 
drug monitoring’ (TDM) als onderdeel van de HIV behandeling. Deel 2 van het 
proefschrift bevat 4 onderzoeken naar interacties tussen anti- HIV geneesmiddelen 
en geneesmiddelen die door HIV geïnfecteerde patiënten gebruikt kunnen worden 
voor de preventie of behandeling van bijkomende ziektes.
I. The rapeu tic  D rug M on ito ring
Hoofdstuk 1 geeft een overzicht van de verschillende argumenten voor én tegen 
het gebruik van TDM bij de behandeling van HIV. Het belangrijkste argument vóór 
het gebruik van TDM is het grote verschil in plasma concentraties tussen personen 
die dezelfde dosering gebruiken, en het feit dat deze verschillen gevolgen hebben 
voor het al dan niet slagen van de HIV behandeling. Er zijn namelijk relaties 
aangetoond tussen de hoogte van de plasmaconcentraties van anti- HIV middelen 
en de virologische respons. Er zijn ook argumenten tegen de inzet van TDM. Er is 
maar voor 2 anti- HIV middelen, te weten indinavir en nelfinavir, middels een 
gerandomiseerd gecontroleerd onderzoek aangetoond dat TDM de behandel 
uitkomst verbetert. Voor alle andere anti- HIV middelen zijn deze gegevens niet 
aanwezig, of alleen uit onderzoeksopzetten met een minder sterke mate van 
bewijskracht. Hoofdstuk 1 eindigt daarom met de conclusie dat TDM niet zonder 
meer moet worden toegepast in alle patiënten die anti- HIV middelen gebruiken, 
maar dat TDM moet worden ingezet in díe situaties waarin er de grootste kans 
bestaat op afwijkende plasma concentraties. Voorbeelden zijn patiënten met 
concentratie gerelateerde bijwerkingen, patiënten die worden verdacht van therapie 
ontrouw, zwangere vrouwen en kinderen.
In de hoofdstukken 2 tot en met 4 staat het anti- HIV middel efavirenz centraal. 
Efavirenz is een middel uit de klasse van de non-nucleoside reverse trancriptase 
remmers (NNRTRs), dat op dit moment veel wordt voorgeschreven aan HIV 
patiënten. Een nadeel van efavirenz is dat meer dan 50% van de patiënten na 
aanvang van therapie tijdelijk last krijgt van centraal zenuwstelsel bijwerkingen, 
zoals hoofdpijn, een slechte nachtrust of duizeligheid. Bij de meeste patiënten 
verdwijnen deze bijwerkingen binnen enkele weken. Echter, bij sommige patiënten 
persisteert de bijwerking.
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Een aantal onderzoeken heeft een relatie gevonden tussen de hierboven genoemde 
bijwerkingen en de hoogte van de efavirenz concentratie in plasma. Het bestaan 
van deze relatie is echter controversieel, omdat andere onderzoeken deze relatie 
niet hebben kunnen vinden.
Hoofdstuk 2 beschrijft een groot retrospectief onderzoek naar deze relatie, dat 
werd uitgevoerd met gegevens van de EuroSIDA studie. Het doel van dit onderzoek 
was om te bepalen of er een relatie was tussen de hoogte van de efavirenz plasma 
concentratie en het risico op het stoppen met efavirenz vanwege bijwerkingen. 
Er werden 843 patiënten geïncludeerd. Hiervan stopten er 138 (16.4%) binnen 2 jaar 
vanwege toxiciteit of op instigatie van arts of patiënt. In de groep patiënten die 
voortijdig stopte had 14.5% een efavirenz plasma concentratie boven de 4.0 mg/L. 
In de groep patiënten die ten minste twee jaar efavirenz bleef gebruiken had 14.0% 
een efavirenz plasma concentratie boven de 4.0 mg/L (p=0.89). Uit de multivariabele 
logistische regressie analyse bleek een positieve hepatitis C status (p=0.026), 
maar niet de efavirenz plasma concentratie, een onafhankelijke voorspeller voor 
het stoppen van efavirenz vanwege toxiciteit.
Een mogelijke verklaring voor deze resultaten is dat veel patiënten die met efavirenz 
moesten stoppen vanwege bijwerkingen (en dus misschien een hoge spiegel 
hadden), al waren gestopt voordat bij hen een bloedmonster was afgenomen. 
Daarnaast suggereert het onderzoek dat een groot aantal patiënten met een hoge 
efavirenz spiegel niet in zo’n mate last heeft van bijwerkingen dat dit leidt tot 
stoppen van efavirenz.
Ondanks de hierboven genoemde tegenstrijdige gegevens, adviseren ziekenhuis­
apothekers om bij patiënten met bijwerkingen en een hoge spiegel (>4.0 mg/L) de 
efavirenz dosering te verlagen. Formeel is niet bekend is of deze interventie veilig 
en zinvol is. Hoofdstuk 3 beschrijft een retrospectief onderzoek naar het effect van 
deze interventie.
Hiertoe werden gegevens gebruikt van de ATHENA cohort studie. Er werden in 
totaal 180 patiënten met hoge efavirenz spiegels (>4.0 mg/L) geïncludeerd in dit 
onderzoek. De minderheid van deze patiënten (n=49, 27.2%) kreeg een 
dosisreductie; de andere 131 patiënten continueerden de standaard efavirenz 
dosering. Na 1 jaar was de met Kaplan-Meier geschatte cumulatieve incidentie van 
het stoppen van efavirenz vanwege bijwerkingen 11.5% in de groep patiënten die 
doorgingen met de standaard dosering versus 2.3% in patiënten die een 
dosisreductie kregen (p=0.07). Dosisreductie was niet geassocieerd met een 
verminderde onderdrukking van de virusreplicatie.
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De conclusie van dit onderzoek is dat het veilig is om bij patiënten met efavirenz 
spiegels boven de 4.0 mg/L de dosering te verlagen op geleide van TDM. Daarnaast 
lijkt het erop dat deze interventie het stoppen van efavirenz vanwege bijwerkingen 
kan helpen te voorkomen.
Internationale richtlijnen bevelen aan om HIV patiënten die tevens geïnfecteerd zijn 
met tuberculose, te behandelen met efavirenz bevattende antiretrovirale regimes. 
De richtlijnen adviseren om bij patiënten met een lichaamsgewicht kleiner dan 50 
kg te starten met de standaard dosering efavirenz (1 x daags 600 mg) en om een 
hogere dosering (1x daags 800 mg) te overwegen bij patiënten die zwaarder zijn 
dan 50-60 kg.
Hoofdstuk 4 beschrijft een 50 kg wegende, met rifampicine behandelde HIV- 
tuberculose geïnfecteerde patiënt die met de standaard dosering efavirenz zeer 
hoge efavirenz spiegels (tot 10.6 mg/L) had. Daarbij had hij veel last van centrale 
bijwerkingen. Op basis van de gemeten efavirenz plasma concentraties werd 
de efavirenz dosering, ondanks gebruik van rifampicine, uiteindelijk verlaagd tot 
1x daags 200 mg, waarbij de centrale bijwerkingen aanzienlijk afnamen.
Genetisch onderzoek van het CYP2B6 enzym, dat verantwoordelijk is voor het 
metabolisme van efavirenz, leerde dat deze patiënt homozygoot was voor 
CYP2B6*15. Dit genotype zorgde ervoor dat deze patiënt een nauwelijks 
functionerend CYP2B6 enzym had. Toediening van rifampicine zorgde bij deze 
patiënt dan ook slechts voor een toegenomen productie van niet functionerend 
CYP2B6 enzym. Hierdoor was bij deze patiënt een zeer lage dosering efavirenz 
nodig, ondanks gebruik van rifampicine. Deze casus onderstreept de toegevoegde 
waarde die TDM en farmacogenetisch onderzoek kunnen hebben bij de HIV 
behandeling.
Hoofdstuk 5 bevat een evaluatie van de implementatie van de Nederlandse HIV 
TDM richtlijnen uit 2005. Hierbij werd gekeken naar het gebruik van TDM bij een 
interactie (lopinavir/ritonavir + een NNRTR), het gebruik van nelfinavir TDM in de 
zwangerschap en het routinematig gebruik van TDM bij patiënten die efavirenz 
therapie startten. Met name voor dit laatste scenario werd de richtlijn zeer matig 
nageleefd (10-30%, afhankelijk van de gehanteerde definitie); voor de eerste twee 
scenario’s kreeg 45-60% van de patiënten TDM volgens de richtlijn. Uit het 
onderzoek bleek dat de TDM richtlijn beter werd nageleefd in die HIV behandelcentra 
waar lokaal een analytische bepalingsmethode aanwezig was voor de anti- HIV 
middelen. Verder bleken academische HIV behandelcentra de richtlijn meer te 
hebben gevolgd. Ten slotte bleek de virale load bij start van therapie voorspellend
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voor de inzet van TDM. Een mogelijke verklaring voor de matige navolging van de 
TDM richtlijn is dat de bewijskracht voor de meeste aanbevelingen niet was 
gebaseerd op hard bewijs, maar op de mening van experts.
Deel II. In te racties
Deel II van dit proefschrift bevat 4 onderzoeken naar mogelijke interacties tussen 
anti- HIV middelen en geneesmiddelen die door HIV geïnfecteerde patiënten 
gebruikt kunnen worden voor de preventie of behandeling van bijkomende 
ziektes.
Atovaquone/proguanil wordt veelvuldig voorgeschreven aan reizigers die naar de 
tropen gaan om malaria te voorkomen, en dus ook aan HIV geïnfecteerde reizigers 
die chronisch anti- HIV medicatie gebruiken. Van atovaquone wordt verondersteld 
dat het wordt gemetaboliseerd door middel van glucuronidering. Langdurig gebruik 
van HIV proteaseremmers of NNRTRs kan glucuronidering induceren (versnellen). 
Daardoor is het mogelijk dat HIV patiënten die proteaseremmers of NNRTRs 
gebruiken verlaagde atovaquone plasma concentraties hebben wanneer zij 
atovaquone/proguanil gebruiken. Dit zou verminderde werkzaamheid van 
atovaquone/proguanil als malaria profylaxe tot gevolg kunnen hebben.
Het onderzoek beschreven in hoofdstuk 6 vergelijkt de farmacokinetiek van 
atovaquone en proguanil na een éénmalige dosis atovaquone/proguanil tussen 18 
gezonde vrijwilligers enerzijds en 58 HIV geïnfecteerde patiënten anderzijds, die de 
proteaseremmers lopinavir/ritonavir (n=19), atazanavir/ritonavir (n=19) of de NNRTR 
efavirenz (n=20) gebruikten. Na een éénmalige dosis atovaquone/proguanil was 
het geometrisch gemiddelde (95% betrouwbaarheidsinterval, BI) van de AUC0^ t 
van atovaquone 104 (79-137) h*mg/L in de gezonde vrijwilligers versus 30 (23-39), 
32 (24-42) en 64 (49-84) h*mg/L in HIV patiënten die respectievelijk efavirenz, 
lopinavir/ritonavir of atazanavir/ritonavir gebruikten. Ook de blootstelling aan 
proguanil bleek beïnvloed: de AUC0^ t van proguanil was 38-43% lager in de 3 
groepen HIV patiënten in vergelijking met de gezonde vrijwilligers. Er dient dus 
rekening te worden gehouden met verminderde werkzaamheid van atovaquone/ 
proguanil in HIV patiënten die efavirenz, lopinavir/ritonavir of atazanavir/ritonavir 
gebruiken.
Hoofdstuk 7 en hoofdstuk 8 bevatten interactie onderzoeken met een nieuw anti­
HIV middel, raltegravir. Raltegravir heeft een ander werkingsmechanisme dan de 
middelen die tot nu toe werden gebruikt bij de HIV behandeling. Het voorkomt de 
incorporatie van HIV DNA in humaan DNA. Raltegravir wordt gemetaboliseerd door
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UDP-glucuronyltransferase (UGT) 1A1. Dientengevolge kan de farmacokinetiek van 
raltegravir worden beïnvloed door remmers van UGT1A1 (zoals atazanavir) of door 
inducers (zoals etravirine, tipranavir, rifampicine) van UGT1A1.
De invloed van raltegravir zelf op andere stoffen die door middel van glucuronide­
ring worden afgebroken was nog niet onderzocht in een klinische studie. Om deze 
reden onderzochten wij de invloed van raltegravir op de glucuronidering van het 
anti epilepticum lamotrigine (hoofdstuk 7). Uit dit onderzoek, dat werd uitgevoerd 
in 24 gezonde mannelijke vrijwilligers, bleek uiteindelijk geen invloed van raltegravir 
op de glucuronidering van lamotrigine.
Uit de literatuur en de klinische praktijk is bekend dat HIV patienten relatief vaak een 
verstoorde lipide huishouding hebben. Statines zijn effectieve geneesmiddelen in 
de behandeling van dyslipidemie; pravastatine is een statine dat veel door HIV 
patiënten wordt gebruikt. Veelvuldig gecombineerd gebruik van raltegravir en 
pravastatine is dus te verwachten in HIV patiënten. Omdat pravastatine en raltegravir 
beide door middel van glucuronidering worden afgebroken, bestond er de kans op 
een interactie tussen deze middelen. Om dit te onderzoeken, voerden wij de studie 
uit welke beschreven is in hoofdstuk 8. Uit dit onderzoek, dat werd uitgevoerd in 
24 gezonde vrijwilligers, bleek dat raltegravir geen invloed had op de plasma 
concentraties van pravastatine, noch op de cholesterol verlagende werking van 
pravastatine.
Pravastatine beïnvloedde wel de raltegravir concentraties in enige mate. Zo werden 
de gemiddelde Cmax en AUC van raltegravir met respectievelijk 31 en 13% verhoogd. 
De Cmin van raltegravir was echter juist 41% lager met pravastatine. Omdat de AUC 
van raltegravir en niet de Cmin van belang is voor het virologisch effect van dit middel, 
zijn deze effecten naar verwachting niet klinisch relevant.
Hoofdstuk 9 beschrijft ten slotte een onderzoek naar de interactie tussen het anti 
schimmel middel posaconazol en de HIV- protease remmer fosamprenavir. 
Fosamprenavir wordt normaal gesproken gebruikt in combinatie met ritonavir, wat 
door remming van CYP3A zorgt voor voldoende blootstelling aan amprenavir. 
Posaconazol remt echter ook CYP3A. Hierdoor zou toevoeging van posaconazol 
aan fosamprenavir/ritonavir tot sterk verhoogde amprenavir spiegels kunnen leiden. 
Aan de andere kant zou de combinatie van fosamprenavir/ritonavir en posaconazol 
tot lagere posaconazol spiegels kunnen leiden. Posaconazol wordt namelijk 
afgebroken door middel van glucuronidering, en het is bekend dat ritonavir glucu­
ronidering kan induceren. In hoofdstuk 9 werd onderzocht of de hierboven 
beschreven interactie kon worden ondervangen door ritonavir weg te laten bij
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gecombineerd gebruik van fosamprenavir en posaconazol. Hierdoor zou het 
negatieve effect van ritonavir op posaconazol spiegels verdwijnen. Daarnaast 
moest worden onderzocht of posaconazol de amprenavir spiegels in dezelfde mate 
zou verhogen als ritonavir. Dit laatste bleek niet het geval: de ratio van het 
geometrisch gemiddelde (90% BI) die werd verkregen met fosamprenavir + 
posaconazol versus fosamprenavir + ritonavir was 0.35 (0.32-0.39) voor de AUC0^ 12 
van amprenavir en 0.64 (0.55-0.76) voor de Cmax van amprenavir. Ook bleek de 
blootstelling aan posaconazol met 23% verlaagd in aanwezigheid van fosamprenavir, 
ondanks weglaten van ritonavir. De conclusie van dit onderzoek is dan ook dat de 
combinatie fosamprenavir - posaconazol zonder ritonavir niet aan HIV patiënten 
moet worden voorgeschreven.
D iscuss ie
Het proefschrift sluit af met een discussie, welke bestaat uit 2 delen. Het eerste deel 
van de discussie is gewijd aan TDM. Er wordt een korte beschrijving gegeven van 
de historie van TDM bij de behandeling van HIV. Verder wordt geconcludeerd dat 
TDM anno 2010 niet routinematig bij iedere patiënt dient te worden ingezet, maar 
wel bij specifieke indicaties, zoals bij interacties, gedurende de zwangerschap of 
bij verdenking van therapie ontrouw. Daarnaast wordt er gesteld dat het van belang 
is om bewijs te vinden voor het (verwachte) nut van TDM bij deze indicaties. Er 
wordt uitgebreid ingegaan op de vraag hoe dit bewijs te verkrijgen, waarbij een 
pleidooi wordt gehouden voor retrospectief TDM onderzoek met behulp van de 
EuroSIDA en ATHENA databases.
Het tweede deel van de discussie gaat nader in op interactie onderzoeken met 
anti- HIV middelen nadat zij zijn toegelaten op de markt (gedurende fase 4). Er 
wordt een algoritme gepresenteerd dat gehanteerd kan worden bij de beslissing 
om al dan niet een mogelijke interactie te onderzoeken. Daarnaast wordt ingegaan 
op de designs van interactie onderzoeken. Er wordt gesteld dat een cross-over 
design in gezonde vrijwilligers in principe het beste design is, maar dat er ook 
situaties zijn waarin een dergelijk design juist niet te verkiezen is. Ook voor dit 
onderwerp wordt een algoritme gepresenteerd. Andere onderwerpen die in dit deel 
van de discussie aan bod komen zijn probe studies voor fenotypering en de 
financiering van interactie onderzoeken.
Tot slot worden aanbevelingen gedaan voor toekomstig onderzoek. Zo wordt er 
aanbevolen om in de toekomst meer aandacht te besteden aan interacties tussen 
cytostatica en anti- HIV middelen.
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Dankwoord
In de herfst van 2006 vroeg mijn toenmalig opleider Paul Kuks of het me wat leek 
om mijn opleiding tot ziekenhuisapotheker binnen de Alysis Zorggroep te combineren 
met promotie onderzoek op de afdeling Apotheek/Klinische Farmacie van het UMC 
St Radboud. Daar hoefde ik niet lang over na te denken. Een geweldige kans, die 
ik met beide handen aangreep.
Terugkijkend zijn de afgelopen jaren omgevlogen: ik heb genoten. Genoten van het 
opzetten van onderzoek, het schrijven van artikelen en de vele verschillende 
contacten die je hebt gedurende een promotie onderzoek. Contacten? Dat beeld 
hebben de meeste mensen niet bij een promotie onderzoek, maar het is toch echt 
zo: promoveren is ook een teamprestatie. Mijn team bestond uit een fantastische 
begeleider, (hulp-)vaardige collega-onderzoekers, kundige epidemiologen en 
statistici, enthousiaste HIV consulenten en HIV behandelaren, analisten, vrijwilligers, 
patiënten, en, last but not least, mijn lieve familie en vriendin. Ik hoop alle mensen 
uit ‘mijn team’ hier de erkenning te geven die zij verdienen.
Prof. Dr. Hekster, promotor, beste Chiel. Wij hebben allebei lang in de veronderstelling 
geleefd dat David mijn promotor zou zijn. Toen dit begin 2010 niet haalbaar bleek, 
schakelde je snel. Je bleek een prettige en enthousiaste promotor. Dank voor je 
steun in het laatste gedeelte van mijn promotietraject!
Dr. D.M. Burger, copromotor, beste David. Jij initieerde het ZAPIKO traject en gaf 
mij zo de kans me te ontwikkelen als onderzoeker. Ik vond het een voorrecht om 
met je samen te werken. Je bent een warme, sociale persoonlijkheid en een enorm 
prettige begeleider. David, enorm bedankt voor alles!
Dr. C. Richter, copromotor, beste Clemens. De afgelopen jaren hebben we al veel 
samengewerkt binnen de HIV zorg in ziekenhuis Rijnstate en dat zullen we blijven 
doen. Bedankt voor je enthousiaste input bij het tot stand komen van dit 
proefschrift.
Dr. P.F.M. Kuks, beste Paul. Jij had als opleider binnen de Alysis Zorggroep de 
moed om mij het registratie onderzoek grotendeels in het UMC St. Radboud te 
laten uitvoeren. Het bleek een succes, dat uiteindelijk zelfs uitmondde in dit 
proefschrift. Ik ben je dankbaar voor de rol die je hierin hebt gespeeld.
Oud-collega onderzoekers: Rafaëlla, Hanneke, bedankt voor jullie tips en 
ervaringen. Ik kon ze goed gebruiken. Roger, collega-onderzoeker, dank voor onze 
goede en gezellige samenwerking! Succes met het afronden van je proefschrift en
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bij het ontwikkelen van de schimmel-onderzoekslijn. Quirine, collega HIV-onder- 
zoeker, ik vond het hartstikke gezellig en leuk om met je samen te werken. Over een 
paar jaar sta je op mijn plaats een schitterend proefschrift te verdedigen! Ik zal er 
bij zijn. Diane, collega-onderzoeker, we hebben kort samengewerkt, maar wat mij 
betreft op een hele prettige manier. Succes met al je toekomstige onderzoeken. 
Beste Klaartje en Marieke. Alles wijst erop dat jullie zullen starten met een promotie 
onderzoek onder begeleiding van David. Ik hoop dat jullie er net zoveel van zullen 
genieten als ik heb gedaan! Rob en Manon, ook jullie wil ik hier bedanken: voor het 
feit dat ik altijd bij jullie terecht kon voor advies, en voor het feit dat de contacten 
dan altijd zo ongedwongen en prettig waren.
Dan nu een woord van dank aan de gevestigd apothekers van het UMC St Radboud 
en de Alysis Zorggroep: Remco de Jong respectievelijk Guus Essink. Dank voor het 
mogelijk maken van dit ZAPIKO traject!
Een speciaal woord van dank past hier voor de ziekenhuisapothekers (i.o) die 
gedurende mijn ZAPIKO traject werkzaam waren binnen de Alysis Zorggroep. 
Guus, Paul, Adriaan, Machiel, Katja, Monique, Margreet, Anita en Claudia. Dank 
voor jullie interesse en flexibele opstelling de afgelopen jaren. Zonder jullie flexibiliteit 
was dit boekje er niet geweest! Ook de ziekenhuisapothekers binnen het UMC St 
Radboud wil ik van harte bedanken voor de getoonde interesse in mijn onderzoek 
en de gezellige contacten.
De analisten van zowel het Laboratorium Klinische Farmacie als van het laboratorium 
in ziekenhuis Rijnstate wil ik van harte bedanken voor het ‘afdraaien’ en meten van 
de vele bloedmonsters van de diverse onderzoeken. Een speciaal woord van dank 
gaat uit naar Noor en Corrien uit het Radboud, die betrokken waren bij de lamotrigine 
(2-N glucuronide) metingen en het opzetten en valideren van de raltegravir assay. 
Binnen ziekenhuis Rijnstate denk ik met name aan Mirjam, met wie ik de atovaquon/ 
proguanil assay opzette en valideerde. En aan Margot en Brigit voor de vele 
metingen die gedaan moesten worden voor het ‘ATOMA onderzoek’ (zie hoofdstuk 6).
Verder wil ik Luuk Gras en Colette Smit van de Stichting HIV monitoring bedanken 
voor hun inzet bij de TDM onderzoeken in dit proefschrift. Een essentiële rol bij 
deze onderzoeken speelde Ferdinand Wit uit het AMC. Ferdinand, bedankt voor je 
hulp en geduld op epidemiologisch en statistisch vlak. Ik heb er ontzettend veel 
van geleerd en ik ervoer ons contact als zeer plezierig.
Wendy Bannister from EuroSIDA, thank you so much for our flne collaboration on 
the EuroSIDA projects.
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de inzet bij de interactieonderzoeken en natuurlijk de gezellige vrijdagmiddagborrels! 
Anita Huisman, ook jou wil ik bedanken voor je bijdrage aan mijn onderzoek in de 
beginperiode van mijn promotie onderzoek.
Diari Faraj, stagiair Farmacie van de Universiteit Utrecht, dank voor je inzet bij het 
ATOMA onderzoek.
Mijn onderzoek was niet mogelijk geweest zonder de grote inzet van diverse HIV 
behandelaren uit den lande: Ineke van der Ende, Luc Gelinck (Erasmus MC), Frank 
Kroon (LUMC), Annemarie Brouwer, Andre van der Ven, Peter Koopmans (UMC St 
Radboud), Clemens Richter, Joop van den Berg, Jet Gisolf (ziekenhuis Rijnstate).
Dat geldt ook voor de vele HIV consultenten die zo’n belangrijke rol speelden bij de 
inclusie van het ATOMA onderzoek: Iman Padmos, Laura van Zonneveld (Erasmus 
MC), Nienke Langebeek, Petra van Bentum, Gerjanne ter Beest (ziekenhuis 
Rijnstate), Marolein Bosch, Bert Zomer, Karin Grintjes-Huisman (UMC St Radboud), 
Willemien Dorama, Conny Moons (LUMC) en Marien Kuipers (Elisabeth Ziekenhuis 
Tilburg).
Natuurlijk wil ik de leden van de manuscriptcommissie, Prof. dr. Russel, Prof. dr. 
Brinkman, Prof. dr. Galama, Prof. dr. Van der Ven en Dr. Van den Bemt bedanken 
voor het bestuderen en beoordelen van dit proefschrift.
Jan, Reinder, Ron, Remco, René, Robert, Jouk, Hylke-Jan, Wouter, Anita. Jammer 
genoeg wonen we niet meer zo dicht bij elkaar als vroeger. Gelukkig is het contact 
gebleven, ondanks onze drukke levens. Laten we dit vooral zo houden en mooie 
avonden en weekendjes blijven plannen!
Jan en Angela. Bedankt dat jullie mijn paranimfen willen zijn. We gaan er een 
fantastische dag van maken!
Beste Jan, 15 jaar geleden samen achterin het klaslokaal bij Wiskunde B in 
Leeuwarden, dezelfde studie, huisgenoten aan Rabenhauptstraat 5. Onze vriendschap 
gaat al een tijd terug! Laten we de goede vrienden blijven die we zijn; hopelijk vinden 
we in ons ‘post -promotie tijdperk’ wat meer tijd om elkaar op te zoeken.
Lieve Angela, jij was een soort nuchtere rots in de branding tijdens mijn 
onderzoekstijd. Als ik eens wat te zeuren had, of een rotkarweitje, hielp je me met 
een grap en een lach of door gewoon te relativeren. Bedankt daarvoor en bedankt 
dat je mijn paranimf wilt zijn.
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Lieve Wilma en Jan, beste Maarten, dank voor jullie oprechte belangstelling de 
afgelopen jaren. Ik heb het met jullie getroffen!
Lieve mama, papa, Jacob, Aletta en Joop, dank voor jullie niet aflatende steun en 
interesse! Ik heb me daardoor enorm gesteund gevoeld!
Lieve Ellen, als er één is die ik wil bedanken dan ben jij het wel. Bedankt voor al je 
steun en liefde de afgelopen jaren! Ik ben blij en gelukkig met je.
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